Duchenne Muscular Dystrophy
Conditions
Brief summary
This is a multicenter, prospective, single cohort study designed to describe the natural history of DMD in Chinese male patients. A total of approximately 330 subjects will be enrolled with the target number of subjects in each group as below: * Group 1, Ambulatory subjects aged \<6 years, approximately 100 subjects; * Group 2, Ambulatory subjects aged \>=6 years, approximately 180 subjects; * Group 3, Non-ambulatory subjects, approximately 50 subjects. Subjects will visit sites every 6 months. Each subject will be observed for at least 24 months. All subjects will remain enrolled until the study completion date, such that some will have data collected after Month 24. Subjects, who complete Visit 5/Month 24 at least 6 months prior to study completion, will be asked to complete an additional visit at Month 30.
Interventions
All subjects need to visit sites more frequently than in routine clinical practice.
Sponsors
Study design
Eligibility
Inclusion criteria
1. Chinese male patients with any age, diagnosed with DMD. Diagnosis must be confirmed in subject's medical history and by genetic testing obtained during routine clinical care for diagnostic purposes as reported from an appropriate regulated laboratory using a clinically validated genetic test (genetic testing is not provided by the sponsor). 2. Subjects who are \>=4 years old must be receiving glucocorticosteroids for a minimum of 6 months prior to signing informed consent. There should be no significant change (\<0.2 mg/kg) in dosage or dose regimen (not related to body weight change) for at least 3 months immediately prior to signing the informed consent. Subjects who are aged \>4 years will be exempt from this requirement; those not taking GC will be eligible if the initiation of GC treatment in these subjects is considered inappropriate in the opinion of Investigators.
Exclusion criteria
1. Any injury which may impact functional testing. Previous injuries must be fully healed prior to consenting. Prior lower limb fractures must be fully healed and at least 3 months from injury date. 2. Presence or history of other musculoskeletal or neurologic disease or somatic disorder not related to DMD including pulmonary, cardiac, and cognitive diseases. 3. Subjects \>=4 years old who have not completed the varicella vaccination. 4. Participation in other studies involving investigational drug(s) for a minimum of 90 days prior to signing the informed consent and/or during study participation.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change From Baseline in Wechsler Intelligence Scale for Children (WISC)-IV Score at Month 24: Ambulatory Participants >= 6 to <=16 Years | Baseline (Day 1) and Month 24 | WISC-IV is an individually administered intelligence test for children between the ages of 6 and 16. The WISC-IV Composites are: Verbal Comprehension, Perceptual Reasoning, Working Memory, and Processing Speed. Scores from the Composites constitute the WISC-IV Full Scale IQ score which ranges from 40 (Exceptionally Low) to 160 (Exceptionally Superior), higher scores indicated more intelligence. The WISC was only performed in ambulatory participants \>= 6 to \<=16 years old as pre-specified in the protocol. |
| Change From Baseline in %pFEV1 at Month 30: Participants Aged >=6 Years | Baseline (Day 1) and Month 30 | FEV1 is the volume of air forcefully exhaled in 1 second and was measured using spirometry. The %pFEV1 was calculated from FEV1 (measured in liter) according to age, height (estimated height as derived from the ulna length for non-ambulatory participants), ethnicity, and gender using multi-ethnic reference values for Spirometry. The pulmonary function assessments were performed only in participants \>=6 years old as pre-specified in protocol. |
| Change From Baseline in %pFVC at Month 24: Participants Aged >=6 Years | Baseline (Day 1) and Month 24 | FVC is the volume of air that can be maximally forcefully exhaled after taking the deepest breath possible and was measured using spirometry. The percent predicted FVC was calculated from FVC (measured in liter) according to age, height (estimated height as derived from the ulna length for non-ambulatory participants), ethnicity, and gender using multi-ethnic reference values for spirometry. The pulmonary function assessments were performed in participants aged \>=6 years as pre-specified in the protocol. |
| Change From Baseline in %pFVC at Month 30: Participants Aged >=6 Years | Baseline (Day 1) and Month 30 | FVC is the volume of air that can be maximally forcefully exhaled after taking the deepest breath possible and was measured using spirometry. The percent predicted FVC was calculated from FVC (measured in liter) according to age, height (estimated height as derived from the ulna length for non-ambulatory participants), ethnicity, and gender using multi-ethnic reference values for spirometry. The pulmonary function assessments were performed in participants aged \>=6 years as pre-specified in the protocol. |
| Change From Baseline in %pFVC at Month 12: Participants Aged >=6 Years (Unplanned Analysis) | Baseline (Day 1) and Month 12 | FVC is the volume of air that can be maximally forcefully exhaled after taking the deepest breath possible and was measured using spirometry. The percent predicted FVC was calculated from FVC (measured in liter) according to age, height (estimated height as derived from the ulna length for non-ambulatory participants), ethnicity, and gender using multi-ethnic reference values for spirometry. The pulmonary function assessments were performed in participants aged \>=6 years as pre-specified in the protocol. Incorrect data were addressed by unplanned analysis. |
| Change From Baseline in %pFVC at Month 24: Participants Aged >=6 Years (Unplanned Analysis) | Baseline (Day 1) and Month 24 | FVC is the volume of air that can be maximally forcefully exhaled after taking the deepest breath possible and was measured using spirometry. The percent predicted FVC was calculated from FVC (measured in liter) according to age, height (estimated height as derived from the ulna length for non-ambulatory participants), ethnicity, and gender using multi-ethnic reference values for spirometry. The pulmonary function assessments were performed in participants aged \>=6 years as pre-specified in the protocol. Incorrect data were addressed by unplanned analysis. |
| Change From Baseline in %pFVC at Month 30: Participants Aged >=6 Years (Unplanned Analysis) | Baseline (Day 1) and Month 30 | FVC is the volume of air that can be maximally forcefully exhaled after taking the deepest breath possible and was measured using spirometry. The percent predicted FVC was calculated from FVC (measured in liter) according to age, height (estimated height as derived from the ulna length for non-ambulatory participants), ethnicity, and gender using multi-ethnic reference values for spirometry. The pulmonary function assessments were performed in participants aged \>=6 years as pre-specified in the protocol. Incorrect data were addressed by unplanned analysis. |
| Change From Baseline in Percent Predicted Forced Expiratory Volume in One Second (%pFEV1) at Month 12: Participants Aged >=6 Years | Baseline (Day 1) and Month 12 | Forced expiratory volume in one second (FEV1) is the volume of air forcefully exhaled in 1 second and was measured using spirometry. The %pFEV1 was calculated from FEV1 (measured in liter) according to age, height (estimated height as derived from the ulna length for non-ambulatory participants), ethnicity, and gender using multi-ethnic reference values for Spirometry. The pulmonary function assessments were performed only in participants \>=6 years old as pre-specified in protocol. |
| Change From Baseline in %pFEV1 at Month 24: Participants Aged >=6 Years | Baseline (Day 1) and Month 24 | FEV1 is the volume of air forcefully exhaled in 1 second and was measured using spirometry. The %pFEV1 was calculated from FEV1 (measured in liter) according to age, height (estimated height as derived from the ulna length for non-ambulatory participants), ethnicity, and gender using multi-ethnic reference values for Spirometry. The pulmonary function assessments were performed only in participants \>=6 years old as pre-specified in protocol. |
| Change From Baseline in %pFEV1 at Month 12: Participants Aged >=6 Years (Unplanned Analysis) | Baseline (Day 1) and Month 12 | FEV1 is the volume of air forcefully exhaled in 1 second and was measured using spirometry. The %pFEV1 was calculated from FEV1 (measured in liter) according to age, height (estimated height as derived from the ulna length for non-ambulatory participants), ethnicity, and gender using multi-ethnic reference values for Spirometry. The pulmonary function assessments were performed only in participants \>=6 years old as pre-specified in protocol. Incorrect data were addressed by unplanned analysis. |
| Change From Baseline in %pFEV1 at Month 24: Participants Aged >=6 Years (Unplanned Analysis) | Baseline (Day 1) and Month 24 | FEV1 is the volume of air forcefully exhaled in 1 second and was measured using spirometry. The %pFEV1 was calculated from FEV1 (measured in liter) according to age, height (estimated height as derived from the ulna length for non-ambulatory participants), ethnicity, and gender using multi-ethnic reference values for Spirometry. The pulmonary function assessments were performed only in participants \>=6 years old as pre-specified in protocol. Incorrect data were addressed by unplanned analysis. |
| Change From Baseline in %pFEV1 at Month 30: Participants Aged >=6 Years (Unplanned Analysis) | Baseline (Day 1) and Month 30 | FEV1 is the volume of air forcefully exhaled in 1 second and was measured using spirometry. The %pFEV1 was calculated from FEV1 (measured in liter) according to age, height (estimated height as derived from the ulna length for non-ambulatory participants), ethnicity, and gender using multi-ethnic reference values for Spirometry. The pulmonary function assessments were performed only in participants \>=6 years old as pre-specified in protocol. Incorrect data were addressed by unplanned analysis. |
| Change From Baseline in Maximum Inspiratory Pressure at Month 12: Participants Aged >=6 Years | Baseline (Day 1) and Month 12 | The pulmonary function assessments were performed only in participants \>=6 years old as pre-specified in protocol. |
| Change From Baseline in Maximum Inspiratory Pressure at Month 24: Participants Aged >=6 Years | Baseline (Day 1) and Month 24 | The pulmonary function assessments were performed only in participants \>=6 years old as pre-specified in protocol. |
| Change From Baseline in Maximum Inspiratory Pressure at Month 30: Participants Aged >=6 Years | Baseline (Day 1) and Month 30 | The pulmonary function assessments were performed only in participants \>=6 years old as pre-specified in protocol. |
| Change From Baseline in Maximum Expiratory Pressure at Month 12: Participants Aged >=6 Years | Baseline (Day 1) and Month 12 | The pulmonary function assessments were performed only in participants \>=6 years old as pre-specified in SAP. |
| Change From Baseline in Maximum Expiratory Pressure at Month 24: Participants Aged >=6 Years | Baseline (Day 1) and Month 24 | The pulmonary function assessments were performed only in participants \>=6 years old as pre-specified in SAP. |
| Change From Baseline in Maximum Expiratory Pressure at Month 30: Participants Aged >=6 Years | Baseline (Day 1) and Month 30 | The pulmonary function assessments were performed only in participants \>=6 years old as pre-specified in SAP. |
| Change From Baseline in Peak Cough Flow at Month 12: Participants Aged >=6 Years | Baseline (Day 1) and Month 12 | The pulmonary function assessments were performed only in participants \>=6 years old as pre-specified in protocol. |
| Change From Baseline in Peak Cough Flow at Month 24: Participants Aged >=6 Years | Baseline (Day 1) and Month 24 | The pulmonary function assessments were performed only in participants \>=6 years old as pre-specified in protocol. |
| Change From Baseline in Peak Cough Flow at Month 30: Participants Aged >=6 Years | Baseline (Day 1) and Month 30 | The pulmonary function assessments were performed only in participants \>=6 years old as pre-specified in protocol. |
| Change From Baseline in Peak Cough Flow at Month 12: Participants Aged >=6 Years (Unplanned Analysis) | Baseline (Day 1) and Month 12 | The pulmonary function assessments were performed only in participants \>=6 years old as pre-specified in protocol. Incorrect data were addressed by unplanned analysis. |
| Change From Baseline in Peak Cough Flow at Month 24: Participants Aged >=6 Years (Unplanned Analysis) | Baseline (Day 1) and Month 24 | The pulmonary function assessments were performed only in participants \>=6 years old as pre-specified in protocol. Incorrect data were addressed by unplanned analysis. |
| Change From Baseline in Peak Cough Flow at Month 30: Participants Aged >=6 Years (Unplanned Analysis) | Baseline (Day 1) and Month 30 | The pulmonary function assessments were performed only in participants \>=6 years old as pre-specified in protocol. Incorrect data were addressed by unplanned analysis. |
| Change From Baseline in Left Ventricular Ejection Fraction (LVEF) at Month 12: Participants Aged >=6 Years | Baseline (Day 1) and Month 12 | LVEF was the percentage of blood that was ejected out of left ventricle with each contraction, estimated by echocardiography. The LVEF was only performed in participants \>=6 years old as pre-specified in protocol. |
| Change From Baseline in LVEF at Month 24: Participants Aged >=6 Years | Baseline (Day 1) and Month 24 | LVEF was the percentage of blood that was ejected out of left ventricle with each contraction, estimated by echocardiography. The LVEF was only performed in participants \>=6 years old as pre-specified in protocol. |
| Change From Baseline in LVEF at Month 30: Participants Aged >=6 Years | Baseline (Day 1) and Month 30 | LVEF was the percentage of blood that was ejected out of left ventricle with each contraction, estimated by echocardiography. The LVEF was only performed in participants \>=6 years old as pre-specified in protocol. |
| Change From Baseline in LVEF at Month 12: Participants Aged >=6 Years (Unplanned Analysis) | Baseline (Day 1) and Month 12 | LVEF was the percentage of blood that was ejected out of left ventricle with each contraction, estimated by echocardiography. The LVEF was only performed in participants \>=6 years old as pre-specified in protocol. Incorrect data were addressed by unplanned analysis. |
| Change From Baseline in LVEF at Month 24: Participants Aged >=6 Years (Unplanned Analysis) | Baseline (Day 1) and Month 24 | LVEF was the percentage of blood that was ejected out of left ventricle with each contraction, estimated by echocardiography. The LVEF was only performed in participants \>=6 years old as pre-specified in protocol. Incorrect data were addressed by unplanned analysis. |
| Change From Baseline in LVEF at Month 30: Participants Aged >=6 Years (Unplanned Analysis) | Baseline (Day 1) and Month 30 | LVEF was the percentage of blood that was ejected out of left ventricle with each contraction, estimated by echocardiography. The LVEF was only performed in participants \>=6 years old as pre-specified in protocol. Incorrect data were addressed by unplanned analysis. |
| Age of Participants When They Failed to Walk | Up to Month 30 | Participant's age at life-altering clinical milestones- failure to walk was calculated based on the birthdate and the date of failure to walk as reported by caregiver during 30 months of this study. Participants who were not reported being failure to walk by their caregivers were censored on the day of their last visit. Kaplan-Meier method was used for analysis. |
| Age of Participants When They Failed to Stand | Up to Month 30 | Participant's age at life-altering clinical milestones- failure to stand was calculated based on the birthdate and the date of failure to stand as reported by caregiver during 30 months of this study. Participants who were not reported being failure to stand by their caregivers were censored on the day of their last visit. Kaplan-Meier method was used for analysis. |
| Age of Participants When They Failed to Self-feed | Up to Month 30 | Participant's age at life-altering clinical milestones- failure to self-feed during 30 months of this study was analyzed using the Kaplan-Meier method. Age was summarized in years. |
| Change From Baseline in Northstar Ambulatory Assessment (NSAA) Total Score at Month 6: Ambulatory Participants Aged >=3 Years | Baseline (Day 1) and Month 6 | NSAA is a 17-item test that grades performance of various functional skills using the following scale: 0 (unable to achieve goal independently), 1 (modified method but achieves goal with no physical assistance), or 2 (normal- no obvious modification of activity). The scale assesses activities required to remain functionally ambulant (e.g. rise from the floor), activities that can be difficult even early in the disease (example \[e.g.\] standing on heels) and activities that are known to progressively deteriorate over time (stand from a chair, walk). NSAA total score was calculated by adding the responses of all 17 items and ranged from 0 to 34, with higher scores indicating better function. NSAA was only performed in ambulatory participants aged \>=3 years old as pre-specified in protocol. |
| Change From Baseline in NSAA Total Score at Month 12: Ambulatory Participants Aged >=3 Years | Baseline (Day 1) and Month 12 | NSAA is a 17-item test that grades performance of various functional skills using the following scale: 0 (unable to achieve goal independently), 1 (modified method but achieves goal with no physical assistance), or 2 (normal- no obvious modification of activity). The scale assesses activities required to remain functionally ambulant (e.g. rise from the floor), activities that can be difficult even early in the disease (e.g. standing on heels) and activities that are known to progressively deteriorate over time (stand from a chair, walk). NSAA total score was calculated by adding the responses of all 17 items and ranged from 0 to 34, with higher scores indicating better function. NSAA was only performed in ambulatory participants aged \>=3 years old as pre-specified in protocol. |
| Change From Baseline in NSAA Total Score at Month 18: Ambulatory Participants Aged >=3 Years | Baseline (Day 1) and Month 18 | NSAA is a 17-item test that grades performance of various functional skills using the following scale: 0 (unable to achieve goal independently), 1 (modified method but achieves goal with no physical assistance), or 2 (normal- no obvious modification of activity). The scale assesses activities required to remain functionally ambulant (e.g. rise from the floor), activities that can be difficult even early in the disease (e.g. standing on heels) and activities that are known to progressively deteriorate over time (stand from a chair, walk). NSAA total score was calculated by adding the responses of all 17 items and ranged from 0 to 34, with higher scores indicating better function. NSAA was only performed in ambulatory participants aged \>=3 years old as pre-specified in protocol. |
| Change From Baseline in NSAA Total Score at Month 24: Ambulatory Participants Aged >=3 Years | Baseline (Day 1) and Month 24 | NSAA is a 17-item test that grades performance of various functional skills using the following scale: 0 (unable to achieve goal independently), 1 (modified method but achieves goal with no physical assistance), or 2 (normal- no obvious modification of activity). The scale assesses activities required to remain functionally ambulant (e.g. rise from the floor), activities that can be difficult even early in the disease (e.g. standing on heels) and activities that are known to progressively deteriorate over time (stand from a chair, walk). NSAA total score was calculated by adding the responses of all 17 items and ranged from 0 to 34, with higher scores indicating better function. NSAA was only performed in ambulatory participants aged \>=3 years old as pre-specified in protocol. |
| Change From Baseline in NSAA Total Score at Month 30: Ambulatory Participants Aged >=3 Years | Baseline (Day 1) and Month 30 | NSAA is a 17-item test that grades performance of various functional skills using the following scale: 0 (unable to achieve goal independently), 1 (modified method but achieves goal with no physical assistance), or 2 (normal- no obvious modification of activity). The scale assesses activities required to remain functionally ambulant (e.g. rise from the floor), activities that can be difficult even early in the disease (e.g. standing on heels) and activities that are known to progressively deteriorate over time (stand from a chair, walk). NSAA total score was calculated by adding the responses of all 17 items and ranged from 0 to 34, with higher scores indicating better function. NSAA was only performed in ambulatory participants aged \>=3 years old as pre-specified in protocol. |
| Change From Baseline in Performance of Upper Limb (PUL) 2.0 Total Score at Month 6: Participants Aged >=10 Years | Baseline (Day 1) and Month 6 | PUL 2.0 scale is a 22-item scale used to assess the change that occurs in motor performance of the upper limb overtime from when a participant is still ambulant to the time participant loses all arm function when non-ambulant. PUL 2.0 includes an entry item to define broad starting functional level and 22 items subdivided into shoulder level (six items), mid-level (nine items), and distal level (seven items). Each dimension (shoulder, mid, distal) can be scored separately. There is maximum score of 12 for shoulder level, 17 for mid-level, and 13 for distal level. The total score was calculated by adding three level scores and ranged from 0-42. Higher score indicates better upper limb function. PUL 2.0 total score was assessed in participants aged \>=10 years only as pre-specified in protocol. |
| Change From Baseline in PUL 2.0 Total Score at Month 12: Participants Aged >=10 Years | Baseline (Day 1) and Month 12 | PUL 2.0 scale is a 22-item scale used to assess the change that occurs in motor performance of the upper limb overtime from when a participant is still ambulant to the time participant loses all arm function when non-ambulant. PUL 2.0 includes an entry item to define broad starting functional level and 22 items subdivided into shoulder level (six items), mid-level (nine items), and distal level (seven items). Each dimension (shoulder, mid, distal) can be scored separately. There is maximum score of 12 for shoulder level, 17 for mid-level, and 13 for distal level. The total score was calculated by adding three level scores and ranged from 0-42. Higher score indicates better upper limb function. PUL 2.0 total score was assessed in participants aged \>=10 years only as pre-specified in protocol. |
| Change From Baseline in PUL 2.0 Total Score at Month 18: Participants Aged >=10 Years | Baseline (Day 1) and Month 18 | PUL 2.0 scale is a 22-item scale used to assess the change that occurs in motor performance of the upper limb overtime from when a participant is still ambulant to the time participant loses all arm function when non-ambulant. PUL 2.0 includes an entry item to define broad starting functional level and 22 items subdivided into shoulder level (six items), mid-level (nine items), and distal level (seven items). Each dimension (shoulder, mid, distal) can be scored separately. There is maximum score of 12 for shoulder level, 17 for mid-level, and 13 for distal level. The total score was calculated by adding three level scores and ranged from 0-42. Higher score indicates better upper limb function. PUL 2.0 total score was assessed in participants aged \>=10 years only as pre-specified in protocol. |
| Change From Baseline in PUL 2.0 Total Score at Month 24: Participants Aged >=10 Years | Baseline (Day 1) and Month 24 | PUL 2.0 scale is a 22-item scale used to assess the change that occurs in motor performance of the upper limb overtime from when a participant is still ambulant to the time participant loses all arm function when non-ambulant. PUL 2.0 includes an entry item to define broad starting functional level and 22 items subdivided into shoulder level (six items), mid-level (nine items), and distal level (seven items). Each dimension (shoulder, mid, distal) can be scored separately. There is maximum score of 12 for shoulder level, 17 for mid-level, and 13 for distal level. The total score was calculated by adding three level scores and ranged from 0-42. Higher score indicates better upper limb function. PUL 2.0 total score was assessed in participants aged \>=10 years only as pre-specified in protocol. |
| Change From Baseline in PUL 2.0 Total Score at Month 30: Participants Aged >=10 Years | Baseline (Day 1) and Month 30 | PUL 2.0 scale is a 22-item scale used to assess the change that occurs in motor performance of the upper limb overtime from when a participant is still ambulant to the time participant loses all arm function when non-ambulant. PUL 2.0 includes an entry item to define broad starting functional level and 22 items subdivided into shoulder level (six items), mid-level (nine items), and distal level (seven items). Each dimension (shoulder, mid, distal) can be scored separately. There is maximum score of 12 for shoulder level, 17 for mid-level, and 13 for distal level. The total score was calculated by adding three level scores and ranged from 0-42. Higher score indicates better upper limb function. PUL 2.0 total score was assessed in participants aged \>=10 years only as pre-specified in protocol. |
| Change From Baseline in Rise From Floor Velocity at Month 6: Ambulatory Participants Aged >=3 Years Only | Baseline (Day 1) and Month 6 | The rise from floor velocity was defined as the reciprocal of the time (in seconds) to rise from floor. The rise from floor test was performed only in ambulatory participants aged \>=3 years old as pre-specified in the protocol. |
| Change From Baseline in Rise From Floor Velocity at Month 12: Ambulatory Participants Aged >=3 Years Only | Baseline (Day 1) and Month 12 | The rise from floor velocity was defined as the reciprocal of the time (in seconds) to rise from floor. The rise from floor test was performed only in ambulatory participants aged \>=3 years old as pre-specified in the protocol. |
| Change From Baseline in Rise From Floor Velocity at Month 18: Ambulatory Participants Aged >=3 Years Only | Baseline (Day 1) and Month 18 | The rise from floor velocity was defined as the reciprocal of the time (in seconds) to rise from floor. The rise from floor test was performed only in ambulatory participants aged \>=3 years old as pre-specified in the protocol. |
| Change From Baseline in Rise From Floor Velocity at Month 24: Ambulatory Participants Aged >=3 Years Only | Baseline (Day 1) and Month 24 | The rise from floor velocity was defined as the reciprocal of the time (in seconds) to rise from floor. The rise from floor test was performed only in ambulatory participants aged \>=3 years old as pre-specified in the protocol. |
| Change From Baseline in Rise From Floor Velocity at Month 30: Ambulatory Participants Aged >=3 Years Only | Baseline (Day 1) and Month 30 | The rise from floor velocity was defined as the reciprocal of the time (in seconds) to rise from floor. The rise from floor test was performed only in ambulatory participants aged \>=3 years old as pre-specified in the protocol. |
| Change From Baseline in 10 Meter Walk or Run Velocity at Month 6: Ambulatory Participants Aged >=3 Years | Baseline (Day 1) and Month 6 | The 10 meter walk or run test was performed as part of NSAA. The 10 meter walk or run velocity was defined as the reciprocal of the time (in seconds) to complete the 10 meter run or walk test. The 10 meter walk or run test was performed in ambulatory children \>=3 years old only as pre-specified in the protocol. |
| Change From Baseline in 10 Meter Walk or Run Velocity at Month 12: Ambulatory Participants Aged >=3 Years | Baseline (Day 1) and Month 12 | The 10 meter walk or run test was performed as part of NSAA. The 10 meter walk or run velocity was defined as the reciprocal of the time (in seconds) to complete the 10 meter run or walk test. The 10 meter walk or run test was performed in ambulatory children \>=3 years old only as pre-specified in the protocol. |
| Change From Baseline in 10 Meter Walk or Run Velocity at Month 18: Ambulatory Participants Aged >=3 Years | Baseline (Day 1) and Month 18 | The 10 meter walk or run test was performed as part of NSAA. The 10 meter walk or run velocity was defined as the reciprocal of the time (in seconds) to complete the 10 meter run or walk test. The 10 meter walk or run test was performed in ambulatory children \>=3 years old only as pre-specified in the protocol. |
| Change From Baseline in 10 Meter Walk or Run Velocity at Month 24: Ambulatory Participants Aged >=3 Years | Baseline (Day 1) and Month 24 | The 10 meter walk or run test was performed as part of NSAA. The 10 meter walk or run velocity was defined as the reciprocal of the time (in seconds) to complete the 10 meter run or walk test. The 10 meter walk or run test was performed in ambulatory children \>=3 years old only as pre-specified in the protocol. |
| Change From Baseline in 10 Meter Walk or Run Velocity at Month 30: Ambulatory Participants Aged >=3 Years | Baseline (Day 1) and Month 30 | The 10 meter walk or run test was performed as part of NSAA. The 10 meter walk or run velocity was defined as the reciprocal of the time (in seconds) to complete the 10 meter run or walk test. The 10 meter walk or run test was performed in ambulatory children \>=3 years old only as pre-specified in the protocol. |
| Change From Baseline in Knee Extension of Muscle Strength at Month 6: Participants Aged >=5 Years | Baseline (Day 1) and Month 6 | Muscle strength was recorded by handheld myometry. Left and right knee extension was analyzed. The muscle strength test was only performed in participants \>=5 years old as pre-specified in protocol. |
| Change From Baseline in Knee Extension of Muscle Strength at Month 12: Participants Aged >=5 Years | Baseline (Day 1) and Month 12 | Muscle strength was recorded by handheld myometry. Left and right knee extension was analyzed. The muscle strength test was only performed in participants \>=5 years old as pre-specified in protocol. |
| Change From Baseline in Knee Extension of Muscle Strength at Month 18: Participants Aged >=5 Years | Baseline (Day 1) and Month 18 | Muscle strength was recorded by handheld myometry. Left and right knee extension was analyzed. The muscle strength test was only performed in participants \>=5 years old as pre-specified in protocol. |
| Change From Baseline in Knee Extension of Muscle Strength at Month 24: Participants Aged >=5 Years | Baseline (Day 1) and Month 24 | Muscle strength was recorded by handheld myometry. Left and right knee extension was analyzed. The muscle strength test was only performed in participants \>=5 years old as pre-specified in protocol. |
| Change From Baseline in Knee Extension of Muscle Strength at Month 30: Participants Aged >=5 Years | Baseline (Day 1) and Month 30 | Muscle strength was recorded by handheld myometry. Left and right knee extension was analyzed. The muscle strength test was only performed in participants \>=5 years old as pre-specified in protocol. |
| Change From Baseline in Elbow Flexion of Muscle Strength at Month 6: Participants Aged >=5 Years | Baseline (Day 1) and Month 6 | Muscle strength was recorded by handheld myometry. Left and right elbow flexion were analyzed. The muscle strength test was only performed in participants \>=5 years old as pre-specified in the protocol. |
| Change From Baseline in Elbow Flexion of Muscle Strength at Month 12: Participants Aged >=5 Years | Baseline (Day 1) and Month 12 | Muscle strength was recorded by handheld myometry. Left and right elbow flexion were analyzed. The muscle strength test was only performed in participants \>=5 years old as pre-specified in the protocol. |
| Change From Baseline in Elbow Flexion of Muscle Strength at Month 18: Participants Aged >=5 Years | Baseline (Day 1) and Month 18 | Muscle strength was recorded by handheld myometry. Left and right elbow flexion were analyzed. The muscle strength test was only performed in participants \>=5 years old as pre-specified in the protocol. |
| Change From Baseline in Elbow Flexion of Muscle Strength at Month 24: Participants Aged >=5 Years | Baseline (Day 1) and Month 24 | Muscle strength was recorded by handheld myometry. Left and right elbow flexion were analyzed. The muscle strength test was only performed in participants \>=5 years old as pre-specified in the protocol. |
| Change From Baseline in Elbow Flexion of Muscle Strength at Month 30: Participants Aged >=5 Years | Baseline (Day 1) and Month 30 | Muscle strength was recorded by handheld myometry. Left and right elbow flexion were analyzed. The muscle strength test was only performed in participants \>=5 years old as pre-specified in the protocol. |
| Change From Baseline in Elbow Extension of Muscle Strength at Month 6: Participants Aged >=5 Years | Baseline (Day 1) and Month 6 | Muscle strength was recorded by handheld myometry. Left and right elbow extension were analyzed. The muscle strength test was only performed in participants \>=5 years old as pre-specified in protocol. |
| Change From Baseline in Elbow Extension Muscle Strength at Month 12: Participants Aged >=5 Years | Baseline (Day 1) and Month 12 | Muscle strength was recorded by handheld myometry. Left and right elbow extension were analyzed. The muscle strength test was only performed in participants \>=5 years old as pre-specified in protocol. |
| Change From Baseline in Elbow Extension Muscle Strength at Month 18: Participants Aged >=5 Years | Baseline (Day 1) and Month 18 | Muscle strength was recorded by handheld myometry. Left and right elbow extension were analyzed. The muscle strength test was only performed in participants \>=5 years old as pre-specified in protocol. |
| Change From Baseline in Elbow Extension Muscle Strength at Month 24: Participants Aged >=5 Years | Baseline (Day 1) and Month 24 | Muscle strength was recorded by handheld myometry. Left and right elbow extension were analyzed. The muscle strength test was only performed in participants \>=5 years old as pre-specified in protocol. |
| Change From Baseline in Elbow Extension Muscle Strength at Month 30: Participants Aged >=5 Years | Baseline (Day 1) and Month 30 | Muscle strength was recorded by handheld myometry. Left and right elbow extension were analyzed. The muscle strength test was only performed in participants \>=5 years old as pre-specified in protocol. |
| Change From Baseline in Shoulder Abduction of Muscle Strength at Month 6: Participants Aged >=5 Years | Baseline (Day 1) and Month 6 | Muscle strength was recorded by handheld myometry. Left and right shoulder abduction were analyzed. The muscle strength test was only performed in participants \>=5 years old as pre-specified in the protocol. |
| Change From Baseline in Shoulder Abduction of Muscle Strength at Month 12: Participants Aged >=5 Years | Baseline (Day 1) and Month 12 | Muscle strength was recorded by handheld myometry. Left and right shoulder abduction were analyzed. The muscle strength test was only performed in participants \>=5 years old as pre-specified in the protocol. |
| Change From Baseline in Shoulder Abduction of Muscle Strength at Month 18: Participants Aged >=5 Years | Baseline (Day 1) and Month 18 | Muscle strength was recorded by handheld myometry. Left and right shoulder abduction were analyzed. The muscle strength test was only performed in participants \>=5 years old as pre-specified in the protocol. |
| Change From Baseline in Shoulder Abduction of Muscle Strength at Month 24: Participants Aged >=5 Years | Baseline (Day 1) and Month 24 | Muscle strength was recorded by handheld myometry. Left and right shoulder abduction were analyzed. The muscle strength test was only performed in participants \>=5 years old as pre-specified in the protocol. |
| Change From Baseline in Shoulder Abduction of Muscle Strength at Month 30: Participants Aged >=5 Years | Baseline (Day 1) and Month 30 | Muscle strength was recorded by handheld myometry. Left and right shoulder abduction were analyzed. The muscle strength test was only performed in participants \>=5 years old as pre-specified in the protocol. |
| Change From Baseline in Range of Motion (ROM) at Bilateral Ankles at Month 6 | Baseline (Day 1) and Month 6 | Range of motion was evaluated by using goniometry to record any occurrences of ankle contractures. The ROM at left and right ankles were measured in degrees of passive dorsiflexion. |
| Change From Baseline in ROM at Bilateral Ankles at Month 12 | Baseline (Day 1) and Month 12 | Range of motion was evaluated by using goniometry to record any occurrences of ankle contractures. The ROM at left and right ankles were measured in degrees of passive dorsiflexion. |
| Change From Baseline in ROM at Bilateral Ankles at Month 18 | Baseline (Day 1) and Month 18 | Range of motion was evaluated by using goniometry to record any occurrences of ankle contractures. The ROM at left and right ankles were measured in degrees of passive dorsiflexion. |
| Change From Baseline in ROM at Bilateral Ankles at Month 24 | Baseline (Day 1) and Month 24 | Range of motion was evaluated by using goniometry to record any occurrences of ankle contractures. The ROM at left and right ankles were measured in degrees of passive dorsiflexion. |
| Change From Baseline in ROM at Bilateral Ankles at Month 30 | Baseline (Day 1) and Month 30 | Range of motion was evaluated by using goniometry to record any occurrences of ankle contractures. The ROM at left and right ankles were measured in degrees of passive dorsiflexion. |
| Change From Baseline in ROM at Bilateral Elbows at Month 6 | Baseline (Day 1) and Month 6 | Range of motion was evaluated by using goniometry to record any occurrences of elbow contractures. The ROM at left and right elbows were measured in degrees of passive extension. |
| Change From Baseline in ROM at Bilateral Elbows at Month 12 | Baseline (Day 1) and Month 12 | Range of motion was evaluated by using goniometry to record any occurrences of elbow contractures. The ROM at left and right elbows were measured in degrees of passive extension. |
| Change From Baseline in ROM at Bilateral Elbows at Month 18 | Baseline (Day 1) and Month 18 | Range of motion was evaluated by using goniometry to record any occurrences of elbow contractures. The ROM at left and right elbows were measured in degrees of passive extension. |
| Change From Baseline in ROM at Bilateral Elbows at Month 24 | Baseline (Day 1) and Month 24 | Range of motion was evaluated by using goniometry to record any occurrences of elbow contractures. The ROM at left and right elbows were measured in degrees of passive extension. |
| Change From Baseline in ROM at Bilateral Elbows at Month 30 | Baseline (Day 1) and Month 30 | Range of motion was evaluated by using goniometry to record any occurrences of elbow contractures. The ROM at left and right elbows were measured in degrees of passive extension. |
| Change From Baseline in Percent Predicted Forced Vital Capacity (%pFVC) at Month 12: Participants Aged >=6 Years | Baseline (Day 1) and Month 12 | Forced vital capacity (FVC) is the volume of air that can be maximally forcefully exhaled after taking the deepest breath possible and was measured using spirometry. The percent predicted FVC was calculated from FVC (measured in liter) according to age, height (estimated height as derived from the ulna length for non-ambulatory participants), ethnicity, and gender using multi-ethnic reference values for spirometry. The pulmonary function assessments were performed in participants aged \>=6 years as pre-specified in the protocol. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants With Each Affected Exon by Mutation Types | Up to Month 30 | Number of participants with each affected exon by mutation types is presented in this outcome measure. Only those categories with non-zero values have been reported. |
| Number of Participants With DMD Mutations Affecting Any Exon Between Exon 9 and Exon 13 or Deletion That Affects Both Exon 29 and Exon 30 | Up to Month 30 | Number of participants with DMD mutations affecting any exon between exon 9 and exon 13 or deletion that affects both exon 29 and exon 30 is presented in this outcome measure. |
| Change From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30 | Baseline (Day 1) and Months 6, 12, 18, 24 and 30 | The PODCI is a participant-reported assessment of musculoskeletal health intended for use in children and adolescents. The pediatric version was intended for completion by parents or caregivers of children \<=10 years old. It included a Global Function Scale along with core scales: Upper Extremity and Physical Function Core Scale (8 items); Transfer and Basic Mobility Core Scale (11 items); Sports and Physical Functioning Core Scale (21 items); Pain/Comfort Core Scale (3 items); Happiness Core Scale (5 items). The scores of each PODCI global functioning scale and core scales are averaged over the number of items answered (omitted no entry items). Mean of the rescaled values is multiplied by a constant so that each global functioning scale and core scales has a final range of values between 0-100. The higher scores represent less disability and better functioning. |
| Change From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Parent Report) at Months 6, 12, 18, 24 and 30 | Baseline (Day 1) and Months 6, 12, 18, 24 and 30 | The PODCI is a participant-reported assessment of musculoskeletal health intended for use in children and adolescents. The pediatric version was intended for completion by parents or caregivers of children \<=10 years old. It included a Global Function Scale along with core scales: Upper Extremity and Physical Function Core Scale (8 items); Transfer and Basic Mobility Core Scale (11 items); Sports and Physical Functioning Core Scale (21 items); Pain/Comfort Core Scale (3 items); Happiness Core Scale (5 items). The scores of each PODCI global functioning scale and core scales are averaged over the number of items answered (omitted no entry items). Mean of the rescaled values is multiplied by a constant so that each global functioning scale and core scales has a final range of values between 0-100. The higher scores represent less disability and better functioning. |
| Change From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Self Report) at Months 6, 12, 18, 24 and 30 | Baseline (Day 1) and Months 6, 12, 18, 24 and 30 | The PODCI is a participant-reported assessment of musculoskeletal health intended for use in children and adolescents. The pediatric version was intended for completion by parents or caregivers of children \<=10 years old. It included a Global Function Scale along with core scales: Upper Extremity and Physical Function Core Scale (8 items); Transfer and Basic Mobility Core Scale (11 items); Sports and Physical Functioning Core Scale (21 items); Pain/Comfort Core Scale (3 items); Happiness Core Scale (5 items). The scores of each PODCI global functioning scale and core scales are averaged over the number of items answered (omitted no entry items). Mean of the rescaled values is multiplied by a constant so that each global functioning scale and core scales has a final range of values between 0-100. The higher scores represent less disability and better functioning. |
| Number of Participants According to Response to Each European Quality of Life (EuroQoL) 5 Dimension 3 Level (EQ-5D-3L) 5 Dimensions at Month 12 | Months 12 | EQ-5D-3L is a participant completed questionnaire designed to assess impact on health related quality of life. It is comprised of five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. The responses record three levels of severity (no problems/some or moderate problems/extreme problems) within a particular EQ-5D dimension. EQ-5D-3L assessment was only performed in participants \>= 16 years old as pre-specified in protocol. |
| Number of Participants According to Response to Each EQ-5D-3L 5 Dimensions at Month 24 | Month 24 | EQ-5D-3L is a participant completed questionnaire designed to assess impact on health related quality of life. It is comprised of five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. The responses record three levels of severity (no problems/some or moderate problems/extreme problems) within a particular EQ-5D dimension. EQ-5D-3L assessment was only performed in participants \>= 16 years old as pre-specified in protocol. |
| Number of Participants According to Response to Each EQ-5D-3L 5 Dimensions at Month 30 | Month 30 | EQ-5D-3L is a participant completed questionnaire designed to assess impact on health related quality of life. It is comprised of five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. The responses record three levels of severity (no problems/some or moderate problems/extreme problems) within a particular EQ-5D dimension. EQ-5D-3L assessment was only performed in participants \>= 16 years old as pre-specified in protocol. |
| Change From Baseline in EQ-5D-3L Visual Analogue Score (VAS) Assessment at Months 12, 24 and 30 | Baseline (Day 1) and Months 12, 24 and 30 | EQ-5D-3L is a participant completed questionnaire designed to assess impact on health related quality of life. EQ-VAS recorded the participant's self-rated health on a vertical scale ranging from 0 (worst imaginable health state) to 100 (best imaginable health state), where higher scores indicated better quality of life. EQ-VAS assessment was only performed in the participants \>= 16 years old. |
| Change From Baseline in EQ-5D-3L Index Score at Months 12, 24 and 30 | Baseline (Day 1) and Months 12, 24, and 30 | EQ-5D-3L index score, participants rated their current health state on 5 single-item dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression with each dimension having three levels of severity: 1=no problems, 2=some problems and 3=extreme problems. Scoring formula developed by EuroQol Group assigns a utility value for each domain in the profile. Score was transformed and results in a total index score range of 0 to 1.00. Higher scores indicating a better quality of life. EQ-5D-3L was only performed in participants \>= 16 years old. |
| Number of Participants According to Response to Each EuroQoL 5 Dimension Youth (EQ-5D-Y) 5 Dimensions at Month 12 | Month 12 | EQ-5D-Y is participant completed questionnaire designed to assess impact on health related quality of life in children and adolescents \<16 years old. It is comprised of five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 3 levels: 1=no problems, 2=some problems, and 3=extreme problems. |
| Number of Participants According to Response to Each EQ-5D-Y 5 Dimensions at Month 24 | Month 24 | EQ-5D-Y is participant completed questionnaire designed to assess impact on health related quality of life in children and adolescents \<16 years old. It is comprised of five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 3 levels: 1=no problems, 2=some problems, and 3=extreme problems. |
| Number of Participants According to Response to EQ-5D-Y 5 Dimensions at Month 30 | Month 30 | EQ-5D-Y is participant completed questionnaire designed to assess impact on health related quality of life in children and adolescents \<16 years old. It is comprised of five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 3 levels: 1=no problems, 2=some problems, and 3=extreme problems. |
| Change From Baseline in EQ-5D-Y VAS Assessment at Months 12, 24, and 30 | Baseline (Day 1) and Months 12, 24, and 30 | EQ-5D-Y is participant completed questionnaire designed to assess impact on health related quality of life in children and adolescents \<16 years old. EQ-VAS recorded the participant's self-rated health on a vertical scale ranging from 0 (worst imaginable health state) to 100 (best imaginable health state). |
| Change From Baseline in EQ-5D-Y Index Score at Months 12, 24, and 30 | Baseline (Day 1) and Months 12, 24, and 30 | EQ-5D-Y is participant completed questionnaire designed to assess impact on health related quality of life in children and adolescents \<=16 years old. It is comprised of five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 3 levels: 1=no problems, 2=some problems, and 3=extreme problems. Participants indicated their health state by choosing the appropriate level from each dimension. The 5 digit health states thus obtained for each dimension were then converted into a single median index value. A health state index score was calculated from individual health profiles using a USA scoring algorithm. Health state index scores generally ranged from -0.109 to 1, where, -0.109= the worst health status, 1= full health. Higher the score the better the better quality of life. |
| Change From Baseline in Healthcare Resource Utilization (HRU) Survey Responses: Visit to Primary Care Physician, Emergency Room and Office Visits at Months 12, 24, and 30 | Baseline (Day 1) and Months 12, 24, and 30 | HRU questionnaire is completed by the caregiver and had questions about healthcare resources utilization related to their child's use of healthcare professionals, emergency room visits, and hospitalizations in past 3 months. Change from baseline in mean number of visits to primary care physician, emergency room and office visits is presented in this outcome measure. |
| Change From Baseline in HRU Survey Responses: Number of Nights in Hospital Due to Disease/Medication for Disease at Months 12, 24, and 30 | Baseline (Day 1) and Months 12, 24, and 30 | HRU questionnaire is completed by the caregiver and had questions about healthcare resources utilization related to number of nights in hospital due to disease/dedication for disease in past 3 months. Change from baseline in mean number of nights in hospital due to disease or medication for disease is presented in this outcome measure. |
| Change From Baseline in Out-of-Pocket Money of HRU Survey at Months 12, 24 and 30 | Baseline (Day 1) and Months 12, 24, and 30 | Caregivers were asked to estimate out-of-pocket costs related to healthcare resource utilization. The number of out of pocket money was defined as the total spent of the past three months in managing child's Duchenne muscular dystrophy. |
| Change From Baseline in Percent Activity Impairment as Per Work Productivity and Activity Impairment Questionnaire Adapted for Caregiving (WPAI:CG) Caregiver Unchanged at Months 12, 24, and 30 | Baseline (Day 1) and Months 12, 24, and 30 | WPAI:CG is a self-reported measure of work productivity and impairment, was completed by caregiver, which had four scores: absenteeism (work time missed); presenteeism (impairment at work/reduced on the job effectiveness); work productivity loss (overall work impairment/absenteeism plus presenteeism); and activity impairment. Each score was expressed as a percentage (0-100%) with higher score indicating greater impairment and less productivity. |
| Change From Baseline in Percent Work Time Missed as Per WPAI: CG Caregiver Unchanged at Month 12 | Baseline (Day 1) and Month 12 | WPAI:CG is a self-reported measure of work productivity and impairment, was completed by caregiver, which had four scores: absenteeism (work time missed); presenteeism (impairment at work/reduced on the job effectiveness); work productivity loss (overall work impairment/absenteeism plus presenteeism); and activity impairment. Each score was expressed as a percentage (0-100%) with higher score indicating greater impairment and less productivity. |
| Change From Baseline in Percent Work Time Missed as Per WPAI: CG Caregiver Unchanged at Month 24 | Baseline (Day 1) and Month 24 | WPAI:CG is a self-reported measure of work productivity and impairment, was completed by caregiver, which had four scores: absenteeism (work time missed); presenteeism (impairment at work/reduced on the job effectiveness); work productivity loss (overall work impairment/absenteeism plus presenteeism); and activity impairment. Each score was expressed as a percentage (0-100%) with higher score indicating greater impairment and less productivity. |
| Change From Baseline in Percent Work Time Missed as Per WPAI: CG Caregiver Unchanged at Month 30 | Baseline (Day 1) and Month 30 | WPAI:CG is a self-reported measure of work productivity and impairment, was completed by caregiver, which had four scores: absenteeism (work time missed); presenteeism (impairment at work/reduced on the job effectiveness); work productivity loss (overall work impairment/absenteeism plus presenteeism); and activity impairment. Each score was expressed as a percentage (0-100%) with higher score indicating greater impairment and less productivity. |
| Change From Baseline in Percent Overall Work Impairment WPAI: CG Caregiver Unchanged at Months 12, 24, and 30 | Baseline (Day 1) and Months 12, 24, and 30 | WPAI:CG is a self-reported measure of work productivity and impairment, was completed by caregiver, which had four scores: absenteeism (work time missed); presenteeism (impairment at work/reduced on the job effectiveness); work productivity loss (overall work impairment/absenteeism plus presenteeism); and activity impairment. Each score was expressed as a percentage (0-100%) with higher score indicating greater impairment and less productivity. |
| Percent Activity Impairment Score as Per WPAI: CG at Months 12, 24, and 30 | Months 12, 24, and 30 | WPAI:CG is a self-reported measure of work productivity and impairment, was completed by caregiver, which had four scores: absenteeism (work time missed); presenteeism (impairment at work/reduced on the job effectiveness); work productivity loss (overall work impairment/absenteeism plus presenteeism); and activity impairment. Each score was expressed as a percentage (0-100%) with higher score indicating greater impairment and less productivity. |
| Percent Work Time Missed Score as Per WPAI: CG at Month 12 | Month 12 | WPAI:CG is a self-reported measure of work productivity and impairment, was completed by caregiver, which had four scores: absenteeism (work time missed); presenteeism (impairment at work/reduced on the job effectiveness); work productivity loss (overall work impairment/absenteeism plus presenteeism); and activity impairment. Each score was expressed as a percentage (0-100%) with higher score indicating greater impairment and less productivity. |
| Percent Work Time Missed Score as Per WPAI: CG at Month 24 | Month 24 | WPAI:CG is a self-reported measure of work productivity and impairment, was completed by caregiver, which had four scores: absenteeism (work time missed); presenteeism (impairment at work/reduced on the job effectiveness); work productivity loss (overall work impairment/absenteeism plus presenteeism); and activity impairment. Each score was expressed as a percentage (0-100%) with higher score indicating greater impairment and less productivity. |
| Percent Work Time Missed Score as Per WPAI: CG at Month 30 | Month 30 | WPAI:CG is a self-reported measure of work productivity and impairment, was completed by caregiver, which had four scores: absenteeism (work time missed); presenteeism (impairment at work/reduced on the job effectiveness); work productivity loss (overall work impairment/absenteeism plus presenteeism); and activity impairment. Each score was expressed as a percentage (0-100%) with higher score indicating greater impairment and less productivity. |
| Percent Overall Work Impairment Scores as Per WPAI: CG at Months 12, 24, and 30 | Months 12, 24, and 30 | WPAI:CG is a self-reported measure of work productivity and impairment, was completed by caregiver, which had four scores: absenteeism (work time missed); presenteeism (impairment at work/reduced on the job effectiveness); work productivity loss (overall work impairment/absenteeism plus presenteeism); and activity impairment. Each score was expressed as a percentage (0-100%) with higher score indicating greater impairment and less productivity. |
| Number of Participants With Type of DMD Mutation | Up to Month 30 | Number of participants as per type of mutation: exon deletion, exon duplication, point mutation, small insertion, small deletion and others is presented in this outcome measure. One participant could have more than 1 mutation type. |
Countries
China
Participant flow
Recruitment details
This was a multicenter, prospective study to describe natural history of Duchenne muscular dystrophy (DMD) in Chinese male participants.
Pre-assignment details
A total of 318 participants were screened of which 6 were screen failures and 312 participants were enrolled at 6 sites in China.
Participants by arm
| Arm | Count |
|---|---|
| Ambulatory Participants With Age <6 Years Participants diagnosed with DMD who were ambulant and were less than 6 years of age at the time of screening were included. No investigational drug was administered, and participants were allowed to take medications prescribed by their physicians, which constituted the standard of care (SOC). | 99 |
| Ambulatory Participants With Age >=6 Years Participants diagnosed with DMD who were ambulant and were greater than or equal to (\>=6) years of age at the time of screening were included. No investigational drug was administered, and participants were allowed to take medications prescribed by their physicians, which constituted the SOC. | 177 |
| Non-ambulatory Participants Participants diagnosed with DMD who were non-ambulatory (i.e., used wheel chair full-time or were unable to complete daily activities \[such as going to bathroom\] by walking independently, based on performance reported at home by participant or caregiver and verification by trained clinical evaluator \[CE\] with the inability to perform the 10-meter run/walk assessment) were included. No investigational drug was administered, and participants were allowed to take medications prescribed by their physicians, which constituted the SOC. | 36 |
| Total | 312 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 |
|---|---|---|---|---|
| Overall Study | Death | 1 | 0 | 0 |
| Overall Study | Lost to Follow-up | 0 | 2 | 1 |
| Overall Study | Other | 2 | 1 | 0 |
| Overall Study | Withdrawal by parent/guardian | 4 | 4 | 1 |
| Overall Study | Withdrawal by Subject | 1 | 4 | 1 |
Baseline characteristics
| Characteristic | Total | Ambulatory Participants With Age <6 Years | Ambulatory Participants With Age >=6 Years | Non-ambulatory Participants |
|---|---|---|---|---|
| Age, Continuous | 7.9 Years STANDARD_DEVIATION 3.43 | 4.0 Years STANDARD_DEVIATION 1.23 | 9.0 Years STANDARD_DEVIATION 1.99 | 12.7 Years STANDARD_DEVIATION 2.71 |
| Ethnicity (NIH/OMB) Hispanic or Latino | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 312 Participants | 99 Participants | 177 Participants | 36 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 312 Participants | 99 Participants | 177 Participants | 36 Participants |
| Race (NIH/OMB) Black or African American | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) White | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Sex: Female, Male Female | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Sex: Female, Male Male | 312 Participants | 99 Participants | 177 Participants | 36 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk |
|---|---|---|---|
| deaths Total, all-cause mortality | 1 / 99 | 0 / 177 | 0 / 36 |
| other Total, other adverse events | 84 / 99 | 136 / 177 | 20 / 36 |
| serious Total, serious adverse events | 0 / 99 | 0 / 177 | 0 / 36 |
Outcome results
Age of Participants When They Failed to Self-feed
Participant's age at life-altering clinical milestones- failure to self-feed during 30 months of this study was analyzed using the Kaplan-Meier method. Age was summarized in years.
Time frame: Up to Month 30
Population: Full Analysis Set included all participants who had been enrolled in the study. Here, 'Number of Participants Analyzed' signifies participants included in the Kaplan-Meier analysis. No participant in Ambulatory participants aged \<6 years and \>=6 years had an event of failure to self-feed.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Ambulatory Participants With Age <6 Years | Age of Participants When They Failed to Self-feed | NA Years |
| Ambulatory Participants With Age >=6 Years | Age of Participants When They Failed to Self-feed | NA Years |
| Total Ambulatory Participants | Age of Participants When They Failed to Self-feed | NA Years |
| Non-ambulatory Participants | Age of Participants When They Failed to Self-feed | 20.0 Years |
| Total Participants | Age of Participants When They Failed to Self-feed | 20.0 Years |
Age of Participants When They Failed to Stand
Participant's age at life-altering clinical milestones- failure to stand was calculated based on the birthdate and the date of failure to stand as reported by caregiver during 30 months of this study. Participants who were not reported being failure to stand by their caregivers were censored on the day of their last visit. Kaplan-Meier method was used for analysis.
Time frame: Up to Month 30
Population: Full Analysis Set included all participants who had been enrolled in the study. Here, 'Number of Participants Analyzed' signifies participants included in the Kaplan-Meier analysis. No participant in Ambulatory participants aged \<6 years had an event of failure to stand.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Ambulatory Participants With Age <6 Years | Age of Participants When They Failed to Stand | NA Years |
| Ambulatory Participants With Age >=6 Years | Age of Participants When They Failed to Stand | 14.4 Years |
| Total Ambulatory Participants | Age of Participants When They Failed to Stand | 14.4 Years |
| Non-ambulatory Participants | Age of Participants When They Failed to Stand | 11.0 Years |
| Total Participants | Age of Participants When They Failed to Stand | 13.1 Years |
Age of Participants When They Failed to Walk
Participant's age at life-altering clinical milestones- failure to walk was calculated based on the birthdate and the date of failure to walk as reported by caregiver during 30 months of this study. Participants who were not reported being failure to walk by their caregivers were censored on the day of their last visit. Kaplan-Meier method was used for analysis.
Time frame: Up to Month 30
Population: Full Analysis Set included all participants who had been enrolled in the study. Here, 'Number of Participants Analyzed' signifies participants included in the Kaplan-Meier analysis. No participant in Ambulatory participants aged \< 6 years had an event of failure to walk.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Ambulatory Participants With Age <6 Years | Age of Participants When They Failed to Walk | NA Years |
| Ambulatory Participants With Age >=6 Years | Age of Participants When They Failed to Walk | 14.4 Years |
| Total Ambulatory Participants | Age of Participants When They Failed to Walk | 14.4 Years |
| Non-ambulatory Participants | Age of Participants When They Failed to Walk | 11.1 Years |
| Total Participants | Age of Participants When They Failed to Walk | 13.1 Years |
Change From Baseline in 10 Meter Walk or Run Velocity at Month 12: Ambulatory Participants Aged >=3 Years
The 10 meter walk or run test was performed as part of NSAA. The 10 meter walk or run velocity was defined as the reciprocal of the time (in seconds) to complete the 10 meter run or walk test. The 10 meter walk or run test was performed in ambulatory children \>=3 years old only as pre-specified in the protocol.
Time frame: Baseline (Day 1) and Month 12
Population: Full Analysis Set included all participants who had been enrolled in the study. Here, Number of Participants Analyzed signifies participants evaluable for this outcome measure.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Ambulatory Participants With Age <6 Years | Change From Baseline in 10 Meter Walk or Run Velocity at Month 12: Ambulatory Participants Aged >=3 Years | 0.3 Meters per second | Standard Deviation 0.35 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in 10 Meter Walk or Run Velocity at Month 12: Ambulatory Participants Aged >=3 Years | -0.1 Meters per second | Standard Deviation 0.34 |
| Total Ambulatory Participants | Change From Baseline in 10 Meter Walk or Run Velocity at Month 12: Ambulatory Participants Aged >=3 Years | -0.0 Meters per second | Standard Deviation 0.4 |
Change From Baseline in 10 Meter Walk or Run Velocity at Month 18: Ambulatory Participants Aged >=3 Years
The 10 meter walk or run test was performed as part of NSAA. The 10 meter walk or run velocity was defined as the reciprocal of the time (in seconds) to complete the 10 meter run or walk test. The 10 meter walk or run test was performed in ambulatory children \>=3 years old only as pre-specified in the protocol.
Time frame: Baseline (Day 1) and Month 18
Population: Full Analysis Set included all participants who had been enrolled in the study. Here, Number of Participants Analyzed signifies participants evaluable for this outcome measure.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Ambulatory Participants With Age <6 Years | Change From Baseline in 10 Meter Walk or Run Velocity at Month 18: Ambulatory Participants Aged >=3 Years | 0.4 Meters per second | Standard Deviation 0.41 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in 10 Meter Walk or Run Velocity at Month 18: Ambulatory Participants Aged >=3 Years | -0.3 Meters per second | Standard Deviation 0.34 |
| Total Ambulatory Participants | Change From Baseline in 10 Meter Walk or Run Velocity at Month 18: Ambulatory Participants Aged >=3 Years | -0.0 Meters per second | Standard Deviation 0.5 |
Change From Baseline in 10 Meter Walk or Run Velocity at Month 24: Ambulatory Participants Aged >=3 Years
The 10 meter walk or run test was performed as part of NSAA. The 10 meter walk or run velocity was defined as the reciprocal of the time (in seconds) to complete the 10 meter run or walk test. The 10 meter walk or run test was performed in ambulatory children \>=3 years old only as pre-specified in the protocol.
Time frame: Baseline (Day 1) and Month 24
Population: Full Analysis Set included all participants who had been enrolled in the study. Here, Number of Participants Analyzed signifies participants evaluable for this outcome measure.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Ambulatory Participants With Age <6 Years | Change From Baseline in 10 Meter Walk or Run Velocity at Month 24: Ambulatory Participants Aged >=3 Years | 0.5 Meters per second | Standard Deviation 0.41 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in 10 Meter Walk or Run Velocity at Month 24: Ambulatory Participants Aged >=3 Years | -0.4 Meters per second | Standard Deviation 0.39 |
| Total Ambulatory Participants | Change From Baseline in 10 Meter Walk or Run Velocity at Month 24: Ambulatory Participants Aged >=3 Years | -0.1 Meters per second | Standard Deviation 0.56 |
Change From Baseline in 10 Meter Walk or Run Velocity at Month 30: Ambulatory Participants Aged >=3 Years
The 10 meter walk or run test was performed as part of NSAA. The 10 meter walk or run velocity was defined as the reciprocal of the time (in seconds) to complete the 10 meter run or walk test. The 10 meter walk or run test was performed in ambulatory children \>=3 years old only as pre-specified in the protocol.
Time frame: Baseline (Day 1) and Month 30
Population: Full Analysis Set included all participants who had been enrolled in the study. Here, Number of Participants Analyzed signifies participants evaluable for this outcome measure.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Ambulatory Participants With Age <6 Years | Change From Baseline in 10 Meter Walk or Run Velocity at Month 30: Ambulatory Participants Aged >=3 Years | 0.4 Meters per second | Standard Deviation 0.52 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in 10 Meter Walk or Run Velocity at Month 30: Ambulatory Participants Aged >=3 Years | -0.6 Meters per second | Standard Deviation 0.44 |
| Total Ambulatory Participants | Change From Baseline in 10 Meter Walk or Run Velocity at Month 30: Ambulatory Participants Aged >=3 Years | -0.3 Meters per second | Standard Deviation 0.62 |
Change From Baseline in 10 Meter Walk or Run Velocity at Month 6: Ambulatory Participants Aged >=3 Years
The 10 meter walk or run test was performed as part of NSAA. The 10 meter walk or run velocity was defined as the reciprocal of the time (in seconds) to complete the 10 meter run or walk test. The 10 meter walk or run test was performed in ambulatory children \>=3 years old only as pre-specified in the protocol.
Time frame: Baseline (Day 1) and Month 6
Population: Full Analysis Set included all participants who had been enrolled in the study. Here, Number of Participants Analyzed signifies participants evaluable for this outcome measure.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Ambulatory Participants With Age <6 Years | Change From Baseline in 10 Meter Walk or Run Velocity at Month 6: Ambulatory Participants Aged >=3 Years | 0.2 Meters per second | Standard Deviation 0.42 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in 10 Meter Walk or Run Velocity at Month 6: Ambulatory Participants Aged >=3 Years | -0.1 Meters per second | Standard Deviation 0.27 |
| Total Ambulatory Participants | Change From Baseline in 10 Meter Walk or Run Velocity at Month 6: Ambulatory Participants Aged >=3 Years | 0.0 Meters per second | Standard Deviation 0.35 |
Change From Baseline in Elbow Extension Muscle Strength at Month 12: Participants Aged >=5 Years
Muscle strength was recorded by handheld myometry. Left and right elbow extension were analyzed. The muscle strength test was only performed in participants \>=5 years old as pre-specified in protocol.
Time frame: Baseline (Day 1) and Month 12
Population: Full Analysis Set included all participants who had been enrolled in the study. Here, Number of Participants Analyzed signifies participants evaluable for this outcome measure.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Ambulatory Participants With Age <6 Years | Change From Baseline in Elbow Extension Muscle Strength at Month 12: Participants Aged >=5 Years | Left Elbow Extension | 0.2 Kilograms | Standard Deviation 0.74 |
| Ambulatory Participants With Age <6 Years | Change From Baseline in Elbow Extension Muscle Strength at Month 12: Participants Aged >=5 Years | Right Elbow Extension | 0.4 Kilograms | Standard Deviation 0.88 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in Elbow Extension Muscle Strength at Month 12: Participants Aged >=5 Years | Left Elbow Extension | 0.2 Kilograms | Standard Deviation 0.87 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in Elbow Extension Muscle Strength at Month 12: Participants Aged >=5 Years | Right Elbow Extension | 0.3 Kilograms | Standard Deviation 0.97 |
| Total Ambulatory Participants | Change From Baseline in Elbow Extension Muscle Strength at Month 12: Participants Aged >=5 Years | Left Elbow Extension | 0.2 Kilograms | Standard Deviation 0.85 |
| Total Ambulatory Participants | Change From Baseline in Elbow Extension Muscle Strength at Month 12: Participants Aged >=5 Years | Right Elbow Extension | 0.3 Kilograms | Standard Deviation 0.96 |
| Non-ambulatory Participants | Change From Baseline in Elbow Extension Muscle Strength at Month 12: Participants Aged >=5 Years | Right Elbow Extension | 0.2 Kilograms | Standard Deviation 0.76 |
| Non-ambulatory Participants | Change From Baseline in Elbow Extension Muscle Strength at Month 12: Participants Aged >=5 Years | Left Elbow Extension | 0.0 Kilograms | Standard Deviation 0.68 |
| Total Participants | Change From Baseline in Elbow Extension Muscle Strength at Month 12: Participants Aged >=5 Years | Left Elbow Extension | 0.2 Kilograms | Standard Deviation 0.83 |
| Total Participants | Change From Baseline in Elbow Extension Muscle Strength at Month 12: Participants Aged >=5 Years | Right Elbow Extension | 0.3 Kilograms | Standard Deviation 0.93 |
Change From Baseline in Elbow Extension Muscle Strength at Month 18: Participants Aged >=5 Years
Muscle strength was recorded by handheld myometry. Left and right elbow extension were analyzed. The muscle strength test was only performed in participants \>=5 years old as pre-specified in protocol.
Time frame: Baseline (Day 1) and Month 18
Population: Full Analysis Set included all participants who had been enrolled in the study. Here, Number of Participants Analyzed signifies participants evaluable for this outcome measure.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Ambulatory Participants With Age <6 Years | Change From Baseline in Elbow Extension Muscle Strength at Month 18: Participants Aged >=5 Years | Left Elbow Extension | 0.6 Kilograms | Standard Deviation 0.8 |
| Ambulatory Participants With Age <6 Years | Change From Baseline in Elbow Extension Muscle Strength at Month 18: Participants Aged >=5 Years | Right Elbow Extension | -0.0 Kilograms | Standard Deviation 0.84 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in Elbow Extension Muscle Strength at Month 18: Participants Aged >=5 Years | Left Elbow Extension | 0.2 Kilograms | Standard Deviation 1 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in Elbow Extension Muscle Strength at Month 18: Participants Aged >=5 Years | Right Elbow Extension | 0.2 Kilograms | Standard Deviation 1.09 |
| Total Ambulatory Participants | Change From Baseline in Elbow Extension Muscle Strength at Month 18: Participants Aged >=5 Years | Left Elbow Extension | 0.2 Kilograms | Standard Deviation 0.99 |
| Total Ambulatory Participants | Change From Baseline in Elbow Extension Muscle Strength at Month 18: Participants Aged >=5 Years | Right Elbow Extension | 0.2 Kilograms | Standard Deviation 1.06 |
| Non-ambulatory Participants | Change From Baseline in Elbow Extension Muscle Strength at Month 18: Participants Aged >=5 Years | Right Elbow Extension | -0.2 Kilograms | Standard Deviation 0.13 |
| Non-ambulatory Participants | Change From Baseline in Elbow Extension Muscle Strength at Month 18: Participants Aged >=5 Years | Left Elbow Extension | -0.4 Kilograms | Standard Deviation 0.73 |
| Total Participants | Change From Baseline in Elbow Extension Muscle Strength at Month 18: Participants Aged >=5 Years | Left Elbow Extension | 0.2 Kilograms | Standard Deviation 0.98 |
| Total Participants | Change From Baseline in Elbow Extension Muscle Strength at Month 18: Participants Aged >=5 Years | Right Elbow Extension | 0.2 Kilograms | Standard Deviation 1.04 |
Change From Baseline in Elbow Extension Muscle Strength at Month 24: Participants Aged >=5 Years
Muscle strength was recorded by handheld myometry. Left and right elbow extension were analyzed. The muscle strength test was only performed in participants \>=5 years old as pre-specified in protocol.
Time frame: Baseline (Day 1) and Month 24
Population: Full Analysis Set included all participants who had been enrolled in the study. Here, Number of Participants Analyzed signifies participants evaluable for this outcome measure.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Ambulatory Participants With Age <6 Years | Change From Baseline in Elbow Extension Muscle Strength at Month 24: Participants Aged >=5 Years | Left Elbow Extension | 1.1 Kilograms | Standard Deviation 1.14 |
| Ambulatory Participants With Age <6 Years | Change From Baseline in Elbow Extension Muscle Strength at Month 24: Participants Aged >=5 Years | Right Elbow Extension | 0.7 Kilograms | Standard Deviation 1.29 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in Elbow Extension Muscle Strength at Month 24: Participants Aged >=5 Years | Left Elbow Extension | 0.1 Kilograms | Standard Deviation 1.03 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in Elbow Extension Muscle Strength at Month 24: Participants Aged >=5 Years | Right Elbow Extension | 0.0 Kilograms | Standard Deviation 1.09 |
| Total Ambulatory Participants | Change From Baseline in Elbow Extension Muscle Strength at Month 24: Participants Aged >=5 Years | Left Elbow Extension | 0.3 Kilograms | Standard Deviation 1.08 |
| Total Ambulatory Participants | Change From Baseline in Elbow Extension Muscle Strength at Month 24: Participants Aged >=5 Years | Right Elbow Extension | 0.1 Kilograms | Standard Deviation 1.13 |
| Non-ambulatory Participants | Change From Baseline in Elbow Extension Muscle Strength at Month 24: Participants Aged >=5 Years | Right Elbow Extension | 0.3 Kilograms | Standard Deviation 0.96 |
| Non-ambulatory Participants | Change From Baseline in Elbow Extension Muscle Strength at Month 24: Participants Aged >=5 Years | Left Elbow Extension | -0.1 Kilograms | Standard Deviation 0.73 |
| Total Participants | Change From Baseline in Elbow Extension Muscle Strength at Month 24: Participants Aged >=5 Years | Left Elbow Extension | 0.2 Kilograms | Standard Deviation 1.05 |
| Total Participants | Change From Baseline in Elbow Extension Muscle Strength at Month 24: Participants Aged >=5 Years | Right Elbow Extension | 0.1 Kilograms | Standard Deviation 1.11 |
Change From Baseline in Elbow Extension Muscle Strength at Month 30: Participants Aged >=5 Years
Muscle strength was recorded by handheld myometry. Left and right elbow extension were analyzed. The muscle strength test was only performed in participants \>=5 years old as pre-specified in protocol.
Time frame: Baseline (Day 1) and Month 30
Population: Full Analysis Set included all participants who had been enrolled in the study. Here, Number of Participants Analyzed signifies participants evaluable for this outcome measure.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Ambulatory Participants With Age <6 Years | Change From Baseline in Elbow Extension Muscle Strength at Month 30: Participants Aged >=5 Years | Left Elbow Extension | 0.8 Kilograms | Standard Deviation 1.55 |
| Ambulatory Participants With Age <6 Years | Change From Baseline in Elbow Extension Muscle Strength at Month 30: Participants Aged >=5 Years | Right Elbow Extension | -0.9 Kilograms | Standard Deviation 0.72 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in Elbow Extension Muscle Strength at Month 30: Participants Aged >=5 Years | Left Elbow Extension | 0.2 Kilograms | Standard Deviation 1.3 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in Elbow Extension Muscle Strength at Month 30: Participants Aged >=5 Years | Right Elbow Extension | 0.3 Kilograms | Standard Deviation 1.37 |
| Total Ambulatory Participants | Change From Baseline in Elbow Extension Muscle Strength at Month 30: Participants Aged >=5 Years | Left Elbow Extension | 0.3 Kilograms | Standard Deviation 1.32 |
| Total Ambulatory Participants | Change From Baseline in Elbow Extension Muscle Strength at Month 30: Participants Aged >=5 Years | Right Elbow Extension | 0.2 Kilograms | Standard Deviation 1.36 |
| Non-ambulatory Participants | Change From Baseline in Elbow Extension Muscle Strength at Month 30: Participants Aged >=5 Years | Right Elbow Extension | -0.0 Kilograms | Standard Deviation 0.37 |
| Non-ambulatory Participants | Change From Baseline in Elbow Extension Muscle Strength at Month 30: Participants Aged >=5 Years | Left Elbow Extension | -0.3 Kilograms | Standard Deviation 0.79 |
| Total Participants | Change From Baseline in Elbow Extension Muscle Strength at Month 30: Participants Aged >=5 Years | Left Elbow Extension | 0.3 Kilograms | Standard Deviation 1.3 |
| Total Participants | Change From Baseline in Elbow Extension Muscle Strength at Month 30: Participants Aged >=5 Years | Right Elbow Extension | 0.2 Kilograms | Standard Deviation 1.33 |
Change From Baseline in Elbow Extension of Muscle Strength at Month 6: Participants Aged >=5 Years
Muscle strength was recorded by handheld myometry. Left and right elbow extension were analyzed. The muscle strength test was only performed in participants \>=5 years old as pre-specified in protocol.
Time frame: Baseline (Day 1) and Month 6
Population: Full Analysis Set included all participants who had been enrolled in the study. Here, Number of Participants Analyzed signifies participants evaluable for this outcome measure.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Ambulatory Participants With Age <6 Years | Change From Baseline in Elbow Extension of Muscle Strength at Month 6: Participants Aged >=5 Years | Left Elbow Extension | 0.4 Kilograms | Standard Deviation 0.85 |
| Ambulatory Participants With Age <6 Years | Change From Baseline in Elbow Extension of Muscle Strength at Month 6: Participants Aged >=5 Years | Right Elbow Extension | 0.3 Kilograms | Standard Deviation 1.22 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in Elbow Extension of Muscle Strength at Month 6: Participants Aged >=5 Years | Left Elbow Extension | 0.2 Kilograms | Standard Deviation 0.78 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in Elbow Extension of Muscle Strength at Month 6: Participants Aged >=5 Years | Right Elbow Extension | 0.3 Kilograms | Standard Deviation 0.87 |
| Total Ambulatory Participants | Change From Baseline in Elbow Extension of Muscle Strength at Month 6: Participants Aged >=5 Years | Left Elbow Extension | 0.2 Kilograms | Standard Deviation 0.79 |
| Total Ambulatory Participants | Change From Baseline in Elbow Extension of Muscle Strength at Month 6: Participants Aged >=5 Years | Right Elbow Extension | 0.3 Kilograms | Standard Deviation 0.92 |
| Non-ambulatory Participants | Change From Baseline in Elbow Extension of Muscle Strength at Month 6: Participants Aged >=5 Years | Right Elbow Extension | 0.1 Kilograms | Standard Deviation 0.26 |
| Non-ambulatory Participants | Change From Baseline in Elbow Extension of Muscle Strength at Month 6: Participants Aged >=5 Years | Left Elbow Extension | 0.1 Kilograms | Standard Deviation 0.21 |
| Total Participants | Change From Baseline in Elbow Extension of Muscle Strength at Month 6: Participants Aged >=5 Years | Left Elbow Extension | 0.2 Kilograms | Standard Deviation 0.78 |
| Total Participants | Change From Baseline in Elbow Extension of Muscle Strength at Month 6: Participants Aged >=5 Years | Right Elbow Extension | 0.3 Kilograms | Standard Deviation 0.91 |
Change From Baseline in Elbow Flexion of Muscle Strength at Month 12: Participants Aged >=5 Years
Muscle strength was recorded by handheld myometry. Left and right elbow flexion were analyzed. The muscle strength test was only performed in participants \>=5 years old as pre-specified in the protocol.
Time frame: Baseline (Day 1) and Month 12
Population: Full Analysis Set included all participants who had been enrolled in the study. Here, Number of Participants Analyzed signifies participants evaluable for this outcome measure. 'Number Analyzed' signifies participants evaluable for specified rows.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Ambulatory Participants With Age <6 Years | Change From Baseline in Elbow Flexion of Muscle Strength at Month 12: Participants Aged >=5 Years | Left Elbow Flexion | 0.5 Kilograms | Standard Deviation 0.97 |
| Ambulatory Participants With Age <6 Years | Change From Baseline in Elbow Flexion of Muscle Strength at Month 12: Participants Aged >=5 Years | Right Elbow Flexion | 0.5 Kilograms | Standard Deviation 0.79 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in Elbow Flexion of Muscle Strength at Month 12: Participants Aged >=5 Years | Left Elbow Flexion | 0.1 Kilograms | Standard Deviation 1.02 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in Elbow Flexion of Muscle Strength at Month 12: Participants Aged >=5 Years | Right Elbow Flexion | 0.2 Kilograms | Standard Deviation 1.07 |
| Total Ambulatory Participants | Change From Baseline in Elbow Flexion of Muscle Strength at Month 12: Participants Aged >=5 Years | Left Elbow Flexion | 0.2 Kilograms | Standard Deviation 1.02 |
| Total Ambulatory Participants | Change From Baseline in Elbow Flexion of Muscle Strength at Month 12: Participants Aged >=5 Years | Right Elbow Flexion | 0.3 Kilograms | Standard Deviation 1.05 |
| Non-ambulatory Participants | Change From Baseline in Elbow Flexion of Muscle Strength at Month 12: Participants Aged >=5 Years | Right Elbow Flexion | -0.1 Kilograms | Standard Deviation 0.89 |
| Non-ambulatory Participants | Change From Baseline in Elbow Flexion of Muscle Strength at Month 12: Participants Aged >=5 Years | Left Elbow Flexion | 0.1 Kilograms | Standard Deviation 1.12 |
| Total Participants | Change From Baseline in Elbow Flexion of Muscle Strength at Month 12: Participants Aged >=5 Years | Left Elbow Flexion | 0.1 Kilograms | Standard Deviation 1.03 |
| Total Participants | Change From Baseline in Elbow Flexion of Muscle Strength at Month 12: Participants Aged >=5 Years | Right Elbow Flexion | 0.2 Kilograms | Standard Deviation 1.03 |
Change From Baseline in Elbow Flexion of Muscle Strength at Month 18: Participants Aged >=5 Years
Muscle strength was recorded by handheld myometry. Left and right elbow flexion were analyzed. The muscle strength test was only performed in participants \>=5 years old as pre-specified in the protocol.
Time frame: Baseline (Day 1) and Month 18
Population: Full Analysis Set included all participants who had been enrolled in the study. Here, Number of Participants Analyzed signifies participants evaluable for this outcome measure. 'Number Analyzed' signifies participants evaluable for specified rows.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Ambulatory Participants With Age <6 Years | Change From Baseline in Elbow Flexion of Muscle Strength at Month 18: Participants Aged >=5 Years | Left Elbow Flexion | 0.7 Kilograms | Standard Deviation 0.8 |
| Ambulatory Participants With Age <6 Years | Change From Baseline in Elbow Flexion of Muscle Strength at Month 18: Participants Aged >=5 Years | Right Elbow Flexion | 0.5 Kilograms | Standard Deviation 0.85 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in Elbow Flexion of Muscle Strength at Month 18: Participants Aged >=5 Years | Left Elbow Flexion | 0.2 Kilograms | Standard Deviation 1.14 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in Elbow Flexion of Muscle Strength at Month 18: Participants Aged >=5 Years | Right Elbow Flexion | 0.2 Kilograms | Standard Deviation 1.16 |
| Total Ambulatory Participants | Change From Baseline in Elbow Flexion of Muscle Strength at Month 18: Participants Aged >=5 Years | Left Elbow Flexion | 0.2 Kilograms | Standard Deviation 1.11 |
| Total Ambulatory Participants | Change From Baseline in Elbow Flexion of Muscle Strength at Month 18: Participants Aged >=5 Years | Right Elbow Flexion | 0.3 Kilograms | Standard Deviation 1.12 |
| Non-ambulatory Participants | Change From Baseline in Elbow Flexion of Muscle Strength at Month 18: Participants Aged >=5 Years | Right Elbow Flexion | -0.9 Kilograms | Standard Deviation 1.35 |
| Non-ambulatory Participants | Change From Baseline in Elbow Flexion of Muscle Strength at Month 18: Participants Aged >=5 Years | Left Elbow Flexion | -1.0 Kilograms | Standard Deviation 0.83 |
| Total Participants | Change From Baseline in Elbow Flexion of Muscle Strength at Month 18: Participants Aged >=5 Years | Left Elbow Flexion | 0.2 Kilograms | Standard Deviation 1.12 |
| Total Participants | Change From Baseline in Elbow Flexion of Muscle Strength at Month 18: Participants Aged >=5 Years | Right Elbow Flexion | 0.2 Kilograms | Standard Deviation 1.13 |
Change From Baseline in Elbow Flexion of Muscle Strength at Month 24: Participants Aged >=5 Years
Muscle strength was recorded by handheld myometry. Left and right elbow flexion were analyzed. The muscle strength test was only performed in participants \>=5 years old as pre-specified in the protocol.
Time frame: Baseline (Day 1) and Month 24
Population: Full Analysis Set included all participants who had been enrolled in the study. Here, Number of Participants Analyzed signifies participants evaluable for this outcome measure.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Ambulatory Participants With Age <6 Years | Change From Baseline in Elbow Flexion of Muscle Strength at Month 24: Participants Aged >=5 Years | Left Elbow Flexion | 0.8 Kilograms | Standard Deviation 0.89 |
| Ambulatory Participants With Age <6 Years | Change From Baseline in Elbow Flexion of Muscle Strength at Month 24: Participants Aged >=5 Years | Right Elbow Flexion | 0.9 Kilograms | Standard Deviation 0.81 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in Elbow Flexion of Muscle Strength at Month 24: Participants Aged >=5 Years | Left Elbow Flexion | 0.0 Kilograms | Standard Deviation 1.18 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in Elbow Flexion of Muscle Strength at Month 24: Participants Aged >=5 Years | Right Elbow Flexion | 0.1 Kilograms | Standard Deviation 1.16 |
| Total Ambulatory Participants | Change From Baseline in Elbow Flexion of Muscle Strength at Month 24: Participants Aged >=5 Years | Left Elbow Flexion | 0.1 Kilograms | Standard Deviation 1.17 |
| Total Ambulatory Participants | Change From Baseline in Elbow Flexion of Muscle Strength at Month 24: Participants Aged >=5 Years | Right Elbow Flexion | 0.2 Kilograms | Standard Deviation 1.15 |
| Non-ambulatory Participants | Change From Baseline in Elbow Flexion of Muscle Strength at Month 24: Participants Aged >=5 Years | Right Elbow Flexion | -0.3 Kilograms | Standard Deviation 1.15 |
| Non-ambulatory Participants | Change From Baseline in Elbow Flexion of Muscle Strength at Month 24: Participants Aged >=5 Years | Left Elbow Flexion | -0.0 Kilograms | Standard Deviation 0.92 |
| Total Participants | Change From Baseline in Elbow Flexion of Muscle Strength at Month 24: Participants Aged >=5 Years | Left Elbow Flexion | 0.1 Kilograms | Standard Deviation 1.14 |
| Total Participants | Change From Baseline in Elbow Flexion of Muscle Strength at Month 24: Participants Aged >=5 Years | Right Elbow Flexion | 0.1 Kilograms | Standard Deviation 1.16 |
Change From Baseline in Elbow Flexion of Muscle Strength at Month 30: Participants Aged >=5 Years
Muscle strength was recorded by handheld myometry. Left and right elbow flexion were analyzed. The muscle strength test was only performed in participants \>=5 years old as pre-specified in the protocol.
Time frame: Baseline (Day 1) and Month 30
Population: Full Analysis Set included all participants who had been enrolled in the study. Here, Number of Participants Analyzed signifies participants evaluable for this outcome measure.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Ambulatory Participants With Age <6 Years | Change From Baseline in Elbow Flexion of Muscle Strength at Month 30: Participants Aged >=5 Years | Left Elbow Flexion | 0.8 Kilograms | Standard Deviation 0.72 |
| Ambulatory Participants With Age <6 Years | Change From Baseline in Elbow Flexion of Muscle Strength at Month 30: Participants Aged >=5 Years | Right Elbow Flexion | 0.4 Kilograms | Standard Deviation 0.7 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in Elbow Flexion of Muscle Strength at Month 30: Participants Aged >=5 Years | Left Elbow Flexion | 0.2 Kilograms | Standard Deviation 1.58 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in Elbow Flexion of Muscle Strength at Month 30: Participants Aged >=5 Years | Right Elbow Flexion | 0.4 Kilograms | Standard Deviation 1.56 |
| Total Ambulatory Participants | Change From Baseline in Elbow Flexion of Muscle Strength at Month 30: Participants Aged >=5 Years | Left Elbow Flexion | 0.2 Kilograms | Standard Deviation 1.53 |
| Total Ambulatory Participants | Change From Baseline in Elbow Flexion of Muscle Strength at Month 30: Participants Aged >=5 Years | Right Elbow Flexion | 0.4 Kilograms | Standard Deviation 1.5 |
| Non-ambulatory Participants | Change From Baseline in Elbow Flexion of Muscle Strength at Month 30: Participants Aged >=5 Years | Right Elbow Flexion | -0.0 Kilograms | Standard Deviation 0.68 |
| Non-ambulatory Participants | Change From Baseline in Elbow Flexion of Muscle Strength at Month 30: Participants Aged >=5 Years | Left Elbow Flexion | -0.0 Kilograms | Standard Deviation 0.83 |
| Total Participants | Change From Baseline in Elbow Flexion of Muscle Strength at Month 30: Participants Aged >=5 Years | Left Elbow Flexion | 0.2 Kilograms | Standard Deviation 1.51 |
| Total Participants | Change From Baseline in Elbow Flexion of Muscle Strength at Month 30: Participants Aged >=5 Years | Right Elbow Flexion | 0.4 Kilograms | Standard Deviation 1.47 |
Change From Baseline in Elbow Flexion of Muscle Strength at Month 6: Participants Aged >=5 Years
Muscle strength was recorded by handheld myometry. Left and right elbow flexion were analyzed. The muscle strength test was only performed in participants \>=5 years old as pre-specified in the protocol.
Time frame: Baseline (Day 1) and Month 6
Population: Full Analysis Set included all participants who had been enrolled in the study. Here, Number of Participants Analyzed signifies participants evaluable for this outcome measure. 'Number Analyzed' signifies participants evaluable for specified rows.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Ambulatory Participants With Age <6 Years | Change From Baseline in Elbow Flexion of Muscle Strength at Month 6: Participants Aged >=5 Years | Left Elbow Flexion | 0.3 Kilograms | Standard Deviation 0.85 |
| Ambulatory Participants With Age <6 Years | Change From Baseline in Elbow Flexion of Muscle Strength at Month 6: Participants Aged >=5 Years | Right Elbow Flexion | 0.4 Kilograms | Standard Deviation 0.81 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in Elbow Flexion of Muscle Strength at Month 6: Participants Aged >=5 Years | Left Elbow Flexion | 0.3 Kilograms | Standard Deviation 0.93 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in Elbow Flexion of Muscle Strength at Month 6: Participants Aged >=5 Years | Right Elbow Flexion | 0.3 Kilograms | Standard Deviation 0.93 |
| Total Ambulatory Participants | Change From Baseline in Elbow Flexion of Muscle Strength at Month 6: Participants Aged >=5 Years | Left Elbow Flexion | 0.3 Kilograms | Standard Deviation 0.92 |
| Total Ambulatory Participants | Change From Baseline in Elbow Flexion of Muscle Strength at Month 6: Participants Aged >=5 Years | Right Elbow Flexion | 0.3 Kilograms | Standard Deviation 0.91 |
| Non-ambulatory Participants | Change From Baseline in Elbow Flexion of Muscle Strength at Month 6: Participants Aged >=5 Years | Right Elbow Flexion | -0.3 Kilograms | Standard Deviation 0.25 |
| Non-ambulatory Participants | Change From Baseline in Elbow Flexion of Muscle Strength at Month 6: Participants Aged >=5 Years | Left Elbow Flexion | -0.4 Kilograms | Standard Deviation 0.3 |
| Total Participants | Change From Baseline in Elbow Flexion of Muscle Strength at Month 6: Participants Aged >=5 Years | Left Elbow Flexion | 0.3 Kilograms | Standard Deviation 0.92 |
| Total Participants | Change From Baseline in Elbow Flexion of Muscle Strength at Month 6: Participants Aged >=5 Years | Right Elbow Flexion | 0.3 Kilograms | Standard Deviation 0.91 |
Change From Baseline in Knee Extension of Muscle Strength at Month 12: Participants Aged >=5 Years
Muscle strength was recorded by handheld myometry. Left and right knee extension was analyzed. The muscle strength test was only performed in participants \>=5 years old as pre-specified in protocol.
Time frame: Baseline (Day 1) and Month 12
Population: Full Analysis Set included all participants who had been enrolled in the study. Here, Number of Participants Analyzed signifies participants evaluable for this outcome measure.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Ambulatory Participants With Age <6 Years | Change From Baseline in Knee Extension of Muscle Strength at Month 12: Participants Aged >=5 Years | Left Knee Extension | -0.1 Kilograms | Standard Deviation 1.25 |
| Ambulatory Participants With Age <6 Years | Change From Baseline in Knee Extension of Muscle Strength at Month 12: Participants Aged >=5 Years | Right Knee Extension | 0.1 Kilograms | Standard Deviation 1.5 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in Knee Extension of Muscle Strength at Month 12: Participants Aged >=5 Years | Left Knee Extension | -0.1 Kilograms | Standard Deviation 1.85 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in Knee Extension of Muscle Strength at Month 12: Participants Aged >=5 Years | Right Knee Extension | -0.4 Kilograms | Standard Deviation 1.87 |
| Total Ambulatory Participants | Change From Baseline in Knee Extension of Muscle Strength at Month 12: Participants Aged >=5 Years | Left Knee Extension | -0.1 Kilograms | Standard Deviation 1.8 |
| Total Ambulatory Participants | Change From Baseline in Knee Extension of Muscle Strength at Month 12: Participants Aged >=5 Years | Right Knee Extension | -0.4 Kilograms | Standard Deviation 1.84 |
| Non-ambulatory Participants | Change From Baseline in Knee Extension of Muscle Strength at Month 12: Participants Aged >=5 Years | Right Knee Extension | -0.3 Kilograms | Standard Deviation 1.1 |
| Non-ambulatory Participants | Change From Baseline in Knee Extension of Muscle Strength at Month 12: Participants Aged >=5 Years | Left Knee Extension | -0.3 Kilograms | Standard Deviation 1.31 |
| Total Participants | Change From Baseline in Knee Extension of Muscle Strength at Month 12: Participants Aged >=5 Years | Left Knee Extension | -0.1 Kilograms | Standard Deviation 1.74 |
| Total Participants | Change From Baseline in Knee Extension of Muscle Strength at Month 12: Participants Aged >=5 Years | Right Knee Extension | -0.4 Kilograms | Standard Deviation 1.75 |
Change From Baseline in Knee Extension of Muscle Strength at Month 18: Participants Aged >=5 Years
Muscle strength was recorded by handheld myometry. Left and right knee extension was analyzed. The muscle strength test was only performed in participants \>=5 years old as pre-specified in protocol.
Time frame: Baseline (Day 1) and Month 18
Population: Full Analysis Set included all participants who had been enrolled in the study. Here, Number of Participants Analyzed signifies participants evaluable for this outcome measure.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Ambulatory Participants With Age <6 Years | Change From Baseline in Knee Extension of Muscle Strength at Month 18: Participants Aged >=5 Years | Left Knee Extension | 0.7 Kilograms | Standard Deviation 1.69 |
| Ambulatory Participants With Age <6 Years | Change From Baseline in Knee Extension of Muscle Strength at Month 18: Participants Aged >=5 Years | Right Knee Extension | 0.5 Kilograms | Standard Deviation 1.96 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in Knee Extension of Muscle Strength at Month 18: Participants Aged >=5 Years | Left Knee Extension | -0.4 Kilograms | Standard Deviation 1.95 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in Knee Extension of Muscle Strength at Month 18: Participants Aged >=5 Years | Right Knee Extension | -0.7 Kilograms | Standard Deviation 2.29 |
| Total Ambulatory Participants | Change From Baseline in Knee Extension of Muscle Strength at Month 18: Participants Aged >=5 Years | Left Knee Extension | -0.3 Kilograms | Standard Deviation 1.95 |
| Total Ambulatory Participants | Change From Baseline in Knee Extension of Muscle Strength at Month 18: Participants Aged >=5 Years | Right Knee Extension | -0.6 Kilograms | Standard Deviation 2.28 |
| Non-ambulatory Participants | Change From Baseline in Knee Extension of Muscle Strength at Month 18: Participants Aged >=5 Years | Right Knee Extension | -0.8 Kilograms | Standard Deviation 0.42 |
| Non-ambulatory Participants | Change From Baseline in Knee Extension of Muscle Strength at Month 18: Participants Aged >=5 Years | Left Knee Extension | -0.7 Kilograms | Standard Deviation 1.05 |
| Total Participants | Change From Baseline in Knee Extension of Muscle Strength at Month 18: Participants Aged >=5 Years | Left Knee Extension | -0.3 Kilograms | Standard Deviation 1.93 |
| Total Participants | Change From Baseline in Knee Extension of Muscle Strength at Month 18: Participants Aged >=5 Years | Right Knee Extension | -0.6 Kilograms | Standard Deviation 2.25 |
Change From Baseline in Knee Extension of Muscle Strength at Month 24: Participants Aged >=5 Years
Muscle strength was recorded by handheld myometry. Left and right knee extension was analyzed. The muscle strength test was only performed in participants \>=5 years old as pre-specified in protocol.
Time frame: Baseline (Day 1) and Month 24
Population: Full Analysis Set included all participants who had been enrolled in the study. Here, Number of Participants Analyzed signifies participants evaluable for this outcome measure.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Ambulatory Participants With Age <6 Years | Change From Baseline in Knee Extension of Muscle Strength at Month 24: Participants Aged >=5 Years | Left Knee Extension | -0.4 Kilograms | Standard Deviation 2.37 |
| Ambulatory Participants With Age <6 Years | Change From Baseline in Knee Extension of Muscle Strength at Month 24: Participants Aged >=5 Years | Right Knee Extension | 0.0 Kilograms | Standard Deviation 2.77 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in Knee Extension of Muscle Strength at Month 24: Participants Aged >=5 Years | Left Knee Extension | -0.6 Kilograms | Standard Deviation 1.95 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in Knee Extension of Muscle Strength at Month 24: Participants Aged >=5 Years | Right Knee Extension | -1.0 Kilograms | Standard Deviation 2.13 |
| Total Ambulatory Participants | Change From Baseline in Knee Extension of Muscle Strength at Month 24: Participants Aged >=5 Years | Left Knee Extension | -0.6 Kilograms | Standard Deviation 2 |
| Total Ambulatory Participants | Change From Baseline in Knee Extension of Muscle Strength at Month 24: Participants Aged >=5 Years | Right Knee Extension | -0.9 Kilograms | Standard Deviation 2.23 |
| Non-ambulatory Participants | Change From Baseline in Knee Extension of Muscle Strength at Month 24: Participants Aged >=5 Years | Right Knee Extension | -0.7 Kilograms | Standard Deviation 1.62 |
| Non-ambulatory Participants | Change From Baseline in Knee Extension of Muscle Strength at Month 24: Participants Aged >=5 Years | Left Knee Extension | -0.5 Kilograms | Standard Deviation 1.64 |
| Total Participants | Change From Baseline in Knee Extension of Muscle Strength at Month 24: Participants Aged >=5 Years | Left Knee Extension | -0.6 Kilograms | Standard Deviation 1.95 |
| Total Participants | Change From Baseline in Knee Extension of Muscle Strength at Month 24: Participants Aged >=5 Years | Right Knee Extension | -0.8 Kilograms | Standard Deviation 2.16 |
Change From Baseline in Knee Extension of Muscle Strength at Month 30: Participants Aged >=5 Years
Muscle strength was recorded by handheld myometry. Left and right knee extension was analyzed. The muscle strength test was only performed in participants \>=5 years old as pre-specified in protocol.
Time frame: Baseline (Day 1) and Month 30
Population: Full Analysis Set included all participants who had been enrolled in the study. Here, Number of Participants Analyzed signifies participants evaluable for this outcome measure.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Ambulatory Participants With Age <6 Years | Change From Baseline in Knee Extension of Muscle Strength at Month 30: Participants Aged >=5 Years | Left Knee Extension | -0.9 Kilograms | Standard Deviation 2.12 |
| Ambulatory Participants With Age <6 Years | Change From Baseline in Knee Extension of Muscle Strength at Month 30: Participants Aged >=5 Years | Right Knee Extension | -2.3 Kilograms | Standard Deviation 2.89 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in Knee Extension of Muscle Strength at Month 30: Participants Aged >=5 Years | Left Knee Extension | -0.7 Kilograms | Standard Deviation 2.66 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in Knee Extension of Muscle Strength at Month 30: Participants Aged >=5 Years | Right Knee Extension | -1.4 Kilograms | Standard Deviation 2.76 |
| Total Ambulatory Participants | Change From Baseline in Knee Extension of Muscle Strength at Month 30: Participants Aged >=5 Years | Left Knee Extension | -0.7 Kilograms | Standard Deviation 2.6 |
| Total Ambulatory Participants | Change From Baseline in Knee Extension of Muscle Strength at Month 30: Participants Aged >=5 Years | Right Knee Extension | -1.4 Kilograms | Standard Deviation 2.76 |
| Non-ambulatory Participants | Change From Baseline in Knee Extension of Muscle Strength at Month 30: Participants Aged >=5 Years | Right Knee Extension | -1.1 Kilograms | Standard Deviation 0.44 |
| Non-ambulatory Participants | Change From Baseline in Knee Extension of Muscle Strength at Month 30: Participants Aged >=5 Years | Left Knee Extension | -0.4 Kilograms | Standard Deviation 0.36 |
| Total Participants | Change From Baseline in Knee Extension of Muscle Strength at Month 30: Participants Aged >=5 Years | Left Knee Extension | -0.7 Kilograms | Standard Deviation 2.56 |
| Total Participants | Change From Baseline in Knee Extension of Muscle Strength at Month 30: Participants Aged >=5 Years | Right Knee Extension | -1.4 Kilograms | Standard Deviation 2.72 |
Change From Baseline in Knee Extension of Muscle Strength at Month 6: Participants Aged >=5 Years
Muscle strength was recorded by handheld myometry. Left and right knee extension was analyzed. The muscle strength test was only performed in participants \>=5 years old as pre-specified in protocol.
Time frame: Baseline (Day 1) and Month 6
Population: Full Analysis Set included all participants who had been enrolled in the study. Here, Number of Participants Analyzed signifies participants evaluable for this outcome measure.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Ambulatory Participants With Age <6 Years | Change From Baseline in Knee Extension of Muscle Strength at Month 6: Participants Aged >=5 Years | Left Knee Extension | 0.5 Kilograms | Standard Deviation 1.91 |
| Ambulatory Participants With Age <6 Years | Change From Baseline in Knee Extension of Muscle Strength at Month 6: Participants Aged >=5 Years | Right Knee Extension | 0.7 Kilograms | Standard Deviation 2.35 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in Knee Extension of Muscle Strength at Month 6: Participants Aged >=5 Years | Left Knee Extension | 0.0 Kilograms | Standard Deviation 1.43 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in Knee Extension of Muscle Strength at Month 6: Participants Aged >=5 Years | Right Knee Extension | -0.1 Kilograms | Standard Deviation 1.78 |
| Total Ambulatory Participants | Change From Baseline in Knee Extension of Muscle Strength at Month 6: Participants Aged >=5 Years | Left Knee Extension | 0.1 Kilograms | Standard Deviation 1.5 |
| Total Ambulatory Participants | Change From Baseline in Knee Extension of Muscle Strength at Month 6: Participants Aged >=5 Years | Right Knee Extension | 0.0 Kilograms | Standard Deviation 1.87 |
| Non-ambulatory Participants | Change From Baseline in Knee Extension of Muscle Strength at Month 6: Participants Aged >=5 Years | Right Knee Extension | -0.0 Kilograms | Standard Deviation 0.37 |
| Non-ambulatory Participants | Change From Baseline in Knee Extension of Muscle Strength at Month 6: Participants Aged >=5 Years | Left Knee Extension | 0.3 Kilograms | Standard Deviation 0.29 |
| Total Participants | Change From Baseline in Knee Extension of Muscle Strength at Month 6: Participants Aged >=5 Years | Left Knee Extension | 0.1 Kilograms | Standard Deviation 1.49 |
| Total Participants | Change From Baseline in Knee Extension of Muscle Strength at Month 6: Participants Aged >=5 Years | Right Knee Extension | 0.0 Kilograms | Standard Deviation 1.85 |
Change From Baseline in Left Ventricular Ejection Fraction (LVEF) at Month 12: Participants Aged >=6 Years
LVEF was the percentage of blood that was ejected out of left ventricle with each contraction, estimated by echocardiography. The LVEF was only performed in participants \>=6 years old as pre-specified in protocol.
Time frame: Baseline (Day 1) and Month 12
Population: Full Analysis Set included all participants who had been enrolled in the study. Here, Number of Participants Analyzed signifies participants evaluable for this outcome measure.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Ambulatory Participants With Age <6 Years | Change From Baseline in Left Ventricular Ejection Fraction (LVEF) at Month 12: Participants Aged >=6 Years | 4.1 Percentage of ejected blood | Standard Deviation 45.37 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in Left Ventricular Ejection Fraction (LVEF) at Month 12: Participants Aged >=6 Years | -0.4 Percentage of ejected blood | Standard Deviation 6.32 |
| Total Ambulatory Participants | Change From Baseline in Left Ventricular Ejection Fraction (LVEF) at Month 12: Participants Aged >=6 Years | 3.4 Percentage of ejected blood | Standard Deviation 41.83 |
Change From Baseline in LVEF at Month 12: Participants Aged >=6 Years (Unplanned Analysis)
LVEF was the percentage of blood that was ejected out of left ventricle with each contraction, estimated by echocardiography. The LVEF was only performed in participants \>=6 years old as pre-specified in protocol. Incorrect data were addressed by unplanned analysis.
Time frame: Baseline (Day 1) and Month 12
Population: Full Analysis Set included all participants who had been enrolled in the study. Here, Number of Participants Analyzed signifies participants evaluable for this outcome measure.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Ambulatory Participants With Age <6 Years | Change From Baseline in LVEF at Month 12: Participants Aged >=6 Years (Unplanned Analysis) | 0.5 Percentage of ejected blood | Standard Deviation 6.27 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in LVEF at Month 12: Participants Aged >=6 Years (Unplanned Analysis) | -0.4 Percentage of ejected blood | Standard Deviation 6.32 |
| Total Ambulatory Participants | Change From Baseline in LVEF at Month 12: Participants Aged >=6 Years (Unplanned Analysis) | 0.4 Percentage of ejected blood | Standard Deviation 6.27 |
Change From Baseline in LVEF at Month 24: Participants Aged >=6 Years
LVEF was the percentage of blood that was ejected out of left ventricle with each contraction, estimated by echocardiography. The LVEF was only performed in participants \>=6 years old as pre-specified in protocol.
Time frame: Baseline (Day 1) and Month 24
Population: Full Analysis Set included all participants who had been enrolled in the study. Here, Number of Participants Analyzed signifies participants evaluable for this outcome measure.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Ambulatory Participants With Age <6 Years | Change From Baseline in LVEF at Month 24: Participants Aged >=6 Years | -0.7 Percentage of ejected blood | Standard Deviation 5.43 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in LVEF at Month 24: Participants Aged >=6 Years | -1.6 Percentage of ejected blood | Standard Deviation 7.58 |
| Total Ambulatory Participants | Change From Baseline in LVEF at Month 24: Participants Aged >=6 Years | -0.8 Percentage of ejected blood | Standard Deviation 5.78 |
Change From Baseline in LVEF at Month 24: Participants Aged >=6 Years (Unplanned Analysis)
LVEF was the percentage of blood that was ejected out of left ventricle with each contraction, estimated by echocardiography. The LVEF was only performed in participants \>=6 years old as pre-specified in protocol. Incorrect data were addressed by unplanned analysis.
Time frame: Baseline (Day 1) and Month 24
Population: Full Analysis Set included all participants who had been enrolled in the study. Here, Number of Participants Analyzed signifies participants evaluable for this outcome measure.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Ambulatory Participants With Age <6 Years | Change From Baseline in LVEF at Month 24: Participants Aged >=6 Years (Unplanned Analysis) | -0.7 Percentage of ejected blood | Standard Deviation 5.43 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in LVEF at Month 24: Participants Aged >=6 Years (Unplanned Analysis) | -1.6 Percentage of ejected blood | Standard Deviation 7.58 |
| Total Ambulatory Participants | Change From Baseline in LVEF at Month 24: Participants Aged >=6 Years (Unplanned Analysis) | -0.8 Percentage of ejected blood | Standard Deviation 5.78 |
Change From Baseline in LVEF at Month 30: Participants Aged >=6 Years
LVEF was the percentage of blood that was ejected out of left ventricle with each contraction, estimated by echocardiography. The LVEF was only performed in participants \>=6 years old as pre-specified in protocol.
Time frame: Baseline (Day 1) and Month 30
Population: Full Analysis Set included all participants who had been enrolled in the study. Here, Number of Participants Analyzed signifies participants evaluable for this outcome measure.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Ambulatory Participants With Age <6 Years | Change From Baseline in LVEF at Month 30: Participants Aged >=6 Years | -0.3 Percentage of ejected blood | Standard Deviation 6.42 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in LVEF at Month 30: Participants Aged >=6 Years | -2.0 Percentage of ejected blood | Standard Deviation 4.69 |
| Total Ambulatory Participants | Change From Baseline in LVEF at Month 30: Participants Aged >=6 Years | -0.4 Percentage of ejected blood | Standard Deviation 6.34 |
Change From Baseline in LVEF at Month 30: Participants Aged >=6 Years (Unplanned Analysis)
LVEF was the percentage of blood that was ejected out of left ventricle with each contraction, estimated by echocardiography. The LVEF was only performed in participants \>=6 years old as pre-specified in protocol. Incorrect data were addressed by unplanned analysis.
Time frame: Baseline (Day 1) and Month 30
Population: Full Analysis Set included all participants who had been enrolled in the study. Here, Number of Participants Analyzed signifies participants evaluable for this outcome measure.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Ambulatory Participants With Age <6 Years | Change From Baseline in LVEF at Month 30: Participants Aged >=6 Years (Unplanned Analysis) | -0.3 Percentage of ejected blood | Standard Deviation 6.42 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in LVEF at Month 30: Participants Aged >=6 Years (Unplanned Analysis) | -2.0 Percentage of ejected blood | Standard Deviation 4.69 |
| Total Ambulatory Participants | Change From Baseline in LVEF at Month 30: Participants Aged >=6 Years (Unplanned Analysis) | -0.4 Percentage of ejected blood | Standard Deviation 6.34 |
Change From Baseline in Maximum Expiratory Pressure at Month 12: Participants Aged >=6 Years
The pulmonary function assessments were performed only in participants \>=6 years old as pre-specified in SAP.
Time frame: Baseline (Day 1) and Month 12
Population: Full Analysis Set included all participants who had been enrolled in the study. Here, Number of Participants Analyzed signifies participants evaluable for this outcome measure.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Ambulatory Participants With Age <6 Years | Change From Baseline in Maximum Expiratory Pressure at Month 12: Participants Aged >=6 Years | 1.0 Centimeter of water (cm H2O) | Standard Deviation 14.72 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in Maximum Expiratory Pressure at Month 12: Participants Aged >=6 Years | -5.5 Centimeter of water (cm H2O) | Standard Deviation 14.24 |
| Total Ambulatory Participants | Change From Baseline in Maximum Expiratory Pressure at Month 12: Participants Aged >=6 Years | -0.0 Centimeter of water (cm H2O) | Standard Deviation 14.8 |
Change From Baseline in Maximum Expiratory Pressure at Month 24: Participants Aged >=6 Years
The pulmonary function assessments were performed only in participants \>=6 years old as pre-specified in SAP.
Time frame: Baseline (Day 1) and Month 24
Population: Full Analysis Set included all participants who had been enrolled in the study. Here, Number of Participants Analyzed signifies participants evaluable for this outcome measure.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Ambulatory Participants With Age <6 Years | Change From Baseline in Maximum Expiratory Pressure at Month 24: Participants Aged >=6 Years | 0.6 Centimeter of water (cm H2O) | Standard Deviation 18.07 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in Maximum Expiratory Pressure at Month 24: Participants Aged >=6 Years | -2.5 Centimeter of water (cm H2O) | Standard Deviation 13.67 |
| Total Ambulatory Participants | Change From Baseline in Maximum Expiratory Pressure at Month 24: Participants Aged >=6 Years | 0.1 Centimeter of water (cm H2O) | Standard Deviation 17.48 |
Change From Baseline in Maximum Expiratory Pressure at Month 30: Participants Aged >=6 Years
The pulmonary function assessments were performed only in participants \>=6 years old as pre-specified in SAP.
Time frame: Baseline (Day 1) and Month 30
Population: Full Analysis Set included all participants who had been enrolled in the study. Here, Number of Participants Analyzed signifies participants evaluable for this outcome measure.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Ambulatory Participants With Age <6 Years | Change From Baseline in Maximum Expiratory Pressure at Month 30: Participants Aged >=6 Years | 1.7 Centimeter of water (cm H2O) | Standard Deviation 17.91 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in Maximum Expiratory Pressure at Month 30: Participants Aged >=6 Years | -20.3 Centimeter of water (cm H2O) | Standard Deviation 23.61 |
| Total Ambulatory Participants | Change From Baseline in Maximum Expiratory Pressure at Month 30: Participants Aged >=6 Years | 0.6 Centimeter of water (cm H2O) | Standard Deviation 18.68 |
Change From Baseline in Maximum Inspiratory Pressure at Month 12: Participants Aged >=6 Years
The pulmonary function assessments were performed only in participants \>=6 years old as pre-specified in protocol.
Time frame: Baseline (Day 1) and Month 12
Population: Full Analysis Set included all participants who had been enrolled in the study. Here, Number of Participants Analyzed signifies participants evaluable for this outcome measure.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Ambulatory Participants With Age <6 Years | Change From Baseline in Maximum Inspiratory Pressure at Month 12: Participants Aged >=6 Years | 1.4 Centimeter of water (cm H2O) | Standard Deviation 18.22 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in Maximum Inspiratory Pressure at Month 12: Participants Aged >=6 Years | -3.1 Centimeter of water (cm H2O) | Standard Deviation 20.46 |
| Total Ambulatory Participants | Change From Baseline in Maximum Inspiratory Pressure at Month 12: Participants Aged >=6 Years | 0.6 Centimeter of water (cm H2O) | Standard Deviation 18.62 |
Change From Baseline in Maximum Inspiratory Pressure at Month 24: Participants Aged >=6 Years
The pulmonary function assessments were performed only in participants \>=6 years old as pre-specified in protocol.
Time frame: Baseline (Day 1) and Month 24
Population: Full Analysis Set included all participants who had been enrolled in the study. Here, Number of Participants Analyzed signifies participants evaluable for this outcome measure.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Ambulatory Participants With Age <6 Years | Change From Baseline in Maximum Inspiratory Pressure at Month 24: Participants Aged >=6 Years | 0.9 Centimeter of water (cm H2O) | Standard Deviation 18.24 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in Maximum Inspiratory Pressure at Month 24: Participants Aged >=6 Years | -2.8 Centimeter of water (cm H2O) | Standard Deviation 17.24 |
| Total Ambulatory Participants | Change From Baseline in Maximum Inspiratory Pressure at Month 24: Participants Aged >=6 Years | 0.3 Centimeter of water (cm H2O) | Standard Deviation 18.08 |
Change From Baseline in Maximum Inspiratory Pressure at Month 30: Participants Aged >=6 Years
The pulmonary function assessments were performed only in participants \>=6 years old as pre-specified in protocol.
Time frame: Baseline (Day 1) and Month 30
Population: Full Analysis Set included all participants who had been enrolled in the study. Here, Number of Participants Analyzed signifies participants evaluable for this outcome measure.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Ambulatory Participants With Age <6 Years | Change From Baseline in Maximum Inspiratory Pressure at Month 30: Participants Aged >=6 Years | 2.5 Centimeter of water (cm H2O) | Standard Deviation 19.19 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in Maximum Inspiratory Pressure at Month 30: Participants Aged >=6 Years | -14.0 Centimeter of water (cm H2O) | Standard Deviation 13.22 |
| Total Ambulatory Participants | Change From Baseline in Maximum Inspiratory Pressure at Month 30: Participants Aged >=6 Years | 1.6 Centimeter of water (cm H2O) | Standard Deviation 19.22 |
Change From Baseline in Northstar Ambulatory Assessment (NSAA) Total Score at Month 6: Ambulatory Participants Aged >=3 Years
NSAA is a 17-item test that grades performance of various functional skills using the following scale: 0 (unable to achieve goal independently), 1 (modified method but achieves goal with no physical assistance), or 2 (normal- no obvious modification of activity). The scale assesses activities required to remain functionally ambulant (e.g. rise from the floor), activities that can be difficult even early in the disease (example \[e.g.\] standing on heels) and activities that are known to progressively deteriorate over time (stand from a chair, walk). NSAA total score was calculated by adding the responses of all 17 items and ranged from 0 to 34, with higher scores indicating better function. NSAA was only performed in ambulatory participants aged \>=3 years old as pre-specified in protocol.
Time frame: Baseline (Day 1) and Month 6
Population: Full Analysis Set included all participants who had been enrolled in the study. Here, Number of Participants Analyzed signifies participants evaluable for this outcome measure.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Ambulatory Participants With Age <6 Years | Change From Baseline in Northstar Ambulatory Assessment (NSAA) Total Score at Month 6: Ambulatory Participants Aged >=3 Years | 1.3 Units on a scale | Standard Deviation 4.44 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in Northstar Ambulatory Assessment (NSAA) Total Score at Month 6: Ambulatory Participants Aged >=3 Years | -1.0 Units on a scale | Standard Deviation 3.98 |
| Total Ambulatory Participants | Change From Baseline in Northstar Ambulatory Assessment (NSAA) Total Score at Month 6: Ambulatory Participants Aged >=3 Years | -0.3 Units on a scale | Standard Deviation 4.24 |
Change From Baseline in NSAA Total Score at Month 12: Ambulatory Participants Aged >=3 Years
NSAA is a 17-item test that grades performance of various functional skills using the following scale: 0 (unable to achieve goal independently), 1 (modified method but achieves goal with no physical assistance), or 2 (normal- no obvious modification of activity). The scale assesses activities required to remain functionally ambulant (e.g. rise from the floor), activities that can be difficult even early in the disease (e.g. standing on heels) and activities that are known to progressively deteriorate over time (stand from a chair, walk). NSAA total score was calculated by adding the responses of all 17 items and ranged from 0 to 34, with higher scores indicating better function. NSAA was only performed in ambulatory participants aged \>=3 years old as pre-specified in protocol.
Time frame: Baseline (Day 1) and Month 12
Population: Full Analysis Set included all participants who had been enrolled in the study. Here, Number of Participants Analyzed signifies participants evaluable for this outcome measure.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Ambulatory Participants With Age <6 Years | Change From Baseline in NSAA Total Score at Month 12: Ambulatory Participants Aged >=3 Years | 2.7 Units on a scale | Standard Deviation 5.37 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in NSAA Total Score at Month 12: Ambulatory Participants Aged >=3 Years | -2.1 Units on a scale | Standard Deviation 4.88 |
| Total Ambulatory Participants | Change From Baseline in NSAA Total Score at Month 12: Ambulatory Participants Aged >=3 Years | -0.9 Units on a scale | Standard Deviation 5.42 |
Change From Baseline in NSAA Total Score at Month 18: Ambulatory Participants Aged >=3 Years
NSAA is a 17-item test that grades performance of various functional skills using the following scale: 0 (unable to achieve goal independently), 1 (modified method but achieves goal with no physical assistance), or 2 (normal- no obvious modification of activity). The scale assesses activities required to remain functionally ambulant (e.g. rise from the floor), activities that can be difficult even early in the disease (e.g. standing on heels) and activities that are known to progressively deteriorate over time (stand from a chair, walk). NSAA total score was calculated by adding the responses of all 17 items and ranged from 0 to 34, with higher scores indicating better function. NSAA was only performed in ambulatory participants aged \>=3 years old as pre-specified in protocol.
Time frame: Baseline (Day 1) and Month 18
Population: Full Analysis Set included all participants who had been enrolled in the study. Here, Number of Participants Analyzed signifies participants evaluable for this outcome measure.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Ambulatory Participants With Age <6 Years | Change From Baseline in NSAA Total Score at Month 18: Ambulatory Participants Aged >=3 Years | 4.1 Units on a scale | Standard Deviation 5.12 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in NSAA Total Score at Month 18: Ambulatory Participants Aged >=3 Years | -3.6 Units on a scale | Standard Deviation 4.53 |
| Total Ambulatory Participants | Change From Baseline in NSAA Total Score at Month 18: Ambulatory Participants Aged >=3 Years | -1.2 Units on a scale | Standard Deviation 5.93 |
Change From Baseline in NSAA Total Score at Month 24: Ambulatory Participants Aged >=3 Years
NSAA is a 17-item test that grades performance of various functional skills using the following scale: 0 (unable to achieve goal independently), 1 (modified method but achieves goal with no physical assistance), or 2 (normal- no obvious modification of activity). The scale assesses activities required to remain functionally ambulant (e.g. rise from the floor), activities that can be difficult even early in the disease (e.g. standing on heels) and activities that are known to progressively deteriorate over time (stand from a chair, walk). NSAA total score was calculated by adding the responses of all 17 items and ranged from 0 to 34, with higher scores indicating better function. NSAA was only performed in ambulatory participants aged \>=3 years old as pre-specified in protocol.
Time frame: Baseline (Day 1) and Month 24
Population: Full Analysis Set included all participants who had been enrolled in the study. Here, Number of Participants Analyzed signifies participants evaluable for this outcome measure.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Ambulatory Participants With Age <6 Years | Change From Baseline in NSAA Total Score at Month 24: Ambulatory Participants Aged >=3 Years | 3.9 Units on a scale | Standard Deviation 4.67 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in NSAA Total Score at Month 24: Ambulatory Participants Aged >=3 Years | -4.9 Units on a scale | Standard Deviation 5.22 |
| Total Ambulatory Participants | Change From Baseline in NSAA Total Score at Month 24: Ambulatory Participants Aged >=3 Years | -2.1 Units on a scale | Standard Deviation 6.5 |
Change From Baseline in NSAA Total Score at Month 30: Ambulatory Participants Aged >=3 Years
NSAA is a 17-item test that grades performance of various functional skills using the following scale: 0 (unable to achieve goal independently), 1 (modified method but achieves goal with no physical assistance), or 2 (normal- no obvious modification of activity). The scale assesses activities required to remain functionally ambulant (e.g. rise from the floor), activities that can be difficult even early in the disease (e.g. standing on heels) and activities that are known to progressively deteriorate over time (stand from a chair, walk). NSAA total score was calculated by adding the responses of all 17 items and ranged from 0 to 34, with higher scores indicating better function. NSAA was only performed in ambulatory participants aged \>=3 years old as pre-specified in protocol.
Time frame: Baseline (Day 1) and Month 30
Population: Full Analysis Set included all participants who had been enrolled in the study. Here, Number of Participants Analyzed signifies participants evaluable for this outcome measure.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Ambulatory Participants With Age <6 Years | Change From Baseline in NSAA Total Score at Month 30: Ambulatory Participants Aged >=3 Years | 4.1 Units on a scale | Standard Deviation 5.09 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in NSAA Total Score at Month 30: Ambulatory Participants Aged >=3 Years | -5.9 Units on a scale | Standard Deviation 5.56 |
| Total Ambulatory Participants | Change From Baseline in NSAA Total Score at Month 30: Ambulatory Participants Aged >=3 Years | -3.6 Units on a scale | Standard Deviation 6.84 |
Change From Baseline in Peak Cough Flow at Month 12: Participants Aged >=6 Years
The pulmonary function assessments were performed only in participants \>=6 years old as pre-specified in protocol.
Time frame: Baseline (Day 1) and Month 12
Population: Full Analysis Set included all participants who had been enrolled in the study. Here, Number of Participants Analyzed signifies participants evaluable for this outcome measure.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Ambulatory Participants With Age <6 Years | Change From Baseline in Peak Cough Flow at Month 12: Participants Aged >=6 Years | 14.0 Liters per minute | Standard Deviation 46.61 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in Peak Cough Flow at Month 12: Participants Aged >=6 Years | 38.6 Liters per minute | Standard Deviation 61.5 |
| Total Ambulatory Participants | Change From Baseline in Peak Cough Flow at Month 12: Participants Aged >=6 Years | 17.9 Liters per minute | Standard Deviation 49.94 |
Change From Baseline in Peak Cough Flow at Month 12: Participants Aged >=6 Years (Unplanned Analysis)
The pulmonary function assessments were performed only in participants \>=6 years old as pre-specified in protocol. Incorrect data were addressed by unplanned analysis.
Time frame: Baseline (Day 1) and Month 12
Population: Full Analysis Set included all participants who had been enrolled in the study. Here, Number of Participants Analyzed signifies participants evaluable for this outcome measure.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Ambulatory Participants With Age <6 Years | Change From Baseline in Peak Cough Flow at Month 12: Participants Aged >=6 Years (Unplanned Analysis) | 14.0 Liters per minute | Standard Deviation 46.61 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in Peak Cough Flow at Month 12: Participants Aged >=6 Years (Unplanned Analysis) | 38.6 Liters per minute | Standard Deviation 61.5 |
| Total Ambulatory Participants | Change From Baseline in Peak Cough Flow at Month 12: Participants Aged >=6 Years (Unplanned Analysis) | 17.9 Liters per minute | Standard Deviation 49.94 |
Change From Baseline in Peak Cough Flow at Month 24: Participants Aged >=6 Years
The pulmonary function assessments were performed only in participants \>=6 years old as pre-specified in protocol.
Time frame: Baseline (Day 1) and Month 24
Population: Full Analysis Set included all participants who had been enrolled in the study. Here, Number of Participants Analyzed signifies participants evaluable for this outcome measure.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Ambulatory Participants With Age <6 Years | Change From Baseline in Peak Cough Flow at Month 24: Participants Aged >=6 Years | 20.7 Liters per minute | Standard Deviation 59.04 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in Peak Cough Flow at Month 24: Participants Aged >=6 Years | 46.1 Liters per minute | Standard Deviation 67.78 |
| Total Ambulatory Participants | Change From Baseline in Peak Cough Flow at Month 24: Participants Aged >=6 Years | 24.4 Liters per minute | Standard Deviation 60.84 |
Change From Baseline in Peak Cough Flow at Month 24: Participants Aged >=6 Years (Unplanned Analysis)
The pulmonary function assessments were performed only in participants \>=6 years old as pre-specified in protocol. Incorrect data were addressed by unplanned analysis.
Time frame: Baseline (Day 1) and Month 24
Population: Full Analysis Set included all participants who had been enrolled in the study. Here, Number of Participants Analyzed signifies participants evaluable for this outcome measure.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Ambulatory Participants With Age <6 Years | Change From Baseline in Peak Cough Flow at Month 24: Participants Aged >=6 Years (Unplanned Analysis) | 22.4 Liters per minute | Standard Deviation 55.94 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in Peak Cough Flow at Month 24: Participants Aged >=6 Years (Unplanned Analysis) | 46.1 Liters per minute | Standard Deviation 67.78 |
| Total Ambulatory Participants | Change From Baseline in Peak Cough Flow at Month 24: Participants Aged >=6 Years (Unplanned Analysis) | 25.9 Liters per minute | Standard Deviation 58.22 |
Change From Baseline in Peak Cough Flow at Month 30: Participants Aged >=6 Years
The pulmonary function assessments were performed only in participants \>=6 years old as pre-specified in protocol.
Time frame: Baseline (Day 1) and Month 30
Population: Full Analysis Set included all participants who had been enrolled in the study. Here, Number of Participants Analyzed signifies participants evaluable for this outcome measure.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Ambulatory Participants With Age <6 Years | Change From Baseline in Peak Cough Flow at Month 30: Participants Aged >=6 Years | 25.2 Liters per minute | Standard Deviation 62.83 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in Peak Cough Flow at Month 30: Participants Aged >=6 Years | 74.0 Liters per minute | Standard Deviation 24.84 |
| Total Ambulatory Participants | Change From Baseline in Peak Cough Flow at Month 30: Participants Aged >=6 Years | 27.7 Liters per minute | Standard Deviation 62.32 |
Change From Baseline in Peak Cough Flow at Month 30: Participants Aged >=6 Years (Unplanned Analysis)
The pulmonary function assessments were performed only in participants \>=6 years old as pre-specified in protocol. Incorrect data were addressed by unplanned analysis.
Time frame: Baseline (Day 1) and Month 30
Population: Full Analysis Set included all participants who had been enrolled in the study. Here, Number of Participants Analyzed signifies participants evaluable for this outcome measure.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Ambulatory Participants With Age <6 Years | Change From Baseline in Peak Cough Flow at Month 30: Participants Aged >=6 Years (Unplanned Analysis) | 25.2 Liters per minute | Standard Deviation 62.83 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in Peak Cough Flow at Month 30: Participants Aged >=6 Years (Unplanned Analysis) | 74.0 Liters per minute | Standard Deviation 24.84 |
| Total Ambulatory Participants | Change From Baseline in Peak Cough Flow at Month 30: Participants Aged >=6 Years (Unplanned Analysis) | 27.7 Liters per minute | Standard Deviation 62.32 |
Change From Baseline in Percent Predicted Forced Expiratory Volume in One Second (%pFEV1) at Month 12: Participants Aged >=6 Years
Forced expiratory volume in one second (FEV1) is the volume of air forcefully exhaled in 1 second and was measured using spirometry. The %pFEV1 was calculated from FEV1 (measured in liter) according to age, height (estimated height as derived from the ulna length for non-ambulatory participants), ethnicity, and gender using multi-ethnic reference values for Spirometry. The pulmonary function assessments were performed only in participants \>=6 years old as pre-specified in protocol.
Time frame: Baseline (Day 1) and Month 12
Population: Full Analysis Set included all participants who had been enrolled in the study. Here, Number of Participants Analyzed signifies participants evaluable for this outcome measure.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Ambulatory Participants With Age <6 Years | Change From Baseline in Percent Predicted Forced Expiratory Volume in One Second (%pFEV1) at Month 12: Participants Aged >=6 Years | -1.8 Percent predicted FEV1 | Standard Deviation 18.65 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in Percent Predicted Forced Expiratory Volume in One Second (%pFEV1) at Month 12: Participants Aged >=6 Years | -4.0 Percent predicted FEV1 | Standard Deviation 19.64 |
| Total Ambulatory Participants | Change From Baseline in Percent Predicted Forced Expiratory Volume in One Second (%pFEV1) at Month 12: Participants Aged >=6 Years | -2.1 Percent predicted FEV1 | Standard Deviation 18.78 |
Change From Baseline in Percent Predicted Forced Vital Capacity (%pFVC) at Month 12: Participants Aged >=6 Years
Forced vital capacity (FVC) is the volume of air that can be maximally forcefully exhaled after taking the deepest breath possible and was measured using spirometry. The percent predicted FVC was calculated from FVC (measured in liter) according to age, height (estimated height as derived from the ulna length for non-ambulatory participants), ethnicity, and gender using multi-ethnic reference values for spirometry. The pulmonary function assessments were performed in participants aged \>=6 years as pre-specified in the protocol.
Time frame: Baseline (Day 1) and Month 12
Population: Full Analysis Set included all participants who had been enrolled in the study. Here, Number of Participants Analyzed signifies participants evaluable for this outcome measure.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Ambulatory Participants With Age <6 Years | Change From Baseline in Percent Predicted Forced Vital Capacity (%pFVC) at Month 12: Participants Aged >=6 Years | -2.9 Percent predicted FVC | Standard Deviation 15.85 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in Percent Predicted Forced Vital Capacity (%pFVC) at Month 12: Participants Aged >=6 Years | -5.7 Percent predicted FVC | Standard Deviation 19.79 |
| Total Ambulatory Participants | Change From Baseline in Percent Predicted Forced Vital Capacity (%pFVC) at Month 12: Participants Aged >=6 Years | -3.4 Percent predicted FVC | Standard Deviation 16.52 |
Change From Baseline in Performance of Upper Limb (PUL) 2.0 Total Score at Month 6: Participants Aged >=10 Years
PUL 2.0 scale is a 22-item scale used to assess the change that occurs in motor performance of the upper limb overtime from when a participant is still ambulant to the time participant loses all arm function when non-ambulant. PUL 2.0 includes an entry item to define broad starting functional level and 22 items subdivided into shoulder level (six items), mid-level (nine items), and distal level (seven items). Each dimension (shoulder, mid, distal) can be scored separately. There is maximum score of 12 for shoulder level, 17 for mid-level, and 13 for distal level. The total score was calculated by adding three level scores and ranged from 0-42. Higher score indicates better upper limb function. PUL 2.0 total score was assessed in participants aged \>=10 years only as pre-specified in protocol.
Time frame: Baseline (Day 1) and Month 6
Population: Full Analysis Set included all participants who had been enrolled in the study. Here, Number of Participants Analyzed signifies participants evaluable for this outcome measure.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Ambulatory Participants With Age <6 Years | Change From Baseline in Performance of Upper Limb (PUL) 2.0 Total Score at Month 6: Participants Aged >=10 Years | -0.0 Units on a scale | Standard Deviation 2.33 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in Performance of Upper Limb (PUL) 2.0 Total Score at Month 6: Participants Aged >=10 Years | -0.8 Units on a scale | Standard Deviation 2.22 |
| Total Ambulatory Participants | Change From Baseline in Performance of Upper Limb (PUL) 2.0 Total Score at Month 6: Participants Aged >=10 Years | -0.1 Units on a scale | Standard Deviation 2.31 |
Change From Baseline in %pFEV1 at Month 12: Participants Aged >=6 Years (Unplanned Analysis)
FEV1 is the volume of air forcefully exhaled in 1 second and was measured using spirometry. The %pFEV1 was calculated from FEV1 (measured in liter) according to age, height (estimated height as derived from the ulna length for non-ambulatory participants), ethnicity, and gender using multi-ethnic reference values for Spirometry. The pulmonary function assessments were performed only in participants \>=6 years old as pre-specified in protocol. Incorrect data were addressed by unplanned analysis.
Time frame: Baseline (Day 1) and Month 12
Population: Full Analysis Set included all participants who had been enrolled in the study. Here, Number of Participants Analyzed signifies participants evaluable for this outcome measure.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Ambulatory Participants With Age <6 Years | Change From Baseline in %pFEV1 at Month 12: Participants Aged >=6 Years (Unplanned Analysis) | -1.8 Percent predicted FEV1 | Standard Deviation 18.65 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in %pFEV1 at Month 12: Participants Aged >=6 Years (Unplanned Analysis) | -4.0 Percent predicted FEV1 | Standard Deviation 19.64 |
| Total Ambulatory Participants | Change From Baseline in %pFEV1 at Month 12: Participants Aged >=6 Years (Unplanned Analysis) | -2.1 Percent predicted FEV1 | Standard Deviation 18.78 |
Change From Baseline in %pFEV1 at Month 24: Participants Aged >=6 Years
FEV1 is the volume of air forcefully exhaled in 1 second and was measured using spirometry. The %pFEV1 was calculated from FEV1 (measured in liter) according to age, height (estimated height as derived from the ulna length for non-ambulatory participants), ethnicity, and gender using multi-ethnic reference values for Spirometry. The pulmonary function assessments were performed only in participants \>=6 years old as pre-specified in protocol.
Time frame: Baseline (Day 1) and Month 24
Population: Full Analysis Set included all participants who had been enrolled in the study. Here, Number of Participants Analyzed signifies participants evaluable for this outcome measure.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Ambulatory Participants With Age <6 Years | Change From Baseline in %pFEV1 at Month 24: Participants Aged >=6 Years | -3.9 Percent predicted FEV1 | Standard Deviation 19.38 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in %pFEV1 at Month 24: Participants Aged >=6 Years | -10.2 Percent predicted FEV1 | Standard Deviation 20.94 |
| Total Ambulatory Participants | Change From Baseline in %pFEV1 at Month 24: Participants Aged >=6 Years | -4.8 Percent predicted FEV1 | Standard Deviation 19.67 |
Change From Baseline in %pFEV1 at Month 24: Participants Aged >=6 Years (Unplanned Analysis)
FEV1 is the volume of air forcefully exhaled in 1 second and was measured using spirometry. The %pFEV1 was calculated from FEV1 (measured in liter) according to age, height (estimated height as derived from the ulna length for non-ambulatory participants), ethnicity, and gender using multi-ethnic reference values for Spirometry. The pulmonary function assessments were performed only in participants \>=6 years old as pre-specified in protocol. Incorrect data were addressed by unplanned analysis.
Time frame: Baseline (Day 1) and Month 24
Population: Full Analysis Set included all participants who had been enrolled in the study. Here, Number of Participants Analyzed signifies participants evaluable for this outcome measure.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Ambulatory Participants With Age <6 Years | Change From Baseline in %pFEV1 at Month 24: Participants Aged >=6 Years (Unplanned Analysis) | -3.9 Percent predicted FEV1 | Standard Deviation 19.38 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in %pFEV1 at Month 24: Participants Aged >=6 Years (Unplanned Analysis) | -10.2 Percent predicted FEV1 | Standard Deviation 20.94 |
| Total Ambulatory Participants | Change From Baseline in %pFEV1 at Month 24: Participants Aged >=6 Years (Unplanned Analysis) | -4.8 Percent predicted FEV1 | Standard Deviation 19.67 |
Change From Baseline in %pFEV1 at Month 30: Participants Aged >=6 Years
FEV1 is the volume of air forcefully exhaled in 1 second and was measured using spirometry. The %pFEV1 was calculated from FEV1 (measured in liter) according to age, height (estimated height as derived from the ulna length for non-ambulatory participants), ethnicity, and gender using multi-ethnic reference values for Spirometry. The pulmonary function assessments were performed only in participants \>=6 years old as pre-specified in protocol.
Time frame: Baseline (Day 1) and Month 30
Population: Full Analysis Set included all participants who had been enrolled in the study. Here, Number of Participants Analyzed signifies participants evaluable for this outcome measure.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Ambulatory Participants With Age <6 Years | Change From Baseline in %pFEV1 at Month 30: Participants Aged >=6 Years | 115.2 Percent predicted FEV1 | Standard Deviation 1037.35 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in %pFEV1 at Month 30: Participants Aged >=6 Years | -5.8 Percent predicted FEV1 | Standard Deviation 8.83 |
| Total Ambulatory Participants | Change From Baseline in %pFEV1 at Month 30: Participants Aged >=6 Years | 109.1 Percent predicted FEV1 | Standard Deviation 1010.75 |
Change From Baseline in %pFEV1 at Month 30: Participants Aged >=6 Years (Unplanned Analysis)
FEV1 is the volume of air forcefully exhaled in 1 second and was measured using spirometry. The %pFEV1 was calculated from FEV1 (measured in liter) according to age, height (estimated height as derived from the ulna length for non-ambulatory participants), ethnicity, and gender using multi-ethnic reference values for Spirometry. The pulmonary function assessments were performed only in participants \>=6 years old as pre-specified in protocol. Incorrect data were addressed by unplanned analysis.
Time frame: Baseline (Day 1) and Month 30
Population: Full Analysis Set included all participants who had been enrolled in the study. Here, Number of Participants Analyzed signifies participants evaluable for this outcome measure.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Ambulatory Participants With Age <6 Years | Change From Baseline in %pFEV1 at Month 30: Participants Aged >=6 Years (Unplanned Analysis) | -4.6 Percent predicted FEV1 | Standard Deviation 18.97 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in %pFEV1 at Month 30: Participants Aged >=6 Years (Unplanned Analysis) | -5.8 Percent predicted FEV1 | Standard Deviation 8.83 |
| Total Ambulatory Participants | Change From Baseline in %pFEV1 at Month 30: Participants Aged >=6 Years (Unplanned Analysis) | -4.6 Percent predicted FEV1 | Standard Deviation 18.56 |
Change From Baseline in %pFVC at Month 12: Participants Aged >=6 Years (Unplanned Analysis)
FVC is the volume of air that can be maximally forcefully exhaled after taking the deepest breath possible and was measured using spirometry. The percent predicted FVC was calculated from FVC (measured in liter) according to age, height (estimated height as derived from the ulna length for non-ambulatory participants), ethnicity, and gender using multi-ethnic reference values for spirometry. The pulmonary function assessments were performed in participants aged \>=6 years as pre-specified in the protocol. Incorrect data were addressed by unplanned analysis.
Time frame: Baseline (Day 1) and Month 12
Population: Full Analysis Set included all participants who had been enrolled in the study. Here, Number of Participants Analyzed signifies participants evaluable for this outcome measure.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Ambulatory Participants With Age <6 Years | Change From Baseline in %pFVC at Month 12: Participants Aged >=6 Years (Unplanned Analysis) | -2.9 Percent predicted FVC | Standard Deviation 15.85 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in %pFVC at Month 12: Participants Aged >=6 Years (Unplanned Analysis) | -5.7 Percent predicted FVC | Standard Deviation 19.79 |
| Total Ambulatory Participants | Change From Baseline in %pFVC at Month 12: Participants Aged >=6 Years (Unplanned Analysis) | -3.4 Percent predicted FVC | Standard Deviation 16.52 |
Change From Baseline in %pFVC at Month 24: Participants Aged >=6 Years
FVC is the volume of air that can be maximally forcefully exhaled after taking the deepest breath possible and was measured using spirometry. The percent predicted FVC was calculated from FVC (measured in liter) according to age, height (estimated height as derived from the ulna length for non-ambulatory participants), ethnicity, and gender using multi-ethnic reference values for spirometry. The pulmonary function assessments were performed in participants aged \>=6 years as pre-specified in the protocol.
Time frame: Baseline (Day 1) and Month 24
Population: Full Analysis Set included all participants who had been enrolled in the study. Here, Number of Participants Analyzed signifies participants evaluable for this outcome measure.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Ambulatory Participants With Age <6 Years | Change From Baseline in %pFVC at Month 24: Participants Aged >=6 Years | -4.3 Percent predicted FVC | Standard Deviation 15.97 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in %pFVC at Month 24: Participants Aged >=6 Years | -14.1 Percent predicted FVC | Standard Deviation 20.68 |
| Total Ambulatory Participants | Change From Baseline in %pFVC at Month 24: Participants Aged >=6 Years | -5.7 Percent predicted FVC | Standard Deviation 17.02 |
Change From Baseline in %pFVC at Month 24: Participants Aged >=6 Years (Unplanned Analysis)
FVC is the volume of air that can be maximally forcefully exhaled after taking the deepest breath possible and was measured using spirometry. The percent predicted FVC was calculated from FVC (measured in liter) according to age, height (estimated height as derived from the ulna length for non-ambulatory participants), ethnicity, and gender using multi-ethnic reference values for spirometry. The pulmonary function assessments were performed in participants aged \>=6 years as pre-specified in the protocol. Incorrect data were addressed by unplanned analysis.
Time frame: Baseline (Day 1) and Month 24
Population: Full Analysis Set included all participants who had been enrolled in the study. Here, Number of Participants Analyzed signifies participants evaluable for this outcome measure.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Ambulatory Participants With Age <6 Years | Change From Baseline in %pFVC at Month 24: Participants Aged >=6 Years (Unplanned Analysis) | -4.3 Percent predicted FVC | Standard Deviation 15.97 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in %pFVC at Month 24: Participants Aged >=6 Years (Unplanned Analysis) | -14.1 Percent predicted FVC | Standard Deviation 20.68 |
| Total Ambulatory Participants | Change From Baseline in %pFVC at Month 24: Participants Aged >=6 Years (Unplanned Analysis) | -5.7 Percent predicted FVC | Standard Deviation 17.02 |
Change From Baseline in %pFVC at Month 30: Participants Aged >=6 Years
FVC is the volume of air that can be maximally forcefully exhaled after taking the deepest breath possible and was measured using spirometry. The percent predicted FVC was calculated from FVC (measured in liter) according to age, height (estimated height as derived from the ulna length for non-ambulatory participants), ethnicity, and gender using multi-ethnic reference values for spirometry. The pulmonary function assessments were performed in participants aged \>=6 years as pre-specified in the protocol.
Time frame: Baseline (Day 1) and Month 30
Population: Full Analysis Set included all participants who had been enrolled in the study. Here, Number of Participants Analyzed signifies participants evaluable for this outcome measure.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Ambulatory Participants With Age <6 Years | Change From Baseline in %pFVC at Month 30: Participants Aged >=6 Years | 105.4 Percent predicted FVC | Standard Deviation 975.57 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in %pFVC at Month 30: Participants Aged >=6 Years | -3.2 Percent predicted FVC | Standard Deviation 9.41 |
| Total Ambulatory Participants | Change From Baseline in %pFVC at Month 30: Participants Aged >=6 Years | 99.9 Percent predicted FVC | Standard Deviation 950.53 |
Change From Baseline in %pFVC at Month 30: Participants Aged >=6 Years (Unplanned Analysis)
FVC is the volume of air that can be maximally forcefully exhaled after taking the deepest breath possible and was measured using spirometry. The percent predicted FVC was calculated from FVC (measured in liter) according to age, height (estimated height as derived from the ulna length for non-ambulatory participants), ethnicity, and gender using multi-ethnic reference values for spirometry. The pulmonary function assessments were performed in participants aged \>=6 years as pre-specified in the protocol. Incorrect data were addressed by unplanned analysis.
Time frame: Baseline (Day 1) and Month 30
Population: Full Analysis Set included all participants who had been enrolled in the study. Here, Number of Participants Analyzed signifies participants evaluable for this outcome measure.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Ambulatory Participants With Age <6 Years | Change From Baseline in %pFVC at Month 30: Participants Aged >=6 Years (Unplanned Analysis) | -7.2 Percent predicted FVC | Standard Deviation 16.41 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in %pFVC at Month 30: Participants Aged >=6 Years (Unplanned Analysis) | -3.2 Percent predicted FVC | Standard Deviation 9.41 |
| Total Ambulatory Participants | Change From Baseline in %pFVC at Month 30: Participants Aged >=6 Years (Unplanned Analysis) | -7.0 Percent predicted FVC | Standard Deviation 16.12 |
Change From Baseline in PUL 2.0 Total Score at Month 12: Participants Aged >=10 Years
PUL 2.0 scale is a 22-item scale used to assess the change that occurs in motor performance of the upper limb overtime from when a participant is still ambulant to the time participant loses all arm function when non-ambulant. PUL 2.0 includes an entry item to define broad starting functional level and 22 items subdivided into shoulder level (six items), mid-level (nine items), and distal level (seven items). Each dimension (shoulder, mid, distal) can be scored separately. There is maximum score of 12 for shoulder level, 17 for mid-level, and 13 for distal level. The total score was calculated by adding three level scores and ranged from 0-42. Higher score indicates better upper limb function. PUL 2.0 total score was assessed in participants aged \>=10 years only as pre-specified in protocol.
Time frame: Baseline (Day 1) and Month 12
Population: Full Analysis Set included all participants who had been enrolled in the study. Here, Number of Participants Analyzed signifies participants evaluable for this outcome measure.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Ambulatory Participants With Age <6 Years | Change From Baseline in PUL 2.0 Total Score at Month 12: Participants Aged >=10 Years | -0.6 Units on a scale | Standard Deviation 2.16 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in PUL 2.0 Total Score at Month 12: Participants Aged >=10 Years | -0.9 Units on a scale | Standard Deviation 2.37 |
| Total Ambulatory Participants | Change From Baseline in PUL 2.0 Total Score at Month 12: Participants Aged >=10 Years | -0.7 Units on a scale | Standard Deviation 2.22 |
Change From Baseline in PUL 2.0 Total Score at Month 18: Participants Aged >=10 Years
PUL 2.0 scale is a 22-item scale used to assess the change that occurs in motor performance of the upper limb overtime from when a participant is still ambulant to the time participant loses all arm function when non-ambulant. PUL 2.0 includes an entry item to define broad starting functional level and 22 items subdivided into shoulder level (six items), mid-level (nine items), and distal level (seven items). Each dimension (shoulder, mid, distal) can be scored separately. There is maximum score of 12 for shoulder level, 17 for mid-level, and 13 for distal level. The total score was calculated by adding three level scores and ranged from 0-42. Higher score indicates better upper limb function. PUL 2.0 total score was assessed in participants aged \>=10 years only as pre-specified in protocol.
Time frame: Baseline (Day 1) and Month 18
Population: Full Analysis Set included all participants who had been enrolled in the study. Here, Number of Participants Analyzed signifies participants evaluable for this outcome measure.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Ambulatory Participants With Age <6 Years | Change From Baseline in PUL 2.0 Total Score at Month 18: Participants Aged >=10 Years | -1.7 Units on a scale | Standard Deviation 3.22 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in PUL 2.0 Total Score at Month 18: Participants Aged >=10 Years | -4.3 Units on a scale | Standard Deviation 2.75 |
| Total Ambulatory Participants | Change From Baseline in PUL 2.0 Total Score at Month 18: Participants Aged >=10 Years | -2.1 Units on a scale | Standard Deviation 3.23 |
Change From Baseline in PUL 2.0 Total Score at Month 24: Participants Aged >=10 Years
PUL 2.0 scale is a 22-item scale used to assess the change that occurs in motor performance of the upper limb overtime from when a participant is still ambulant to the time participant loses all arm function when non-ambulant. PUL 2.0 includes an entry item to define broad starting functional level and 22 items subdivided into shoulder level (six items), mid-level (nine items), and distal level (seven items). Each dimension (shoulder, mid, distal) can be scored separately. There is maximum score of 12 for shoulder level, 17 for mid-level, and 13 for distal level. The total score was calculated by adding three level scores and ranged from 0-42. Higher score indicates better upper limb function. PUL 2.0 total score was assessed in participants aged \>=10 years only as pre-specified in protocol.
Time frame: Baseline (Day 1) and Month 24
Population: Full Analysis Set included all participants who had been enrolled in the study. Here, Number of Participants Analyzed signifies participants evaluable for this outcome measure.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Ambulatory Participants With Age <6 Years | Change From Baseline in PUL 2.0 Total Score at Month 24: Participants Aged >=10 Years | -2.8 Units on a scale | Standard Deviation 3.92 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in PUL 2.0 Total Score at Month 24: Participants Aged >=10 Years | -2.9 Units on a scale | Standard Deviation 3.23 |
| Total Ambulatory Participants | Change From Baseline in PUL 2.0 Total Score at Month 24: Participants Aged >=10 Years | -2.8 Units on a scale | Standard Deviation 3.65 |
Change From Baseline in PUL 2.0 Total Score at Month 30: Participants Aged >=10 Years
PUL 2.0 scale is a 22-item scale used to assess the change that occurs in motor performance of the upper limb overtime from when a participant is still ambulant to the time participant loses all arm function when non-ambulant. PUL 2.0 includes an entry item to define broad starting functional level and 22 items subdivided into shoulder level (six items), mid-level (nine items), and distal level (seven items). Each dimension (shoulder, mid, distal) can be scored separately. There is maximum score of 12 for shoulder level, 17 for mid-level, and 13 for distal level. The total score was calculated by adding three level scores and ranged from 0-42. Higher score indicates better upper limb function. PUL 2.0 total score was assessed in participants aged \>=10 years only as pre-specified in protocol.
Time frame: Baseline (Day 1) and Month 30
Population: Full Analysis Set included all participants who had been enrolled in the study. Here, Number of Participants Analyzed signifies participants evaluable for this outcome measure.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Ambulatory Participants With Age <6 Years | Change From Baseline in PUL 2.0 Total Score at Month 30: Participants Aged >=10 Years | -1.7 Units on a scale | Standard Deviation 3.37 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in PUL 2.0 Total Score at Month 30: Participants Aged >=10 Years | -3.8 Units on a scale | Standard Deviation 1.71 |
| Total Ambulatory Participants | Change From Baseline in PUL 2.0 Total Score at Month 30: Participants Aged >=10 Years | -2.1 Units on a scale | Standard Deviation 3.21 |
Change From Baseline in Range of Motion (ROM) at Bilateral Ankles at Month 6
Range of motion was evaluated by using goniometry to record any occurrences of ankle contractures. The ROM at left and right ankles were measured in degrees of passive dorsiflexion.
Time frame: Baseline (Day 1) and Month 6
Population: Full Analysis Set included all participants who had been enrolled in the study. Here, Number of Participants Analyzed signifies participants evaluable for this outcome measure.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Ambulatory Participants With Age <6 Years | Change From Baseline in Range of Motion (ROM) at Bilateral Ankles at Month 6 | Left Ankle Joint | -0.5 Degrees of passive dorsiflexion | Standard Deviation 9.12 |
| Ambulatory Participants With Age <6 Years | Change From Baseline in Range of Motion (ROM) at Bilateral Ankles at Month 6 | Right Ankle Joint | -1.2 Degrees of passive dorsiflexion | Standard Deviation 8.59 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in Range of Motion (ROM) at Bilateral Ankles at Month 6 | Left Ankle Joint | 0.8 Degrees of passive dorsiflexion | Standard Deviation 10.94 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in Range of Motion (ROM) at Bilateral Ankles at Month 6 | Right Ankle Joint | -0.4 Degrees of passive dorsiflexion | Standard Deviation 10.69 |
| Total Ambulatory Participants | Change From Baseline in Range of Motion (ROM) at Bilateral Ankles at Month 6 | Left Ankle Joint | 0.3 Degrees of passive dorsiflexion | Standard Deviation 10.31 |
| Total Ambulatory Participants | Change From Baseline in Range of Motion (ROM) at Bilateral Ankles at Month 6 | Right Ankle Joint | -0.7 Degrees of passive dorsiflexion | Standard Deviation 9.96 |
| Non-ambulatory Participants | Change From Baseline in Range of Motion (ROM) at Bilateral Ankles at Month 6 | Right Ankle Joint | -8.2 Degrees of passive dorsiflexion | Standard Deviation 5.45 |
| Non-ambulatory Participants | Change From Baseline in Range of Motion (ROM) at Bilateral Ankles at Month 6 | Left Ankle Joint | -8.2 Degrees of passive dorsiflexion | Standard Deviation 8.5 |
| Total Participants | Change From Baseline in Range of Motion (ROM) at Bilateral Ankles at Month 6 | Left Ankle Joint | 0.2 Degrees of passive dorsiflexion | Standard Deviation 10.33 |
| Total Participants | Change From Baseline in Range of Motion (ROM) at Bilateral Ankles at Month 6 | Right Ankle Joint | -0.8 Degrees of passive dorsiflexion | Standard Deviation 9.94 |
Change From Baseline in Rise From Floor Velocity at Month 12: Ambulatory Participants Aged >=3 Years Only
The rise from floor velocity was defined as the reciprocal of the time (in seconds) to rise from floor. The rise from floor test was performed only in ambulatory participants aged \>=3 years old as pre-specified in the protocol.
Time frame: Baseline (Day 1) and Month 12
Population: Full Analysis Set included all participants who had been enrolled in the study. Here, Number of Participants Analyzed signifies participants evaluable for this outcome measure.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Ambulatory Participants With Age <6 Years | Change From Baseline in Rise From Floor Velocity at Month 12: Ambulatory Participants Aged >=3 Years Only | 0.0 Rise per second | Standard Deviation 0.08 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in Rise From Floor Velocity at Month 12: Ambulatory Participants Aged >=3 Years Only | -0.0 Rise per second | Standard Deviation 0.07 |
| Total Ambulatory Participants | Change From Baseline in Rise From Floor Velocity at Month 12: Ambulatory Participants Aged >=3 Years Only | -0.0 Rise per second | Standard Deviation 0.08 |
Change From Baseline in Rise From Floor Velocity at Month 18: Ambulatory Participants Aged >=3 Years Only
The rise from floor velocity was defined as the reciprocal of the time (in seconds) to rise from floor. The rise from floor test was performed only in ambulatory participants aged \>=3 years old as pre-specified in the protocol.
Time frame: Baseline (Day 1) and Month 18
Population: Full Analysis Set included all participants who had been enrolled in the study. Here, Number of Participants Analyzed signifies participants evaluable for this outcome measure.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Ambulatory Participants With Age <6 Years | Change From Baseline in Rise From Floor Velocity at Month 18: Ambulatory Participants Aged >=3 Years Only | 0.0 Rise per second | Standard Deviation 0.08 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in Rise From Floor Velocity at Month 18: Ambulatory Participants Aged >=3 Years Only | -0.0 Rise per second | Standard Deviation 0.06 |
| Total Ambulatory Participants | Change From Baseline in Rise From Floor Velocity at Month 18: Ambulatory Participants Aged >=3 Years Only | -0.0 Rise per second | Standard Deviation 0.08 |
Change From Baseline in Rise From Floor Velocity at Month 24: Ambulatory Participants Aged >=3 Years Only
The rise from floor velocity was defined as the reciprocal of the time (in seconds) to rise from floor. The rise from floor test was performed only in ambulatory participants aged \>=3 years old as pre-specified in the protocol.
Time frame: Baseline (Day 1) and Month 24
Population: Full Analysis Set included all participants who had been enrolled in the study. Here, Number of Participants Analyzed signifies participants evaluable for this outcome measure.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Ambulatory Participants With Age <6 Years | Change From Baseline in Rise From Floor Velocity at Month 24: Ambulatory Participants Aged >=3 Years Only | 0.0 Rise per second | Standard Deviation 0.09 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in Rise From Floor Velocity at Month 24: Ambulatory Participants Aged >=3 Years Only | -0.1 Rise per second | Standard Deviation 0.07 |
| Total Ambulatory Participants | Change From Baseline in Rise From Floor Velocity at Month 24: Ambulatory Participants Aged >=3 Years Only | -0.0 Rise per second | Standard Deviation 0.09 |
Change From Baseline in Rise From Floor Velocity at Month 30: Ambulatory Participants Aged >=3 Years Only
The rise from floor velocity was defined as the reciprocal of the time (in seconds) to rise from floor. The rise from floor test was performed only in ambulatory participants aged \>=3 years old as pre-specified in the protocol.
Time frame: Baseline (Day 1) and Month 30
Population: Full Analysis Set included all participants who had been enrolled in the study. Here, Number of Participants Analyzed signifies participants evaluable for this outcome measure.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Ambulatory Participants With Age <6 Years | Change From Baseline in Rise From Floor Velocity at Month 30: Ambulatory Participants Aged >=3 Years Only | 0.0 Rise per second | Standard Deviation 0.1 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in Rise From Floor Velocity at Month 30: Ambulatory Participants Aged >=3 Years Only | -0.1 Rise per second | Standard Deviation 0.08 |
| Total Ambulatory Participants | Change From Baseline in Rise From Floor Velocity at Month 30: Ambulatory Participants Aged >=3 Years Only | -0.1 Rise per second | Standard Deviation 0.1 |
Change From Baseline in Rise From Floor Velocity at Month 6: Ambulatory Participants Aged >=3 Years Only
The rise from floor velocity was defined as the reciprocal of the time (in seconds) to rise from floor. The rise from floor test was performed only in ambulatory participants aged \>=3 years old as pre-specified in the protocol.
Time frame: Baseline (Day 1) and Month 6
Population: Full Analysis Set included all participants who had been enrolled in the study. Here, Number of Participants Analyzed signifies participants evaluable for this outcome measure.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Ambulatory Participants With Age <6 Years | Change From Baseline in Rise From Floor Velocity at Month 6: Ambulatory Participants Aged >=3 Years Only | 0.0 Rise per second | Standard Deviation 0.07 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in Rise From Floor Velocity at Month 6: Ambulatory Participants Aged >=3 Years Only | -0.0 Rise per second | Standard Deviation 0.05 |
| Total Ambulatory Participants | Change From Baseline in Rise From Floor Velocity at Month 6: Ambulatory Participants Aged >=3 Years Only | 0.0 Rise per second | Standard Deviation 0.06 |
Change From Baseline in ROM at Bilateral Ankles at Month 12
Range of motion was evaluated by using goniometry to record any occurrences of ankle contractures. The ROM at left and right ankles were measured in degrees of passive dorsiflexion.
Time frame: Baseline (Day 1) and Month 12
Population: Full Analysis Set included all participants who had been enrolled in the study. Here, Number of Participants Analyzed signifies participants evaluable for this outcome measure.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Ambulatory Participants With Age <6 Years | Change From Baseline in ROM at Bilateral Ankles at Month 12 | Left Ankle Joint | -2.6 Degrees of passive dorsiflexion | Standard Deviation 10.13 |
| Ambulatory Participants With Age <6 Years | Change From Baseline in ROM at Bilateral Ankles at Month 12 | Right Ankle Joint | -3.1 Degrees of passive dorsiflexion | Standard Deviation 9.19 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in ROM at Bilateral Ankles at Month 12 | Right Ankle Joint | -2.8 Degrees of passive dorsiflexion | Standard Deviation 10.85 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in ROM at Bilateral Ankles at Month 12 | Left Ankle Joint | -2.0 Degrees of passive dorsiflexion | Standard Deviation 11.06 |
| Total Ambulatory Participants | Change From Baseline in ROM at Bilateral Ankles at Month 12 | Right Ankle Joint | -2.9 Degrees of passive dorsiflexion | Standard Deviation 10.31 |
| Total Ambulatory Participants | Change From Baseline in ROM at Bilateral Ankles at Month 12 | Left Ankle Joint | -2.2 Degrees of passive dorsiflexion | Standard Deviation 10.74 |
| Non-ambulatory Participants | Change From Baseline in ROM at Bilateral Ankles at Month 12 | Left Ankle Joint | -11.6 Degrees of passive dorsiflexion | Standard Deviation 18.18 |
| Non-ambulatory Participants | Change From Baseline in ROM at Bilateral Ankles at Month 12 | Right Ankle Joint | -7.9 Degrees of passive dorsiflexion | Standard Deviation 19.74 |
| Total Participants | Change From Baseline in ROM at Bilateral Ankles at Month 12 | Right Ankle Joint | -3.4 Degrees of passive dorsiflexion | Standard Deviation 11.7 |
| Total Participants | Change From Baseline in ROM at Bilateral Ankles at Month 12 | Left Ankle Joint | -3.2 Degrees of passive dorsiflexion | Standard Deviation 12.05 |
Change From Baseline in ROM at Bilateral Ankles at Month 18
Range of motion was evaluated by using goniometry to record any occurrences of ankle contractures. The ROM at left and right ankles were measured in degrees of passive dorsiflexion.
Time frame: Baseline (Day 1) and Month 18
Population: Full Analysis Set included all participants who had been enrolled in the study. Here, Number of Participants Analyzed signifies participants evaluable for this outcome measure.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Ambulatory Participants With Age <6 Years | Change From Baseline in ROM at Bilateral Ankles at Month 18 | Left Ankle Joint | -1.8 Degrees of passive dorsiflexion | Standard Deviation 9.19 |
| Ambulatory Participants With Age <6 Years | Change From Baseline in ROM at Bilateral Ankles at Month 18 | Right Ankle Joint | -2.2 Degrees of passive dorsiflexion | Standard Deviation 8.91 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in ROM at Bilateral Ankles at Month 18 | Left Ankle Joint | -4.0 Degrees of passive dorsiflexion | Standard Deviation 10.9 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in ROM at Bilateral Ankles at Month 18 | Right Ankle Joint | -4.5 Degrees of passive dorsiflexion | Standard Deviation 11.5 |
| Total Ambulatory Participants | Change From Baseline in ROM at Bilateral Ankles at Month 18 | Left Ankle Joint | -3.1 Degrees of passive dorsiflexion | Standard Deviation 10.28 |
| Total Ambulatory Participants | Change From Baseline in ROM at Bilateral Ankles at Month 18 | Right Ankle Joint | -3.6 Degrees of passive dorsiflexion | Standard Deviation 10.58 |
| Non-ambulatory Participants | Change From Baseline in ROM at Bilateral Ankles at Month 18 | Right Ankle Joint | -5.0 Degrees of passive dorsiflexion | Standard Deviation 4.24 |
| Non-ambulatory Participants | Change From Baseline in ROM at Bilateral Ankles at Month 18 | Left Ankle Joint | -8.8 Degrees of passive dorsiflexion | Standard Deviation 12.47 |
| Total Participants | Change From Baseline in ROM at Bilateral Ankles at Month 18 | Left Ankle Joint | -3.2 Degrees of passive dorsiflexion | Standard Deviation 10.32 |
| Total Participants | Change From Baseline in ROM at Bilateral Ankles at Month 18 | Right Ankle Joint | -3.6 Degrees of passive dorsiflexion | Standard Deviation 10.48 |
Change From Baseline in ROM at Bilateral Ankles at Month 24
Range of motion was evaluated by using goniometry to record any occurrences of ankle contractures. The ROM at left and right ankles were measured in degrees of passive dorsiflexion.
Time frame: Baseline (Day 1) and Month 24
Population: Full Analysis Set included all participants who had been enrolled in the study. Here, Number of Participants Analyzed signifies participants evaluable for this outcome measure.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Ambulatory Participants With Age <6 Years | Change From Baseline in ROM at Bilateral Ankles at Month 24 | Left Ankle Joint | -2.8 Degrees of passive dorsiflexion | Standard Deviation 8.59 |
| Ambulatory Participants With Age <6 Years | Change From Baseline in ROM at Bilateral Ankles at Month 24 | Right Ankle Joint | -3.6 Degrees of passive dorsiflexion | Standard Deviation 8.78 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in ROM at Bilateral Ankles at Month 24 | Left Ankle Joint | -4.8 Degrees of passive dorsiflexion | Standard Deviation 12.09 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in ROM at Bilateral Ankles at Month 24 | Right Ankle Joint | -6.0 Degrees of passive dorsiflexion | Standard Deviation 12.88 |
| Total Ambulatory Participants | Change From Baseline in ROM at Bilateral Ankles at Month 24 | Left Ankle Joint | -4.1 Degrees of passive dorsiflexion | Standard Deviation 11 |
| Total Ambulatory Participants | Change From Baseline in ROM at Bilateral Ankles at Month 24 | Right Ankle Joint | -5.1 Degrees of passive dorsiflexion | Standard Deviation 11.62 |
| Non-ambulatory Participants | Change From Baseline in ROM at Bilateral Ankles at Month 24 | Right Ankle Joint | -11.4 Degrees of passive dorsiflexion | Standard Deviation 15.77 |
| Non-ambulatory Participants | Change From Baseline in ROM at Bilateral Ankles at Month 24 | Left Ankle Joint | -8.5 Degrees of passive dorsiflexion | Standard Deviation 15.79 |
| Total Participants | Change From Baseline in ROM at Bilateral Ankles at Month 24 | Left Ankle Joint | -4.6 Degrees of passive dorsiflexion | Standard Deviation 11.59 |
| Total Participants | Change From Baseline in ROM at Bilateral Ankles at Month 24 | Right Ankle Joint | -5.8 Degrees of passive dorsiflexion | Standard Deviation 12.2 |
Change From Baseline in ROM at Bilateral Ankles at Month 30
Range of motion was evaluated by using goniometry to record any occurrences of ankle contractures. The ROM at left and right ankles were measured in degrees of passive dorsiflexion.
Time frame: Baseline (Day 1) and Month 30
Population: Full Analysis Set included all participants who had been enrolled in the study. Here, Number of Participants Analyzed signifies participants evaluable for this outcome measure.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Ambulatory Participants With Age <6 Years | Change From Baseline in ROM at Bilateral Ankles at Month 30 | Left Ankle Joint | 0.3 Degrees of passive dorsiflexion | Standard Deviation 9.5 |
| Ambulatory Participants With Age <6 Years | Change From Baseline in ROM at Bilateral Ankles at Month 30 | Right Ankle Joint | 0.1 Degrees of passive dorsiflexion | Standard Deviation 8.08 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in ROM at Bilateral Ankles at Month 30 | Left Ankle Joint | -4.9 Degrees of passive dorsiflexion | Standard Deviation 12.23 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in ROM at Bilateral Ankles at Month 30 | Right Ankle Joint | -6.5 Degrees of passive dorsiflexion | Standard Deviation 13.04 |
| Total Ambulatory Participants | Change From Baseline in ROM at Bilateral Ankles at Month 30 | Left Ankle Joint | -3.4 Degrees of passive dorsiflexion | Standard Deviation 11.71 |
| Total Ambulatory Participants | Change From Baseline in ROM at Bilateral Ankles at Month 30 | Right Ankle Joint | -4.6 Degrees of passive dorsiflexion | Standard Deviation 12.18 |
| Non-ambulatory Participants | Change From Baseline in ROM at Bilateral Ankles at Month 30 | Right Ankle Joint | -2.5 Degrees of passive dorsiflexion | Standard Deviation 6.24 |
| Non-ambulatory Participants | Change From Baseline in ROM at Bilateral Ankles at Month 30 | Left Ankle Joint | -4.8 Degrees of passive dorsiflexion | Standard Deviation 14.08 |
| Total Participants | Change From Baseline in ROM at Bilateral Ankles at Month 30 | Left Ankle Joint | -3.5 Degrees of passive dorsiflexion | Standard Deviation 11.73 |
| Total Participants | Change From Baseline in ROM at Bilateral Ankles at Month 30 | Right Ankle Joint | -4.5 Degrees of passive dorsiflexion | Standard Deviation 12.01 |
Change From Baseline in ROM at Bilateral Elbows at Month 12
Range of motion was evaluated by using goniometry to record any occurrences of elbow contractures. The ROM at left and right elbows were measured in degrees of passive extension.
Time frame: Baseline (Day 1) and Month 12
Population: Full Analysis Set included all participants who had been enrolled in the study. Here, Number of Participants Analyzed signifies participants evaluable for this outcome measure.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Ambulatory Participants With Age <6 Years | Change From Baseline in ROM at Bilateral Elbows at Month 12 | Right Elbow Joint | -2.7 Degrees of passive extension | Standard Deviation 9.86 |
| Ambulatory Participants With Age <6 Years | Change From Baseline in ROM at Bilateral Elbows at Month 12 | Left Elbow Joint | -2.3 Degrees of passive extension | Standard Deviation 10.33 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in ROM at Bilateral Elbows at Month 12 | Right Elbow Joint | -0.3 Degrees of passive extension | Standard Deviation 7.85 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in ROM at Bilateral Elbows at Month 12 | Left Elbow Joint | -1.3 Degrees of passive extension | Standard Deviation 7.9 |
| Total Ambulatory Participants | Change From Baseline in ROM at Bilateral Elbows at Month 12 | Right Elbow Joint | -1.1 Degrees of passive extension | Standard Deviation 8.63 |
| Total Ambulatory Participants | Change From Baseline in ROM at Bilateral Elbows at Month 12 | Left Elbow Joint | -1.6 Degrees of passive extension | Standard Deviation 8.77 |
| Non-ambulatory Participants | Change From Baseline in ROM at Bilateral Elbows at Month 12 | Left Elbow Joint | -3.3 Degrees of passive extension | Standard Deviation 11.52 |
| Non-ambulatory Participants | Change From Baseline in ROM at Bilateral Elbows at Month 12 | Right Elbow Joint | -2.7 Degrees of passive extension | Standard Deviation 11.19 |
| Total Participants | Change From Baseline in ROM at Bilateral Elbows at Month 12 | Right Elbow Joint | -1.3 Degrees of passive extension | Standard Deviation 8.93 |
| Total Participants | Change From Baseline in ROM at Bilateral Elbows at Month 12 | Left Elbow Joint | -1.8 Degrees of passive extension | Standard Deviation 9.1 |
Change From Baseline in ROM at Bilateral Elbows at Month 18
Range of motion was evaluated by using goniometry to record any occurrences of elbow contractures. The ROM at left and right elbows were measured in degrees of passive extension.
Time frame: Baseline (Day 1) and Month 18
Population: Full Analysis Set included all participants who had been enrolled in the study. Here, Number of Participants Analyzed signifies participants evaluable for this outcome measure. Number Analyzed signifies participants evaluable for the specified rows.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Ambulatory Participants With Age <6 Years | Change From Baseline in ROM at Bilateral Elbows at Month 18 | Right Elbow Joint | -1.6 Degrees of passive extension | Standard Deviation 8.44 |
| Ambulatory Participants With Age <6 Years | Change From Baseline in ROM at Bilateral Elbows at Month 18 | Left Elbow Joint | -1.1 Degrees of passive extension | Standard Deviation 8.43 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in ROM at Bilateral Elbows at Month 18 | Right Elbow Joint | -1.8 Degrees of passive extension | Standard Deviation 8.03 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in ROM at Bilateral Elbows at Month 18 | Left Elbow Joint | -2.6 Degrees of passive extension | Standard Deviation 6.41 |
| Total Ambulatory Participants | Change From Baseline in ROM at Bilateral Elbows at Month 18 | Right Elbow Joint | -1.7 Degrees of passive extension | Standard Deviation 8.18 |
| Total Ambulatory Participants | Change From Baseline in ROM at Bilateral Elbows at Month 18 | Left Elbow Joint | -2.0 Degrees of passive extension | Standard Deviation 7.3 |
| Non-ambulatory Participants | Change From Baseline in ROM at Bilateral Elbows at Month 18 | Left Elbow Joint | -10.3 Degrees of passive extension | Standard Deviation 2.63 |
| Non-ambulatory Participants | Change From Baseline in ROM at Bilateral Elbows at Month 18 | Right Elbow Joint | -7.0 Degrees of passive extension | Standard Deviation 12.99 |
| Total Participants | Change From Baseline in ROM at Bilateral Elbows at Month 18 | Right Elbow Joint | -1.8 Degrees of passive extension | Standard Deviation 8.28 |
| Total Participants | Change From Baseline in ROM at Bilateral Elbows at Month 18 | Left Elbow Joint | -2.1 Degrees of passive extension | Standard Deviation 7.33 |
Change From Baseline in ROM at Bilateral Elbows at Month 24
Range of motion was evaluated by using goniometry to record any occurrences of elbow contractures. The ROM at left and right elbows were measured in degrees of passive extension.
Time frame: Baseline (Day 1) and Month 24
Population: Full Analysis Set included all participants who had been enrolled in the study. Here, Number of Participants Analyzed signifies participants evaluable for this outcome measure.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Ambulatory Participants With Age <6 Years | Change From Baseline in ROM at Bilateral Elbows at Month 24 | Right Elbow Joint | 0.1 Degrees of passive extension | Standard Deviation 6.68 |
| Ambulatory Participants With Age <6 Years | Change From Baseline in ROM at Bilateral Elbows at Month 24 | Left Elbow Joint | 0.7 Degrees of passive extension | Standard Deviation 6.79 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in ROM at Bilateral Elbows at Month 24 | Right Elbow Joint | -1.0 Degrees of passive extension | Standard Deviation 7.42 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in ROM at Bilateral Elbows at Month 24 | Left Elbow Joint | -1.5 Degrees of passive extension | Standard Deviation 6.99 |
| Total Ambulatory Participants | Change From Baseline in ROM at Bilateral Elbows at Month 24 | Right Elbow Joint | -0.6 Degrees of passive extension | Standard Deviation 7.17 |
| Total Ambulatory Participants | Change From Baseline in ROM at Bilateral Elbows at Month 24 | Left Elbow Joint | -0.7 Degrees of passive extension | Standard Deviation 6.98 |
| Non-ambulatory Participants | Change From Baseline in ROM at Bilateral Elbows at Month 24 | Left Elbow Joint | -5.7 Degrees of passive extension | Standard Deviation 13.87 |
| Non-ambulatory Participants | Change From Baseline in ROM at Bilateral Elbows at Month 24 | Right Elbow Joint | -5.1 Degrees of passive extension | Standard Deviation 13.22 |
| Total Participants | Change From Baseline in ROM at Bilateral Elbows at Month 24 | Right Elbow Joint | -1.1 Degrees of passive extension | Standard Deviation 8.04 |
| Total Participants | Change From Baseline in ROM at Bilateral Elbows at Month 24 | Left Elbow Joint | -1.2 Degrees of passive extension | Standard Deviation 8.02 |
Change From Baseline in ROM at Bilateral Elbows at Month 30
Range of motion was evaluated by using goniometry to record any occurrences of elbow contractures. The ROM at left and right elbows were measured in degrees of passive extension.
Time frame: Baseline (Day 1) and Month 30
Population: Full Analysis Set included all participants who had been enrolled in the study. Here, Number of Participants Analyzed signifies participants evaluable for this outcome measure.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Ambulatory Participants With Age <6 Years | Change From Baseline in ROM at Bilateral Elbows at Month 30 | Right Elbow Joint | 1.0 Degrees of passive extension | Standard Deviation 5.47 |
| Ambulatory Participants With Age <6 Years | Change From Baseline in ROM at Bilateral Elbows at Month 30 | Left Elbow Joint | 1.0 Degrees of passive extension | Standard Deviation 6.69 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in ROM at Bilateral Elbows at Month 30 | Right Elbow Joint | -1.9 Degrees of passive extension | Standard Deviation 7.52 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in ROM at Bilateral Elbows at Month 30 | Left Elbow Joint | -2.2 Degrees of passive extension | Standard Deviation 7.23 |
| Total Ambulatory Participants | Change From Baseline in ROM at Bilateral Elbows at Month 30 | Right Elbow Joint | -1.1 Degrees of passive extension | Standard Deviation 7.1 |
| Total Ambulatory Participants | Change From Baseline in ROM at Bilateral Elbows at Month 30 | Left Elbow Joint | -1.3 Degrees of passive extension | Standard Deviation 7.19 |
| Non-ambulatory Participants | Change From Baseline in ROM at Bilateral Elbows at Month 30 | Left Elbow Joint | -9.0 Degrees of passive extension | Standard Deviation 14.26 |
| Non-ambulatory Participants | Change From Baseline in ROM at Bilateral Elbows at Month 30 | Right Elbow Joint | -5.0 Degrees of passive extension | Standard Deviation 17.74 |
| Total Participants | Change From Baseline in ROM at Bilateral Elbows at Month 30 | Right Elbow Joint | -1.2 Degrees of passive extension | Standard Deviation 7.6 |
| Total Participants | Change From Baseline in ROM at Bilateral Elbows at Month 30 | Left Elbow Joint | -1.5 Degrees of passive extension | Standard Deviation 7.58 |
Change From Baseline in ROM at Bilateral Elbows at Month 6
Range of motion was evaluated by using goniometry to record any occurrences of elbow contractures. The ROM at left and right elbows were measured in degrees of passive extension.
Time frame: Baseline (Day 1) and Month 6
Population: Full Analysis Set included all participants who had been enrolled in the study. Here, Number of Participants Analyzed signifies participants evaluable for this outcome measure.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Ambulatory Participants With Age <6 Years | Change From Baseline in ROM at Bilateral Elbows at Month 6 | Right Elbow Joint | 1.0 Degrees of passive extension | Standard Deviation 7.13 |
| Ambulatory Participants With Age <6 Years | Change From Baseline in ROM at Bilateral Elbows at Month 6 | Left Elbow Joint | 0.8 Degrees of passive extension | Standard Deviation 7.13 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in ROM at Bilateral Elbows at Month 6 | Right Elbow Joint | 1.0 Degrees of passive extension | Standard Deviation 6.82 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in ROM at Bilateral Elbows at Month 6 | Left Elbow Joint | 0.7 Degrees of passive extension | Standard Deviation 6.17 |
| Total Ambulatory Participants | Change From Baseline in ROM at Bilateral Elbows at Month 6 | Right Elbow Joint | 1.0 Degrees of passive extension | Standard Deviation 6.92 |
| Total Ambulatory Participants | Change From Baseline in ROM at Bilateral Elbows at Month 6 | Left Elbow Joint | 0.8 Degrees of passive extension | Standard Deviation 6.53 |
| Non-ambulatory Participants | Change From Baseline in ROM at Bilateral Elbows at Month 6 | Left Elbow Joint | -4.0 Degrees of passive extension | Standard Deviation 2.92 |
| Non-ambulatory Participants | Change From Baseline in ROM at Bilateral Elbows at Month 6 | Right Elbow Joint | -3.2 Degrees of passive extension | Standard Deviation 7.79 |
| Total Participants | Change From Baseline in ROM at Bilateral Elbows at Month 6 | Right Elbow Joint | 0.9 Degrees of passive extension | Standard Deviation 6.95 |
| Total Participants | Change From Baseline in ROM at Bilateral Elbows at Month 6 | Left Elbow Joint | 0.7 Degrees of passive extension | Standard Deviation 6.51 |
Change From Baseline in Shoulder Abduction of Muscle Strength at Month 12: Participants Aged >=5 Years
Muscle strength was recorded by handheld myometry. Left and right shoulder abduction were analyzed. The muscle strength test was only performed in participants \>=5 years old as pre-specified in the protocol.
Time frame: Baseline (Day 1) and Month 12
Population: Full Analysis Set included all participants who had been enrolled in the study. Here, Number of Participants Analyzed signifies participants evaluable for this outcome measure. 'Number Analyzed' signifies participants evaluable for specified rows.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Ambulatory Participants With Age <6 Years | Change From Baseline in Shoulder Abduction of Muscle Strength at Month 12: Participants Aged >=5 Years | Left Shoulder Abduction | 0.5 Kilograms | Standard Deviation 0.76 |
| Ambulatory Participants With Age <6 Years | Change From Baseline in Shoulder Abduction of Muscle Strength at Month 12: Participants Aged >=5 Years | Right Shoulder Abduction | 0.6 Kilograms | Standard Deviation 0.86 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in Shoulder Abduction of Muscle Strength at Month 12: Participants Aged >=5 Years | Left Shoulder Abduction | 0.4 Kilograms | Standard Deviation 0.89 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in Shoulder Abduction of Muscle Strength at Month 12: Participants Aged >=5 Years | Right Shoulder Abduction | 0.5 Kilograms | Standard Deviation 1 |
| Total Ambulatory Participants | Change From Baseline in Shoulder Abduction of Muscle Strength at Month 12: Participants Aged >=5 Years | Left Shoulder Abduction | 0.4 Kilograms | Standard Deviation 0.88 |
| Total Ambulatory Participants | Change From Baseline in Shoulder Abduction of Muscle Strength at Month 12: Participants Aged >=5 Years | Right Shoulder Abduction | 0.5 Kilograms | Standard Deviation 0.99 |
| Non-ambulatory Participants | Change From Baseline in Shoulder Abduction of Muscle Strength at Month 12: Participants Aged >=5 Years | Right Shoulder Abduction | 0.1 Kilograms | Standard Deviation 0.97 |
| Non-ambulatory Participants | Change From Baseline in Shoulder Abduction of Muscle Strength at Month 12: Participants Aged >=5 Years | Left Shoulder Abduction | 0.1 Kilograms | Standard Deviation 0.82 |
| Total Participants | Change From Baseline in Shoulder Abduction of Muscle Strength at Month 12: Participants Aged >=5 Years | Left Shoulder Abduction | 0.4 Kilograms | Standard Deviation 0.88 |
| Total Participants | Change From Baseline in Shoulder Abduction of Muscle Strength at Month 12: Participants Aged >=5 Years | Right Shoulder Abduction | 0.4 Kilograms | Standard Deviation 0.99 |
Change From Baseline in Shoulder Abduction of Muscle Strength at Month 18: Participants Aged >=5 Years
Muscle strength was recorded by handheld myometry. Left and right shoulder abduction were analyzed. The muscle strength test was only performed in participants \>=5 years old as pre-specified in the protocol.
Time frame: Baseline (Day 1) and Month 18
Population: Full Analysis Set included all participants who had been enrolled in the study. Here, Number of Participants Analyzed signifies participants evaluable for this outcome measure. 'Number Analyzed' signifies participants evaluable for specified rows.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Ambulatory Participants With Age <6 Years | Change From Baseline in Shoulder Abduction of Muscle Strength at Month 18: Participants Aged >=5 Years | Left Shoulder Abduction | 0.5 Kilograms | Standard Deviation 0.65 |
| Ambulatory Participants With Age <6 Years | Change From Baseline in Shoulder Abduction of Muscle Strength at Month 18: Participants Aged >=5 Years | Right Shoulder Abduction | 0.8 Kilograms | Standard Deviation 0.98 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in Shoulder Abduction of Muscle Strength at Month 18: Participants Aged >=5 Years | Left Shoulder Abduction | 0.4 Kilograms | Standard Deviation 0.98 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in Shoulder Abduction of Muscle Strength at Month 18: Participants Aged >=5 Years | Right Shoulder Abduction | 0.4 Kilograms | Standard Deviation 1.05 |
| Total Ambulatory Participants | Change From Baseline in Shoulder Abduction of Muscle Strength at Month 18: Participants Aged >=5 Years | Left Shoulder Abduction | 0.4 Kilograms | Standard Deviation 0.94 |
| Total Ambulatory Participants | Change From Baseline in Shoulder Abduction of Muscle Strength at Month 18: Participants Aged >=5 Years | Right Shoulder Abduction | 0.5 Kilograms | Standard Deviation 1.04 |
| Non-ambulatory Participants | Change From Baseline in Shoulder Abduction of Muscle Strength at Month 18: Participants Aged >=5 Years | Right Shoulder Abduction | -0.8 Kilograms | Standard Deviation 0.55 |
| Non-ambulatory Participants | Change From Baseline in Shoulder Abduction of Muscle Strength at Month 18: Participants Aged >=5 Years | Left Shoulder Abduction | -1.0 Kilograms | Standard Deviation 0.6 |
| Total Participants | Change From Baseline in Shoulder Abduction of Muscle Strength at Month 18: Participants Aged >=5 Years | Left Shoulder Abduction | 0.3 Kilograms | Standard Deviation 0.96 |
| Total Participants | Change From Baseline in Shoulder Abduction of Muscle Strength at Month 18: Participants Aged >=5 Years | Right Shoulder Abduction | 0.4 Kilograms | Standard Deviation 1.05 |
Change From Baseline in Shoulder Abduction of Muscle Strength at Month 24: Participants Aged >=5 Years
Muscle strength was recorded by handheld myometry. Left and right shoulder abduction were analyzed. The muscle strength test was only performed in participants \>=5 years old as pre-specified in the protocol.
Time frame: Baseline (Day 1) and Month 24
Population: Full Analysis Set included all participants who had been enrolled in the study. Here, Number of Participants Analyzed signifies participants evaluable for this outcome measure. 'Number Analyzed' signifies participants evaluable for specified rows.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Ambulatory Participants With Age <6 Years | Change From Baseline in Shoulder Abduction of Muscle Strength at Month 24: Participants Aged >=5 Years | Left Shoulder Abduction | 1.1 Kilograms | Standard Deviation 1.04 |
| Ambulatory Participants With Age <6 Years | Change From Baseline in Shoulder Abduction of Muscle Strength at Month 24: Participants Aged >=5 Years | Right Shoulder Abduction | 1.2 Kilograms | Standard Deviation 1.11 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in Shoulder Abduction of Muscle Strength at Month 24: Participants Aged >=5 Years | Left Shoulder Abduction | 0.3 Kilograms | Standard Deviation 1.13 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in Shoulder Abduction of Muscle Strength at Month 24: Participants Aged >=5 Years | Right Shoulder Abduction | 0.6 Kilograms | Standard Deviation 1.25 |
| Total Ambulatory Participants | Change From Baseline in Shoulder Abduction of Muscle Strength at Month 24: Participants Aged >=5 Years | Left Shoulder Abduction | 0.4 Kilograms | Standard Deviation 1.15 |
| Total Ambulatory Participants | Change From Baseline in Shoulder Abduction of Muscle Strength at Month 24: Participants Aged >=5 Years | Right Shoulder Abduction | 0.6 Kilograms | Standard Deviation 1.24 |
| Non-ambulatory Participants | Change From Baseline in Shoulder Abduction of Muscle Strength at Month 24: Participants Aged >=5 Years | Right Shoulder Abduction | -0.1 Kilograms | Standard Deviation 1.04 |
| Non-ambulatory Participants | Change From Baseline in Shoulder Abduction of Muscle Strength at Month 24: Participants Aged >=5 Years | Left Shoulder Abduction | 0.0 Kilograms | Standard Deviation 0.8 |
| Total Participants | Change From Baseline in Shoulder Abduction of Muscle Strength at Month 24: Participants Aged >=5 Years | Left Shoulder Abduction | 0.4 Kilograms | Standard Deviation 1.12 |
| Total Participants | Change From Baseline in Shoulder Abduction of Muscle Strength at Month 24: Participants Aged >=5 Years | Right Shoulder Abduction | 0.5 Kilograms | Standard Deviation 1.24 |
Change From Baseline in Shoulder Abduction of Muscle Strength at Month 30: Participants Aged >=5 Years
Muscle strength was recorded by handheld myometry. Left and right shoulder abduction were analyzed. The muscle strength test was only performed in participants \>=5 years old as pre-specified in the protocol.
Time frame: Baseline (Day 1) and Month 30
Population: Full Analysis Set included all participants who had been enrolled in the study. Here, Number of Participants Analyzed signifies participants evaluable for this outcome measure.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Ambulatory Participants With Age <6 Years | Change From Baseline in Shoulder Abduction of Muscle Strength at Month 30: Participants Aged >=5 Years | Left Shoulder Abduction | 0.6 Kilograms | Standard Deviation 1.28 |
| Ambulatory Participants With Age <6 Years | Change From Baseline in Shoulder Abduction of Muscle Strength at Month 30: Participants Aged >=5 Years | Right Shoulder Abduction | 0.8 Kilograms | Standard Deviation 0.93 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in Shoulder Abduction of Muscle Strength at Month 30: Participants Aged >=5 Years | Left Shoulder Abduction | 0.6 Kilograms | Standard Deviation 1.25 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in Shoulder Abduction of Muscle Strength at Month 30: Participants Aged >=5 Years | Right Shoulder Abduction | 0.8 Kilograms | Standard Deviation 1.34 |
| Total Ambulatory Participants | Change From Baseline in Shoulder Abduction of Muscle Strength at Month 30: Participants Aged >=5 Years | Left Shoulder Abduction | 0.6 Kilograms | Standard Deviation 1.25 |
| Total Ambulatory Participants | Change From Baseline in Shoulder Abduction of Muscle Strength at Month 30: Participants Aged >=5 Years | Right Shoulder Abduction | 0.8 Kilograms | Standard Deviation 1.31 |
| Non-ambulatory Participants | Change From Baseline in Shoulder Abduction of Muscle Strength at Month 30: Participants Aged >=5 Years | Right Shoulder Abduction | 1.3 Kilograms | Standard Deviation 1.77 |
| Non-ambulatory Participants | Change From Baseline in Shoulder Abduction of Muscle Strength at Month 30: Participants Aged >=5 Years | Left Shoulder Abduction | 0.8 Kilograms | Standard Deviation 1 |
| Total Participants | Change From Baseline in Shoulder Abduction of Muscle Strength at Month 30: Participants Aged >=5 Years | Left Shoulder Abduction | 0.6 Kilograms | Standard Deviation 1.23 |
| Total Participants | Change From Baseline in Shoulder Abduction of Muscle Strength at Month 30: Participants Aged >=5 Years | Right Shoulder Abduction | 0.8 Kilograms | Standard Deviation 1.32 |
Change From Baseline in Shoulder Abduction of Muscle Strength at Month 6: Participants Aged >=5 Years
Muscle strength was recorded by handheld myometry. Left and right shoulder abduction were analyzed. The muscle strength test was only performed in participants \>=5 years old as pre-specified in the protocol.
Time frame: Baseline (Day 1) and Month 6
Population: Full Analysis Set included all participants who had been enrolled in the study. Here, Number of Participants Analyzed signifies participants evaluable for this outcome measure. 'Number Analyzed' signifies participants evaluable for specified rows.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Ambulatory Participants With Age <6 Years | Change From Baseline in Shoulder Abduction of Muscle Strength at Month 6: Participants Aged >=5 Years | Left Shoulder Abduction | 0.4 Kilograms | Standard Deviation 1.15 |
| Ambulatory Participants With Age <6 Years | Change From Baseline in Shoulder Abduction of Muscle Strength at Month 6: Participants Aged >=5 Years | Right Shoulder Abduction | 0.5 Kilograms | Standard Deviation 0.95 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in Shoulder Abduction of Muscle Strength at Month 6: Participants Aged >=5 Years | Left Shoulder Abduction | 0.4 Kilograms | Standard Deviation 0.87 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in Shoulder Abduction of Muscle Strength at Month 6: Participants Aged >=5 Years | Right Shoulder Abduction | 0.4 Kilograms | Standard Deviation 0.9 |
| Total Ambulatory Participants | Change From Baseline in Shoulder Abduction of Muscle Strength at Month 6: Participants Aged >=5 Years | Left Shoulder Abduction | 0.4 Kilograms | Standard Deviation 0.91 |
| Total Ambulatory Participants | Change From Baseline in Shoulder Abduction of Muscle Strength at Month 6: Participants Aged >=5 Years | Right Shoulder Abduction | 0.4 Kilograms | Standard Deviation 0.9 |
| Non-ambulatory Participants | Change From Baseline in Shoulder Abduction of Muscle Strength at Month 6: Participants Aged >=5 Years | Right Shoulder Abduction | 0.3 Kilograms | Standard Deviation 0.1 |
| Non-ambulatory Participants | Change From Baseline in Shoulder Abduction of Muscle Strength at Month 6: Participants Aged >=5 Years | Left Shoulder Abduction | -0.1 Kilograms | Standard Deviation 0.45 |
| Total Participants | Change From Baseline in Shoulder Abduction of Muscle Strength at Month 6: Participants Aged >=5 Years | Left Shoulder Abduction | 0.4 Kilograms | Standard Deviation 0.9 |
| Total Participants | Change From Baseline in Shoulder Abduction of Muscle Strength at Month 6: Participants Aged >=5 Years | Right Shoulder Abduction | 0.4 Kilograms | Standard Deviation 0.89 |
Change From Baseline in Wechsler Intelligence Scale for Children (WISC)-IV Score at Month 24: Ambulatory Participants >= 6 to <=16 Years
WISC-IV is an individually administered intelligence test for children between the ages of 6 and 16. The WISC-IV Composites are: Verbal Comprehension, Perceptual Reasoning, Working Memory, and Processing Speed. Scores from the Composites constitute the WISC-IV Full Scale IQ score which ranges from 40 (Exceptionally Low) to 160 (Exceptionally Superior), higher scores indicated more intelligence. The WISC was only performed in ambulatory participants \>= 6 to \<=16 years old as pre-specified in the protocol.
Time frame: Baseline (Day 1) and Month 24
Population: Full Analysis Set included all participants who had been enrolled in the study. Here, Number of Participants Analyzed signifies participants evaluable for this outcome measure.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Ambulatory Participants With Age <6 Years | Change From Baseline in Wechsler Intelligence Scale for Children (WISC)-IV Score at Month 24: Ambulatory Participants >= 6 to <=16 Years | 1.0 Units on a scale | Standard Deviation 8.59 |
Change From Baseline in EQ-5D-3L Index Score at Months 12, 24 and 30
EQ-5D-3L index score, participants rated their current health state on 5 single-item dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression with each dimension having three levels of severity: 1=no problems, 2=some problems and 3=extreme problems. Scoring formula developed by EuroQol Group assigns a utility value for each domain in the profile. Score was transformed and results in a total index score range of 0 to 1.00. Higher scores indicating a better quality of life. EQ-5D-3L was only performed in participants \>= 16 years old.
Time frame: Baseline (Day 1) and Months 12, 24, and 30
Population: Full Analysis Set included all participants who had been enrolled in the study. Number of Participants Analyzed' signifies all participants in the Full Analysis Set with age \>=16 years. 'Number Analyzed' signifies participants evaluable for specified rows.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Ambulatory Participants With Age <6 Years | Change From Baseline in EQ-5D-3L Index Score at Months 12, 24 and 30 | Month 12 | -0.0 Units on a scale | Standard Deviation 0.14 |
| Ambulatory Participants With Age <6 Years | Change From Baseline in EQ-5D-3L Index Score at Months 12, 24 and 30 | Month 24 | -0.2 Units on a scale | Standard Deviation 0.16 |
| Ambulatory Participants With Age <6 Years | Change From Baseline in EQ-5D-3L Index Score at Months 12, 24 and 30 | Month 30 | -0.3 Units on a scale | — |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in EQ-5D-3L Index Score at Months 12, 24 and 30 | Month 12 | -0.0 Units on a scale | Standard Deviation 0.14 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in EQ-5D-3L Index Score at Months 12, 24 and 30 | Month 24 | -0.2 Units on a scale | Standard Deviation 0.16 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in EQ-5D-3L Index Score at Months 12, 24 and 30 | Month 30 | -0.3 Units on a scale | — |
Change From Baseline in EQ-5D-3L Visual Analogue Score (VAS) Assessment at Months 12, 24 and 30
EQ-5D-3L is a participant completed questionnaire designed to assess impact on health related quality of life. EQ-VAS recorded the participant's self-rated health on a vertical scale ranging from 0 (worst imaginable health state) to 100 (best imaginable health state), where higher scores indicated better quality of life. EQ-VAS assessment was only performed in the participants \>= 16 years old.
Time frame: Baseline (Day 1) and Months 12, 24 and 30
Population: Full Analysis Set included all participants who had been enrolled in the study. Number of Participants Analyzed' signifies all participants in the Full Analysis Set with age \>=16 years. 'Number Analyzed' signifies participants evaluable for specified rows.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Ambulatory Participants With Age <6 Years | Change From Baseline in EQ-5D-3L Visual Analogue Score (VAS) Assessment at Months 12, 24 and 30 | Month 12 | -4.0 Units on a scale | Standard Deviation 9.54 |
| Ambulatory Participants With Age <6 Years | Change From Baseline in EQ-5D-3L Visual Analogue Score (VAS) Assessment at Months 12, 24 and 30 | Month 24 | -11.3 Units on a scale | Standard Deviation 7.37 |
| Ambulatory Participants With Age <6 Years | Change From Baseline in EQ-5D-3L Visual Analogue Score (VAS) Assessment at Months 12, 24 and 30 | Month 30 | -14.0 Units on a scale | — |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in EQ-5D-3L Visual Analogue Score (VAS) Assessment at Months 12, 24 and 30 | Month 12 | -4.0 Units on a scale | Standard Deviation 9.54 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in EQ-5D-3L Visual Analogue Score (VAS) Assessment at Months 12, 24 and 30 | Month 24 | -11.3 Units on a scale | Standard Deviation 7.37 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in EQ-5D-3L Visual Analogue Score (VAS) Assessment at Months 12, 24 and 30 | Month 30 | -14.0 Units on a scale | — |
Change From Baseline in EQ-5D-Y Index Score at Months 12, 24, and 30
EQ-5D-Y is participant completed questionnaire designed to assess impact on health related quality of life in children and adolescents \<=16 years old. It is comprised of five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 3 levels: 1=no problems, 2=some problems, and 3=extreme problems. Participants indicated their health state by choosing the appropriate level from each dimension. The 5 digit health states thus obtained for each dimension were then converted into a single median index value. A health state index score was calculated from individual health profiles using a USA scoring algorithm. Health state index scores generally ranged from -0.109 to 1, where, -0.109= the worst health status, 1= full health. Higher the score the better the better quality of life.
Time frame: Baseline (Day 1) and Months 12, 24, and 30
Population: Full Analysis Set included all participants who had been enrolled in the study. 'Number of Participants Analyzed' signifies all participants in the Full Analysis Set with age \<16 years and contributed data to table, may not have evaluable data for every row. 'Number Analyzed' signifies participants evaluable for specified rows.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Ambulatory Participants With Age <6 Years | Change From Baseline in EQ-5D-Y Index Score at Months 12, 24, and 30 | Month 12 | -0.0 Units on a scale | Standard Deviation 0.12 |
| Ambulatory Participants With Age <6 Years | Change From Baseline in EQ-5D-Y Index Score at Months 12, 24, and 30 | Month 30 | 0.0 Units on a scale | Standard Deviation 0.09 |
| Ambulatory Participants With Age <6 Years | Change From Baseline in EQ-5D-Y Index Score at Months 12, 24, and 30 | Month 24 | 0.0 Units on a scale | Standard Deviation 0.13 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in EQ-5D-Y Index Score at Months 12, 24, and 30 | Month 24 | -0.1 Units on a scale | Standard Deviation 0.16 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in EQ-5D-Y Index Score at Months 12, 24, and 30 | Month 12 | -0.0 Units on a scale | Standard Deviation 0.16 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in EQ-5D-Y Index Score at Months 12, 24, and 30 | Month 30 | -0.1 Units on a scale | Standard Deviation 0.18 |
| Total Ambulatory Participants | Change From Baseline in EQ-5D-Y Index Score at Months 12, 24, and 30 | Month 24 | -0.1 Units on a scale | Standard Deviation 0.16 |
| Total Ambulatory Participants | Change From Baseline in EQ-5D-Y Index Score at Months 12, 24, and 30 | Month 12 | -0.0 Units on a scale | Standard Deviation 0.15 |
| Total Ambulatory Participants | Change From Baseline in EQ-5D-Y Index Score at Months 12, 24, and 30 | Month 30 | -0.1 Units on a scale | Standard Deviation 0.17 |
| Non-ambulatory Participants | Change From Baseline in EQ-5D-Y Index Score at Months 12, 24, and 30 | Month 12 | -0.0 Units on a scale | Standard Deviation 0.13 |
| Non-ambulatory Participants | Change From Baseline in EQ-5D-Y Index Score at Months 12, 24, and 30 | Month 30 | 0.0 Units on a scale | Standard Deviation 0.09 |
| Non-ambulatory Participants | Change From Baseline in EQ-5D-Y Index Score at Months 12, 24, and 30 | Month 24 | -0.0 Units on a scale | Standard Deviation 0.12 |
| Total Participants | Change From Baseline in EQ-5D-Y Index Score at Months 12, 24, and 30 | Month 24 | -0.1 Units on a scale | Standard Deviation 0.16 |
| Total Participants | Change From Baseline in EQ-5D-Y Index Score at Months 12, 24, and 30 | Month 12 | -0.0 Units on a scale | Standard Deviation 0.15 |
| Total Participants | Change From Baseline in EQ-5D-Y Index Score at Months 12, 24, and 30 | Month 30 | -0.1 Units on a scale | Standard Deviation 0.17 |
Change From Baseline in EQ-5D-Y VAS Assessment at Months 12, 24, and 30
EQ-5D-Y is participant completed questionnaire designed to assess impact on health related quality of life in children and adolescents \<16 years old. EQ-VAS recorded the participant's self-rated health on a vertical scale ranging from 0 (worst imaginable health state) to 100 (best imaginable health state).
Time frame: Baseline (Day 1) and Months 12, 24, and 30
Population: Full Analysis Set included all participants who had been enrolled in the study. 'Number of Participants Analyzed' signifies all participants in the Full Analysis Set with age \<16 years and contributed data to table, may not have evaluable data for every row. 'Number Analyzed' signifies participants evaluable for specified rows.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Ambulatory Participants With Age <6 Years | Change From Baseline in EQ-5D-Y VAS Assessment at Months 12, 24, and 30 | Month 30 | -1.0 Units on a scale | Standard Deviation 12.16 |
| Ambulatory Participants With Age <6 Years | Change From Baseline in EQ-5D-Y VAS Assessment at Months 12, 24, and 30 | Month 24 | -3.0 Units on a scale | Standard Deviation 15.08 |
| Ambulatory Participants With Age <6 Years | Change From Baseline in EQ-5D-Y VAS Assessment at Months 12, 24, and 30 | Month 12 | -1.0 Units on a scale | Standard Deviation 19.84 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in EQ-5D-Y VAS Assessment at Months 12, 24, and 30 | Month 30 | -6.1 Units on a scale | Standard Deviation 21.71 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in EQ-5D-Y VAS Assessment at Months 12, 24, and 30 | Month 12 | -4.3 Units on a scale | Standard Deviation 23.02 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in EQ-5D-Y VAS Assessment at Months 12, 24, and 30 | Month 24 | -5.6 Units on a scale | Standard Deviation 21.59 |
| Total Ambulatory Participants | Change From Baseline in EQ-5D-Y VAS Assessment at Months 12, 24, and 30 | Month 30 | -5.1 Units on a scale | Standard Deviation 20.3 |
| Total Ambulatory Participants | Change From Baseline in EQ-5D-Y VAS Assessment at Months 12, 24, and 30 | Month 24 | -5.0 Units on a scale | Standard Deviation 20.19 |
| Total Ambulatory Participants | Change From Baseline in EQ-5D-Y VAS Assessment at Months 12, 24, and 30 | Month 12 | -3.5 Units on a scale | Standard Deviation 22.36 |
| Non-ambulatory Participants | Change From Baseline in EQ-5D-Y VAS Assessment at Months 12, 24, and 30 | Month 30 | 5.0 Units on a scale | Standard Deviation 5 |
| Non-ambulatory Participants | Change From Baseline in EQ-5D-Y VAS Assessment at Months 12, 24, and 30 | Month 12 | -5.0 Units on a scale | Standard Deviation 22.94 |
| Non-ambulatory Participants | Change From Baseline in EQ-5D-Y VAS Assessment at Months 12, 24, and 30 | Month 24 | -5.9 Units on a scale | Standard Deviation 14.59 |
| Total Participants | Change From Baseline in EQ-5D-Y VAS Assessment at Months 12, 24, and 30 | Month 12 | -3.7 Units on a scale | Standard Deviation 22.37 |
| Total Participants | Change From Baseline in EQ-5D-Y VAS Assessment at Months 12, 24, and 30 | Month 30 | -4.8 Units on a scale | Standard Deviation 20.07 |
| Total Participants | Change From Baseline in EQ-5D-Y VAS Assessment at Months 12, 24, and 30 | Month 24 | -5.1 Units on a scale | Standard Deviation 19.78 |
Change From Baseline in Healthcare Resource Utilization (HRU) Survey Responses: Visit to Primary Care Physician, Emergency Room and Office Visits at Months 12, 24, and 30
HRU questionnaire is completed by the caregiver and had questions about healthcare resources utilization related to their child's use of healthcare professionals, emergency room visits, and hospitalizations in past 3 months. Change from baseline in mean number of visits to primary care physician, emergency room and office visits is presented in this outcome measure.
Time frame: Baseline (Day 1) and Months 12, 24, and 30
Population: Full Analysis Set included all participants who had been enrolled in the study. Number of Participants Analyzed' signifies all participants in the Full Analysis Set. All participants reported under Number of Participants Analyzed contributed data to the table; however, may not have evaluable data for every row. 'Number Analyzed' signifies participants evaluable for specified rows.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Ambulatory Participants With Age <6 Years | Change From Baseline in Healthcare Resource Utilization (HRU) Survey Responses: Visit to Primary Care Physician, Emergency Room and Office Visits at Months 12, 24, and 30 | To ER Due to Disease at Month 24 | -0.0 Visits | Standard Deviation 0.12 |
| Ambulatory Participants With Age <6 Years | Change From Baseline in Healthcare Resource Utilization (HRU) Survey Responses: Visit to Primary Care Physician, Emergency Room and Office Visits at Months 12, 24, and 30 | Office Visits at Month 24 | -0.4 Visits | Standard Deviation 9.09 |
| Ambulatory Participants With Age <6 Years | Change From Baseline in Healthcare Resource Utilization (HRU) Survey Responses: Visit to Primary Care Physician, Emergency Room and Office Visits at Months 12, 24, and 30 | To Primary Care Physician at Month 12 | -0.1 Visits | Standard Deviation 0.27 |
| Ambulatory Participants With Age <6 Years | Change From Baseline in Healthcare Resource Utilization (HRU) Survey Responses: Visit to Primary Care Physician, Emergency Room and Office Visits at Months 12, 24, and 30 | To General Practitioner at Month 12 | -0.1 Visits | Standard Deviation 0.45 |
| Ambulatory Participants With Age <6 Years | Change From Baseline in Healthcare Resource Utilization (HRU) Survey Responses: Visit to Primary Care Physician, Emergency Room and Office Visits at Months 12, 24, and 30 | To General Practitioner at Month 30 | -0.1 Visits | Standard Deviation 0.4 |
| Ambulatory Participants With Age <6 Years | Change From Baseline in Healthcare Resource Utilization (HRU) Survey Responses: Visit to Primary Care Physician, Emergency Room and Office Visits at Months 12, 24, and 30 | Office Visits at Month 30 | -2.0 Visits | Standard Deviation 12.84 |
| Ambulatory Participants With Age <6 Years | Change From Baseline in Healthcare Resource Utilization (HRU) Survey Responses: Visit to Primary Care Physician, Emergency Room and Office Visits at Months 12, 24, and 30 | Office Visits at Month 12 | -1.6 Visits | Standard Deviation 7.04 |
| Ambulatory Participants With Age <6 Years | Change From Baseline in Healthcare Resource Utilization (HRU) Survey Responses: Visit to Primary Care Physician, Emergency Room and Office Visits at Months 12, 24, and 30 | To Primary Care Physician at Month 30 | -0.1 Visits | Standard Deviation 0.43 |
| Ambulatory Participants With Age <6 Years | Change From Baseline in Healthcare Resource Utilization (HRU) Survey Responses: Visit to Primary Care Physician, Emergency Room and Office Visits at Months 12, 24, and 30 | To General Practitioner at Month 24 | 0.0 Visits | Standard Deviation 0.57 |
| Ambulatory Participants With Age <6 Years | Change From Baseline in Healthcare Resource Utilization (HRU) Survey Responses: Visit to Primary Care Physician, Emergency Room and Office Visits at Months 12, 24, and 30 | To ER Due to Disease at Month 12 | -0.0 Visits | Standard Deviation 0.11 |
| Ambulatory Participants With Age <6 Years | Change From Baseline in Healthcare Resource Utilization (HRU) Survey Responses: Visit to Primary Care Physician, Emergency Room and Office Visits at Months 12, 24, and 30 | To Primary Care Physician at Month 24 | 0.0 Visits | Standard Deviation 0.23 |
| Ambulatory Participants With Age <6 Years | Change From Baseline in Healthcare Resource Utilization (HRU) Survey Responses: Visit to Primary Care Physician, Emergency Room and Office Visits at Months 12, 24, and 30 | To ER Due to Disease at Month 30 | -0.0 Visits | Standard Deviation 0.18 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in Healthcare Resource Utilization (HRU) Survey Responses: Visit to Primary Care Physician, Emergency Room and Office Visits at Months 12, 24, and 30 | Office Visits at Month 30 | -0.2 Visits | Standard Deviation 7.6 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in Healthcare Resource Utilization (HRU) Survey Responses: Visit to Primary Care Physician, Emergency Room and Office Visits at Months 12, 24, and 30 | To General Practitioner at Month 30 | -0.1 Visits | Standard Deviation 0.44 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in Healthcare Resource Utilization (HRU) Survey Responses: Visit to Primary Care Physician, Emergency Room and Office Visits at Months 12, 24, and 30 | To Primary Care Physician at Month 24 | -0.0 Visits | Standard Deviation 0.41 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in Healthcare Resource Utilization (HRU) Survey Responses: Visit to Primary Care Physician, Emergency Room and Office Visits at Months 12, 24, and 30 | To ER Due to Disease at Month 12 | 0.0 Visits | Standard Deviation 0.27 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in Healthcare Resource Utilization (HRU) Survey Responses: Visit to Primary Care Physician, Emergency Room and Office Visits at Months 12, 24, and 30 | To Primary Care Physician at Month 12 | -0.0 Visits | Standard Deviation 0.41 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in Healthcare Resource Utilization (HRU) Survey Responses: Visit to Primary Care Physician, Emergency Room and Office Visits at Months 12, 24, and 30 | Office Visits at Month 24 | 0.5 Visits | Standard Deviation 6.44 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in Healthcare Resource Utilization (HRU) Survey Responses: Visit to Primary Care Physician, Emergency Room and Office Visits at Months 12, 24, and 30 | To Primary Care Physician at Month 30 | 0.0 Visits | Standard Deviation 0.55 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in Healthcare Resource Utilization (HRU) Survey Responses: Visit to Primary Care Physician, Emergency Room and Office Visits at Months 12, 24, and 30 | To ER Due to Disease at Month 24 | 0.0 Visits | Standard Deviation 0.1 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in Healthcare Resource Utilization (HRU) Survey Responses: Visit to Primary Care Physician, Emergency Room and Office Visits at Months 12, 24, and 30 | Office Visits at Month 12 | 0.5 Visits | Standard Deviation 5.58 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in Healthcare Resource Utilization (HRU) Survey Responses: Visit to Primary Care Physician, Emergency Room and Office Visits at Months 12, 24, and 30 | To General Practitioner at Month 12 | -0.0 Visits | Standard Deviation 0.4 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in Healthcare Resource Utilization (HRU) Survey Responses: Visit to Primary Care Physician, Emergency Room and Office Visits at Months 12, 24, and 30 | To ER Due to Disease at Month 30 | -0.0 Visits | Standard Deviation 0.2 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in Healthcare Resource Utilization (HRU) Survey Responses: Visit to Primary Care Physician, Emergency Room and Office Visits at Months 12, 24, and 30 | To General Practitioner at Month 24 | -0.1 Visits | Standard Deviation 0.36 |
| Total Ambulatory Participants | Change From Baseline in Healthcare Resource Utilization (HRU) Survey Responses: Visit to Primary Care Physician, Emergency Room and Office Visits at Months 12, 24, and 30 | Office Visits at Month 24 | 0.2 Visits | Standard Deviation 7.48 |
| Total Ambulatory Participants | Change From Baseline in Healthcare Resource Utilization (HRU) Survey Responses: Visit to Primary Care Physician, Emergency Room and Office Visits at Months 12, 24, and 30 | To Primary Care Physician at Month 12 | -0.0 Visits | Standard Deviation 0.37 |
| Total Ambulatory Participants | Change From Baseline in Healthcare Resource Utilization (HRU) Survey Responses: Visit to Primary Care Physician, Emergency Room and Office Visits at Months 12, 24, and 30 | To Primary Care Physician at Month 24 | -0.0 Visits | Standard Deviation 0.35 |
| Total Ambulatory Participants | Change From Baseline in Healthcare Resource Utilization (HRU) Survey Responses: Visit to Primary Care Physician, Emergency Room and Office Visits at Months 12, 24, and 30 | To Primary Care Physician at Month 30 | -0.0 Visits | Standard Deviation 0.53 |
| Total Ambulatory Participants | Change From Baseline in Healthcare Resource Utilization (HRU) Survey Responses: Visit to Primary Care Physician, Emergency Room and Office Visits at Months 12, 24, and 30 | To General Practitioner at Month 12 | -0.1 Visits | Standard Deviation 0.42 |
| Total Ambulatory Participants | Change From Baseline in Healthcare Resource Utilization (HRU) Survey Responses: Visit to Primary Care Physician, Emergency Room and Office Visits at Months 12, 24, and 30 | To General Practitioner at Month 24 | -0.0 Visits | Standard Deviation 0.44 |
| Total Ambulatory Participants | Change From Baseline in Healthcare Resource Utilization (HRU) Survey Responses: Visit to Primary Care Physician, Emergency Room and Office Visits at Months 12, 24, and 30 | To General Practitioner at Month 30 | -0.1 Visits | Standard Deviation 0.43 |
| Total Ambulatory Participants | Change From Baseline in Healthcare Resource Utilization (HRU) Survey Responses: Visit to Primary Care Physician, Emergency Room and Office Visits at Months 12, 24, and 30 | To ER Due to Disease at Month 12 | -0.0 Visits | Standard Deviation 0.23 |
| Total Ambulatory Participants | Change From Baseline in Healthcare Resource Utilization (HRU) Survey Responses: Visit to Primary Care Physician, Emergency Room and Office Visits at Months 12, 24, and 30 | To ER Due to Disease at Month 24 | 0.0 Visits | Standard Deviation 0.1 |
| Total Ambulatory Participants | Change From Baseline in Healthcare Resource Utilization (HRU) Survey Responses: Visit to Primary Care Physician, Emergency Room and Office Visits at Months 12, 24, and 30 | To ER Due to Disease at Month 30 | -0.0 Visits | Standard Deviation 0.19 |
| Total Ambulatory Participants | Change From Baseline in Healthcare Resource Utilization (HRU) Survey Responses: Visit to Primary Care Physician, Emergency Room and Office Visits at Months 12, 24, and 30 | Office Visits at Month 12 | -0.2 Visits | Standard Deviation 6.18 |
| Total Ambulatory Participants | Change From Baseline in Healthcare Resource Utilization (HRU) Survey Responses: Visit to Primary Care Physician, Emergency Room and Office Visits at Months 12, 24, and 30 | Office Visits at Month 30 | -0.7 Visits | Standard Deviation 9.32 |
| Non-ambulatory Participants | Change From Baseline in Healthcare Resource Utilization (HRU) Survey Responses: Visit to Primary Care Physician, Emergency Room and Office Visits at Months 12, 24, and 30 | To General Practitioner at Month 30 | 0.0 Visits | Standard Deviation 0 |
| Non-ambulatory Participants | Change From Baseline in Healthcare Resource Utilization (HRU) Survey Responses: Visit to Primary Care Physician, Emergency Room and Office Visits at Months 12, 24, and 30 | To Primary Care Physician at Month 12 | -0.0 Visits | Standard Deviation 0.18 |
| Non-ambulatory Participants | Change From Baseline in Healthcare Resource Utilization (HRU) Survey Responses: Visit to Primary Care Physician, Emergency Room and Office Visits at Months 12, 24, and 30 | To ER Due to Disease at Month 24 | 0.0 Visits | Standard Deviation 0 |
| Non-ambulatory Participants | Change From Baseline in Healthcare Resource Utilization (HRU) Survey Responses: Visit to Primary Care Physician, Emergency Room and Office Visits at Months 12, 24, and 30 | To General Practitioner at Month 24 | -0.2 Visits | Standard Deviation 0.52 |
| Non-ambulatory Participants | Change From Baseline in Healthcare Resource Utilization (HRU) Survey Responses: Visit to Primary Care Physician, Emergency Room and Office Visits at Months 12, 24, and 30 | To ER Due to Disease at Month 30 | 0.0 Visits | Standard Deviation 0 |
| Non-ambulatory Participants | Change From Baseline in Healthcare Resource Utilization (HRU) Survey Responses: Visit to Primary Care Physician, Emergency Room and Office Visits at Months 12, 24, and 30 | To General Practitioner at Month 12 | -0.1 Visits | Standard Deviation 0.35 |
| Non-ambulatory Participants | Change From Baseline in Healthcare Resource Utilization (HRU) Survey Responses: Visit to Primary Care Physician, Emergency Room and Office Visits at Months 12, 24, and 30 | Office Visits at Month 30 | -17.0 Visits | Standard Deviation 32.67 |
| Non-ambulatory Participants | Change From Baseline in Healthcare Resource Utilization (HRU) Survey Responses: Visit to Primary Care Physician, Emergency Room and Office Visits at Months 12, 24, and 30 | Office Visits at Month 12 | -3.4 Visits | Standard Deviation 11.2 |
| Non-ambulatory Participants | Change From Baseline in Healthcare Resource Utilization (HRU) Survey Responses: Visit to Primary Care Physician, Emergency Room and Office Visits at Months 12, 24, and 30 | To Primary Care Physician at Month 30 | 0.0 Visits | Standard Deviation 0 |
| Non-ambulatory Participants | Change From Baseline in Healthcare Resource Utilization (HRU) Survey Responses: Visit to Primary Care Physician, Emergency Room and Office Visits at Months 12, 24, and 30 | To Primary Care Physician at Month 24 | 0.1 Visits | Standard Deviation 0.51 |
| Non-ambulatory Participants | Change From Baseline in Healthcare Resource Utilization (HRU) Survey Responses: Visit to Primary Care Physician, Emergency Room and Office Visits at Months 12, 24, and 30 | Office Visits at Month 24 | -6.2 Visits | Standard Deviation 15.7 |
| Non-ambulatory Participants | Change From Baseline in Healthcare Resource Utilization (HRU) Survey Responses: Visit to Primary Care Physician, Emergency Room and Office Visits at Months 12, 24, and 30 | To ER Due to Disease at Month 12 | 0.0 Visits | Standard Deviation 0 |
| Total Participants | Change From Baseline in Healthcare Resource Utilization (HRU) Survey Responses: Visit to Primary Care Physician, Emergency Room and Office Visits at Months 12, 24, and 30 | To General Practitioner at Month 30 | -0.1 Visits | Standard Deviation 0.42 |
| Total Participants | Change From Baseline in Healthcare Resource Utilization (HRU) Survey Responses: Visit to Primary Care Physician, Emergency Room and Office Visits at Months 12, 24, and 30 | Office Visits at Month 12 | -0.6 Visits | Standard Deviation 6.96 |
| Total Participants | Change From Baseline in Healthcare Resource Utilization (HRU) Survey Responses: Visit to Primary Care Physician, Emergency Room and Office Visits at Months 12, 24, and 30 | To Primary Care Physician at Month 12 | -0.0 Visits | Standard Deviation 0.36 |
| Total Participants | Change From Baseline in Healthcare Resource Utilization (HRU) Survey Responses: Visit to Primary Care Physician, Emergency Room and Office Visits at Months 12, 24, and 30 | To ER Due to Disease at Month 24 | 0.0 Visits | Standard Deviation 0.09 |
| Total Participants | Change From Baseline in Healthcare Resource Utilization (HRU) Survey Responses: Visit to Primary Care Physician, Emergency Room and Office Visits at Months 12, 24, and 30 | To Primary Care Physician at Month 24 | -0.0 Visits | Standard Deviation 0.37 |
| Total Participants | Change From Baseline in Healthcare Resource Utilization (HRU) Survey Responses: Visit to Primary Care Physician, Emergency Room and Office Visits at Months 12, 24, and 30 | To General Practitioner at Month 12 | -0.1 Visits | Standard Deviation 0.41 |
| Total Participants | Change From Baseline in Healthcare Resource Utilization (HRU) Survey Responses: Visit to Primary Care Physician, Emergency Room and Office Visits at Months 12, 24, and 30 | Office Visits at Month 30 | -1.3 Visits | Standard Deviation 11.04 |
| Total Participants | Change From Baseline in Healthcare Resource Utilization (HRU) Survey Responses: Visit to Primary Care Physician, Emergency Room and Office Visits at Months 12, 24, and 30 | To General Practitioner at Month 24 | -0.1 Visits | Standard Deviation 0.45 |
| Total Participants | Change From Baseline in Healthcare Resource Utilization (HRU) Survey Responses: Visit to Primary Care Physician, Emergency Room and Office Visits at Months 12, 24, and 30 | To ER Due to Disease at Month 30 | -0.0 Visits | Standard Deviation 0.19 |
| Total Participants | Change From Baseline in Healthcare Resource Utilization (HRU) Survey Responses: Visit to Primary Care Physician, Emergency Room and Office Visits at Months 12, 24, and 30 | To ER Due to Disease at Month 12 | -0.0 Visits | Standard Deviation 0.22 |
| Total Participants | Change From Baseline in Healthcare Resource Utilization (HRU) Survey Responses: Visit to Primary Care Physician, Emergency Room and Office Visits at Months 12, 24, and 30 | To Primary Care Physician at Month 30 | -0.0 Visits | Standard Deviation 0.52 |
| Total Participants | Change From Baseline in Healthcare Resource Utilization (HRU) Survey Responses: Visit to Primary Care Physician, Emergency Room and Office Visits at Months 12, 24, and 30 | Office Visits at Month 24 | -0.5 Visits | Standard Deviation 8.78 |
Change From Baseline in HRU Survey Responses: Number of Nights in Hospital Due to Disease/Medication for Disease at Months 12, 24, and 30
HRU questionnaire is completed by the caregiver and had questions about healthcare resources utilization related to number of nights in hospital due to disease/dedication for disease in past 3 months. Change from baseline in mean number of nights in hospital due to disease or medication for disease is presented in this outcome measure.
Time frame: Baseline (Day 1) and Months 12, 24, and 30
Population: Full Analysis Set included all participants who had been enrolled in the study. 'Number of Participants Analyzed' signifies all participants in the Full Analysis Set and contributed data to the table; however, may not have evaluable data for every row. 'Number Analyzed' signifies participants evaluable for specified rows.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Ambulatory Participants With Age <6 Years | Change From Baseline in HRU Survey Responses: Number of Nights in Hospital Due to Disease/Medication for Disease at Months 12, 24, and 30 | Month 12 | -0.2 Nights | Standard Deviation 1.02 |
| Ambulatory Participants With Age <6 Years | Change From Baseline in HRU Survey Responses: Number of Nights in Hospital Due to Disease/Medication for Disease at Months 12, 24, and 30 | Month 30 | 0.0 Nights | Standard Deviation 0 |
| Ambulatory Participants With Age <6 Years | Change From Baseline in HRU Survey Responses: Number of Nights in Hospital Due to Disease/Medication for Disease at Months 12, 24, and 30 | Month 24 | -0.2 Nights | Standard Deviation 1.06 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in HRU Survey Responses: Number of Nights in Hospital Due to Disease/Medication for Disease at Months 12, 24, and 30 | Month 24 | -0.2 Nights | Standard Deviation 1.97 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in HRU Survey Responses: Number of Nights in Hospital Due to Disease/Medication for Disease at Months 12, 24, and 30 | Month 12 | -0.2 Nights | Standard Deviation 1.82 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in HRU Survey Responses: Number of Nights in Hospital Due to Disease/Medication for Disease at Months 12, 24, and 30 | Month 30 | -0.1 Nights | Standard Deviation 0.79 |
| Total Ambulatory Participants | Change From Baseline in HRU Survey Responses: Number of Nights in Hospital Due to Disease/Medication for Disease at Months 12, 24, and 30 | Month 24 | -0.2 Nights | Standard Deviation 1.7 |
| Total Ambulatory Participants | Change From Baseline in HRU Survey Responses: Number of Nights in Hospital Due to Disease/Medication for Disease at Months 12, 24, and 30 | Month 12 | -0.2 Nights | Standard Deviation 1.6 |
| Total Ambulatory Participants | Change From Baseline in HRU Survey Responses: Number of Nights in Hospital Due to Disease/Medication for Disease at Months 12, 24, and 30 | Month 30 | -0.1 Nights | Standard Deviation 0.67 |
| Non-ambulatory Participants | Change From Baseline in HRU Survey Responses: Number of Nights in Hospital Due to Disease/Medication for Disease at Months 12, 24, and 30 | Month 12 | 0.0 Nights | Standard Deviation 0 |
| Non-ambulatory Participants | Change From Baseline in HRU Survey Responses: Number of Nights in Hospital Due to Disease/Medication for Disease at Months 12, 24, and 30 | Month 30 | 0.0 Nights | Standard Deviation 0 |
| Non-ambulatory Participants | Change From Baseline in HRU Survey Responses: Number of Nights in Hospital Due to Disease/Medication for Disease at Months 12, 24, and 30 | Month 24 | 0.2 Nights | Standard Deviation 0.83 |
| Total Participants | Change From Baseline in HRU Survey Responses: Number of Nights in Hospital Due to Disease/Medication for Disease at Months 12, 24, and 30 | Month 24 | -0.2 Nights | Standard Deviation 1.64 |
| Total Participants | Change From Baseline in HRU Survey Responses: Number of Nights in Hospital Due to Disease/Medication for Disease at Months 12, 24, and 30 | Month 12 | -0.2 Nights | Standard Deviation 1.51 |
| Total Participants | Change From Baseline in HRU Survey Responses: Number of Nights in Hospital Due to Disease/Medication for Disease at Months 12, 24, and 30 | Month 30 | -0.1 Nights | Standard Deviation 0.66 |
Change From Baseline in Out-of-Pocket Money of HRU Survey at Months 12, 24 and 30
Caregivers were asked to estimate out-of-pocket costs related to healthcare resource utilization. The number of out of pocket money was defined as the total spent of the past three months in managing child's Duchenne muscular dystrophy.
Time frame: Baseline (Day 1) and Months 12, 24, and 30
Population: Full Analysis Set included all participants who had been enrolled in the study. 'Number of Participants Analyzed' signifies all participants in the Full Analysis Set and contributed data to the table; however, may not have evaluable data for every row. 'Number Analyzed' signifies participants evaluable for specified rows.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Ambulatory Participants With Age <6 Years | Change From Baseline in Out-of-Pocket Money of HRU Survey at Months 12, 24 and 30 | Month 30 | -1794.5 Chinese Yuan (CYN) | Standard Deviation 6772.8 |
| Ambulatory Participants With Age <6 Years | Change From Baseline in Out-of-Pocket Money of HRU Survey at Months 12, 24 and 30 | Month 24 | 352.8 Chinese Yuan (CYN) | Standard Deviation 8484.07 |
| Ambulatory Participants With Age <6 Years | Change From Baseline in Out-of-Pocket Money of HRU Survey at Months 12, 24 and 30 | Month 12 | -2748.1 Chinese Yuan (CYN) | Standard Deviation 6100.61 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in Out-of-Pocket Money of HRU Survey at Months 12, 24 and 30 | Month 24 | 777.6 Chinese Yuan (CYN) | Standard Deviation 7630.02 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in Out-of-Pocket Money of HRU Survey at Months 12, 24 and 30 | Month 12 | 476.0 Chinese Yuan (CYN) | Standard Deviation 10947.21 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in Out-of-Pocket Money of HRU Survey at Months 12, 24 and 30 | Month 30 | 1213.6 Chinese Yuan (CYN) | Standard Deviation 6820.65 |
| Total Ambulatory Participants | Change From Baseline in Out-of-Pocket Money of HRU Survey at Months 12, 24 and 30 | Month 30 | 378.0 Chinese Yuan (CYN) | Standard Deviation 6909.59 |
| Total Ambulatory Participants | Change From Baseline in Out-of-Pocket Money of HRU Survey at Months 12, 24 and 30 | Month 12 | -598.7 Chinese Yuan (CYN) | Standard Deviation 9713.33 |
| Total Ambulatory Participants | Change From Baseline in Out-of-Pocket Money of HRU Survey at Months 12, 24 and 30 | Month 24 | 627.3 Chinese Yuan (CYN) | Standard Deviation 7925.23 |
| Non-ambulatory Participants | Change From Baseline in Out-of-Pocket Money of HRU Survey at Months 12, 24 and 30 | Month 30 | -675.0 Chinese Yuan (CYN) | Standard Deviation 4592.29 |
| Non-ambulatory Participants | Change From Baseline in Out-of-Pocket Money of HRU Survey at Months 12, 24 and 30 | Month 12 | 1836.7 Chinese Yuan (CYN) | Standard Deviation 6410.95 |
| Non-ambulatory Participants | Change From Baseline in Out-of-Pocket Money of HRU Survey at Months 12, 24 and 30 | Month 24 | 2326.1 Chinese Yuan (CYN) | Standard Deviation 6126.93 |
| Total Participants | Change From Baseline in Out-of-Pocket Money of HRU Survey at Months 12, 24 and 30 | Month 12 | -328.1 Chinese Yuan (CYN) | Standard Deviation 9425.78 |
| Total Participants | Change From Baseline in Out-of-Pocket Money of HRU Survey at Months 12, 24 and 30 | Month 24 | 793.6 Chinese Yuan (CYN) | Standard Deviation 7773.09 |
| Total Participants | Change From Baseline in Out-of-Pocket Money of HRU Survey at Months 12, 24 and 30 | Month 30 | 340.4 Chinese Yuan (CYN) | Standard Deviation 6828.66 |
Change From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30
The PODCI is a participant-reported assessment of musculoskeletal health intended for use in children and adolescents. The pediatric version was intended for completion by parents or caregivers of children \<=10 years old. It included a Global Function Scale along with core scales: Upper Extremity and Physical Function Core Scale (8 items); Transfer and Basic Mobility Core Scale (11 items); Sports and Physical Functioning Core Scale (21 items); Pain/Comfort Core Scale (3 items); Happiness Core Scale (5 items). The scores of each PODCI global functioning scale and core scales are averaged over the number of items answered (omitted no entry items). Mean of the rescaled values is multiplied by a constant so that each global functioning scale and core scales has a final range of values between 0-100. The higher scores represent less disability and better functioning.
Time frame: Baseline (Day 1) and Months 6, 12, 18, 24 and 30
Population: Full Analysis Set included all participants who had been enrolled in the study. Here, Number of Participants Analyzed signifies all participants in the Full Analysis Set with age \<=10 years contributed data to the table; however, may not have evaluable data for every row. 'Number Analyzed' signifies participants evaluable for specified rows.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Ambulatory Participants With Age <6 Years | Change From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30 | Sports, Month 30 | 1.1 Units on a scale | Standard Deviation 10.29 |
| Ambulatory Participants With Age <6 Years | Change From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30 | Sports, Month 24 | -1.1 Units on a scale | Standard Deviation 14.61 |
| Ambulatory Participants With Age <6 Years | Change From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30 | Transfer and Mobility, Month 18 | 1.6 Units on a scale | Standard Deviation 8.38 |
| Ambulatory Participants With Age <6 Years | Change From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30 | Global Function, Month 6 | 1.0 Units on a scale | Standard Deviation 7.99 |
| Ambulatory Participants With Age <6 Years | Change From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30 | Sports, Month 18 | 2.6 Units on a scale | Standard Deviation 14.05 |
| Ambulatory Participants With Age <6 Years | Change From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30 | Sports, Month 12 | 2.7 Units on a scale | Standard Deviation 14.76 |
| Ambulatory Participants With Age <6 Years | Change From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30 | Transfer and Mobility, Month 24 | -0.5 Units on a scale | Standard Deviation 8.69 |
| Ambulatory Participants With Age <6 Years | Change From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30 | Happiness, Month 30 | 4.9 Units on a scale | Standard Deviation 12.73 |
| Ambulatory Participants With Age <6 Years | Change From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30 | Sports, Month 6 | 1.6 Units on a scale | Standard Deviation 13.79 |
| Ambulatory Participants With Age <6 Years | Change From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30 | Transfer and Mobility, Month 30 | 1.0 Units on a scale | Standard Deviation 6.23 |
| Ambulatory Participants With Age <6 Years | Change From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30 | Upper Extremity, Month 18 | 2.0 Units on a scale | Standard Deviation 10.54 |
| Ambulatory Participants With Age <6 Years | Change From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30 | Global Function, Month 24 | -2.3 Units on a scale | Standard Deviation 10.32 |
| Ambulatory Participants With Age <6 Years | Change From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30 | Happiness, Month 24 | -4.4 Units on a scale | Standard Deviation 19.15 |
| Ambulatory Participants With Age <6 Years | Change From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30 | Upper Extremity, Month 6 | 1.2 Units on a scale | Standard Deviation 9.58 |
| Ambulatory Participants With Age <6 Years | Change From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30 | Upper Extremity, Month 24 | -0.8 Units on a scale | Standard Deviation 11.41 |
| Ambulatory Participants With Age <6 Years | Change From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30 | Global Function, Month 18 | 1.1 Units on a scale | Standard Deviation 9.54 |
| Ambulatory Participants With Age <6 Years | Change From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30 | Happiness, Month 18 | 4.2 Units on a scale | Standard Deviation 14.59 |
| Ambulatory Participants With Age <6 Years | Change From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30 | Happiness, Month 12 | 2.4 Units on a scale | Standard Deviation 14.41 |
| Ambulatory Participants With Age <6 Years | Change From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30 | Upper Extremity, Month 30 | 4.1 Units on a scale | Standard Deviation 9.9 |
| Ambulatory Participants With Age <6 Years | Change From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30 | Upper Extremity, Month 12 | 0.7 Units on a scale | Standard Deviation 10.9 |
| Ambulatory Participants With Age <6 Years | Change From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30 | Happiness, Month 6 | 0.2 Units on a scale | Standard Deviation 15.69 |
| Ambulatory Participants With Age <6 Years | Change From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30 | Pain, Month 30 | -6.4 Units on a scale | Standard Deviation 13.8 |
| Ambulatory Participants With Age <6 Years | Change From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30 | Transfer and Mobility, Month 6 | 1.5 Units on a scale | Standard Deviation 7.91 |
| Ambulatory Participants With Age <6 Years | Change From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30 | Global Function, Month 30 | -0.1 Units on a scale | Standard Deviation 5.81 |
| Ambulatory Participants With Age <6 Years | Change From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30 | Pain, Month 24 | -7.1 Units on a scale | Standard Deviation 18.46 |
| Ambulatory Participants With Age <6 Years | Change From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30 | Pain, Month 18 | -2.1 Units on a scale | Standard Deviation 19.31 |
| Ambulatory Participants With Age <6 Years | Change From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30 | Pain, Month 12 | -1.4 Units on a scale | Standard Deviation 16.72 |
| Ambulatory Participants With Age <6 Years | Change From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30 | Transfer and Mobility, Month 12 | 1.9 Units on a scale | Standard Deviation 7.67 |
| Ambulatory Participants With Age <6 Years | Change From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30 | Global Function, Month 12 | 1.0 Units on a scale | Standard Deviation 9.04 |
| Ambulatory Participants With Age <6 Years | Change From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30 | Pain, Month 6 | -0.3 Units on a scale | Standard Deviation 16.88 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30 | Happiness, Month 18 | -4.2 Units on a scale | Standard Deviation 22.57 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30 | Upper Extremity, Month 6 | 0.3 Units on a scale | Standard Deviation 7.61 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30 | Upper Extremity, Month 12 | -1.4 Units on a scale | Standard Deviation 11.05 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30 | Upper Extremity, Month 18 | -0.3 Units on a scale | Standard Deviation 9.13 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30 | Upper Extremity, Month 24 | -4.1 Units on a scale | Standard Deviation 11.83 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30 | Upper Extremity, Month 30 | -2.2 Units on a scale | Standard Deviation 10.91 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30 | Transfer and Mobility, Month 6 | -1.2 Units on a scale | Standard Deviation 8.59 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30 | Transfer and Mobility, Month 12 | -5.5 Units on a scale | Standard Deviation 14.75 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30 | Transfer and Mobility, Month 18 | -4.1 Units on a scale | Standard Deviation 12.12 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30 | Transfer and Mobility, Month 24 | -9.8 Units on a scale | Standard Deviation 15.48 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30 | Transfer and Mobility, Month 30 | -11.0 Units on a scale | Standard Deviation 17.83 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30 | Sports, Month 6 | -1.5 Units on a scale | Standard Deviation 12.75 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30 | Sports, Month 12 | -7.5 Units on a scale | Standard Deviation 15.78 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30 | Sports, Month 18 | -7.5 Units on a scale | Standard Deviation 15.88 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30 | Sports, Month 24 | -12.4 Units on a scale | Standard Deviation 16.74 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30 | Sports, Month 30 | -19.9 Units on a scale | Standard Deviation 20.49 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30 | Pain, Month 6 | 1.0 Units on a scale | Standard Deviation 19.01 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30 | Pain, Month 12 | -5.0 Units on a scale | Standard Deviation 21.95 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30 | Pain, Month 18 | -3.7 Units on a scale | Standard Deviation 20.12 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30 | Pain, Month 24 | -8.5 Units on a scale | Standard Deviation 21.36 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30 | Pain, Month 30 | -15.2 Units on a scale | Standard Deviation 19.27 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30 | Happiness, Month 6 | 0.0 Units on a scale | Standard Deviation 20.09 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30 | Happiness, Month 12 | -5.6 Units on a scale | Standard Deviation 23.49 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30 | Happiness, Month 24 | -12.3 Units on a scale | Standard Deviation 21.44 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30 | Happiness, Month 30 | -12.8 Units on a scale | Standard Deviation 20.68 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30 | Global Function, Month 6 | -0.4 Units on a scale | Standard Deviation 8.65 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30 | Global Function, Month 12 | -4.9 Units on a scale | Standard Deviation 12.12 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30 | Global Function, Month 18 | -3.9 Units on a scale | Standard Deviation 10.05 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30 | Global Function, Month 24 | -8.7 Units on a scale | Standard Deviation 10.99 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30 | Global Function, Month 30 | -12.0 Units on a scale | Standard Deviation 13.73 |
| Total Ambulatory Participants | Change From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30 | Sports, Month 24 | -7.0 Units on a scale | Standard Deviation 16.69 |
| Total Ambulatory Participants | Change From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30 | Global Function, Month 12 | -2.6 Units on a scale | Standard Deviation 11.36 |
| Total Ambulatory Participants | Change From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30 | Sports, Month 30 | -10.5 Units on a scale | Standard Deviation 19.64 |
| Total Ambulatory Participants | Change From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30 | Transfer and Mobility, Month 12 | -2.6 Units on a scale | Standard Deviation 12.95 |
| Total Ambulatory Participants | Change From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30 | Pain, Month 6 | 0.5 Units on a scale | Standard Deviation 18.13 |
| Total Ambulatory Participants | Change From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30 | Pain, Month 12 | -3.6 Units on a scale | Standard Deviation 20.09 |
| Total Ambulatory Participants | Change From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30 | Pain, Month 18 | -2.9 Units on a scale | Standard Deviation 19.69 |
| Total Ambulatory Participants | Change From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30 | Transfer and Mobility, Month 6 | -0.1 Units on a scale | Standard Deviation 8.4 |
| Total Ambulatory Participants | Change From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30 | Pain, Month 24 | -7.8 Units on a scale | Standard Deviation 19.97 |
| Total Ambulatory Participants | Change From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30 | Global Function, Month 18 | -1.6 Units on a scale | Standard Deviation 10.1 |
| Total Ambulatory Participants | Change From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30 | Pain, Month 30 | -11.2 Units on a scale | Standard Deviation 17.45 |
| Total Ambulatory Participants | Change From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30 | Upper Extremity, Month 30 | 0.6 Units on a scale | Standard Deviation 10.85 |
| Total Ambulatory Participants | Change From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30 | Happiness, Month 6 | 0.1 Units on a scale | Standard Deviation 18.37 |
| Total Ambulatory Participants | Change From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30 | Happiness, Month 12 | -2.4 Units on a scale | Standard Deviation 20.74 |
| Total Ambulatory Participants | Change From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30 | Upper Extremity, Month 24 | -2.5 Units on a scale | Standard Deviation 11.71 |
| Total Ambulatory Participants | Change From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30 | Happiness, Month 18 | -0.3 Units on a scale | Standard Deviation 19.65 |
| Total Ambulatory Participants | Change From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30 | Upper Extremity, Month 18 | 0.8 Units on a scale | Standard Deviation 9.85 |
| Total Ambulatory Participants | Change From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30 | Global Function, Month 30 | -6.7 Units on a scale | Standard Deviation 12.37 |
| Total Ambulatory Participants | Change From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30 | Happiness, Month 24 | -8.5 Units on a scale | Standard Deviation 20.69 |
| Total Ambulatory Participants | Change From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30 | Global Function, Month 24 | -5.7 Units on a scale | Standard Deviation 11.11 |
| Total Ambulatory Participants | Change From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30 | Happiness, Month 30 | -4.9 Units on a scale | Standard Deviation 19.54 |
| Total Ambulatory Participants | Change From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30 | Global Function, Month 6 | 0.2 Units on a scale | Standard Deviation 8.39 |
| Total Ambulatory Participants | Change From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30 | Transfer and Mobility, Month 30 | -5.6 Units on a scale | Standard Deviation 15.02 |
| Total Ambulatory Participants | Change From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30 | Transfer and Mobility, Month 24 | -5.4 Units on a scale | Standard Deviation 13.47 |
| Total Ambulatory Participants | Change From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30 | Sports, Month 6 | -0.2 Units on a scale | Standard Deviation 13.24 |
| Total Ambulatory Participants | Change From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30 | Sports, Month 12 | -3.5 Units on a scale | Standard Deviation 16.14 |
| Total Ambulatory Participants | Change From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30 | Transfer and Mobility, Month 18 | -1.4 Units on a scale | Standard Deviation 10.89 |
| Total Ambulatory Participants | Change From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30 | Upper Extremity, Month 12 | -0.6 Units on a scale | Standard Deviation 11.01 |
| Total Ambulatory Participants | Change From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30 | Sports, Month 18 | -2.8 Units on a scale | Standard Deviation 15.83 |
| Total Ambulatory Participants | Change From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30 | Upper Extremity, Month 6 | 0.7 Units on a scale | Standard Deviation 8.47 |
| Non-ambulatory Participants | Change From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30 | Sports, Month 12 | -4.3 Units on a scale | Standard Deviation 3.1 |
| Non-ambulatory Participants | Change From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30 | Happiness, Month 6 | -10.0 Units on a scale | Standard Deviation 7.07 |
| Non-ambulatory Participants | Change From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30 | Upper Extremity, Month 6 | 16.5 Units on a scale | Standard Deviation 12.02 |
| Non-ambulatory Participants | Change From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30 | Happiness, Month 12 | -17.5 Units on a scale | Standard Deviation 11.9 |
| Non-ambulatory Participants | Change From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30 | Global Function, Month 6 | 7.5 Units on a scale | Standard Deviation 10.61 |
| Non-ambulatory Participants | Change From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30 | Transfer and Mobility, Month 12 | -2.8 Units on a scale | Standard Deviation 17.02 |
| Non-ambulatory Participants | Change From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30 | Sports, Month 6 | 1.0 Units on a scale | Standard Deviation 7.07 |
| Non-ambulatory Participants | Change From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30 | Global Function, Month 12 | -5.5 Units on a scale | Standard Deviation 6.4 |
| Non-ambulatory Participants | Change From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30 | Pain, Month 6 | 5.5 Units on a scale | Standard Deviation 7.78 |
| Non-ambulatory Participants | Change From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30 | Pain, Month 12 | -6.8 Units on a scale | Standard Deviation 14.2 |
| Non-ambulatory Participants | Change From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30 | Transfer and Mobility, Month 6 | 7.5 Units on a scale | Standard Deviation 14.85 |
| Non-ambulatory Participants | Change From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30 | Upper Extremity, Month 12 | -8.3 Units on a scale | Standard Deviation 17.56 |
| Total Participants | Change From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30 | Transfer and Mobility, Month 12 | -2.6 Units on a scale | Standard Deviation 12.99 |
| Total Participants | Change From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30 | Sports, Month 24 | -7.0 Units on a scale | Standard Deviation 16.69 |
| Total Participants | Change From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30 | Pain, Month 24 | -7.8 Units on a scale | Standard Deviation 19.97 |
| Total Participants | Change From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30 | Upper Extremity, Month 30 | 0.6 Units on a scale | Standard Deviation 10.85 |
| Total Participants | Change From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30 | Sports, Month 6 | -0.2 Units on a scale | Standard Deviation 13.19 |
| Total Participants | Change From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30 | Sports, Month 30 | -10.5 Units on a scale | Standard Deviation 19.64 |
| Total Participants | Change From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30 | Happiness, Month 24 | -8.5 Units on a scale | Standard Deviation 20.69 |
| Total Participants | Change From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30 | Global Function, Month 24 | -5.7 Units on a scale | Standard Deviation 11.11 |
| Total Participants | Change From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30 | Upper Extremity, Month 12 | -0.7 Units on a scale | Standard Deviation 11.17 |
| Total Participants | Change From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30 | Transfer and Mobility, Month 24 | -5.4 Units on a scale | Standard Deviation 13.47 |
| Total Participants | Change From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30 | Pain, Month 6 | 0.5 Units on a scale | Standard Deviation 18.06 |
| Total Participants | Change From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30 | Transfer and Mobility, Month 6 | 0.0 Units on a scale | Standard Deviation 8.46 |
| Total Participants | Change From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30 | Global Function, Month 12 | -2.7 Units on a scale | Standard Deviation 11.28 |
| Total Participants | Change From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30 | Transfer and Mobility, Month 18 | -1.4 Units on a scale | Standard Deviation 10.89 |
| Total Participants | Change From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30 | Pain, Month 30 | -11.2 Units on a scale | Standard Deviation 17.45 |
| Total Participants | Change From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30 | Pain, Month 12 | -3.7 Units on a scale | Standard Deviation 19.96 |
| Total Participants | Change From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30 | Sports, Month 18 | -2.8 Units on a scale | Standard Deviation 15.83 |
| Total Participants | Change From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30 | Upper Extremity, Month 6 | 0.8 Units on a scale | Standard Deviation 8.61 |
| Total Participants | Change From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30 | Global Function, Month 6 | 0.3 Units on a scale | Standard Deviation 8.41 |
| Total Participants | Change From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30 | Pain, Month 18 | -2.9 Units on a scale | Standard Deviation 19.69 |
| Total Participants | Change From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30 | Happiness, Month 6 | -0.0 Units on a scale | Standard Deviation 18.32 |
| Total Participants | Change From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30 | Upper Extremity, Month 24 | -2.5 Units on a scale | Standard Deviation 11.71 |
| Total Participants | Change From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30 | Happiness, Month 30 | -4.9 Units on a scale | Standard Deviation 19.54 |
| Total Participants | Change From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30 | Transfer and Mobility, Month 30 | -5.6 Units on a scale | Standard Deviation 15.02 |
| Total Participants | Change From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30 | Global Function, Month 30 | -6.7 Units on a scale | Standard Deviation 12.37 |
| Total Participants | Change From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30 | Happiness, Month 12 | -2.7 Units on a scale | Standard Deviation 20.69 |
| Total Participants | Change From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30 | Sports, Month 12 | -3.5 Units on a scale | Standard Deviation 15.98 |
| Total Participants | Change From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30 | Upper Extremity, Month 18 | 0.8 Units on a scale | Standard Deviation 9.85 |
| Total Participants | Change From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30 | Global Function, Month 18 | -1.6 Units on a scale | Standard Deviation 10.1 |
| Total Participants | Change From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30 | Happiness, Month 18 | -0.3 Units on a scale | Standard Deviation 19.65 |
Change From Baseline in Percent Activity Impairment as Per Work Productivity and Activity Impairment Questionnaire Adapted for Caregiving (WPAI:CG) Caregiver Unchanged at Months 12, 24, and 30
WPAI:CG is a self-reported measure of work productivity and impairment, was completed by caregiver, which had four scores: absenteeism (work time missed); presenteeism (impairment at work/reduced on the job effectiveness); work productivity loss (overall work impairment/absenteeism plus presenteeism); and activity impairment. Each score was expressed as a percentage (0-100%) with higher score indicating greater impairment and less productivity.
Time frame: Baseline (Day 1) and Months 12, 24, and 30
Population: Full Analysis Set included all participants who had been enrolled in the study. 'Number of Participants Analyzed' signifies all participants in the Full Analysis Set and contributed data to the table; however, may not have evaluable data for every row. 'Number Analyzed' signifies participants evaluable for specified rows.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Ambulatory Participants With Age <6 Years | Change From Baseline in Percent Activity Impairment as Per Work Productivity and Activity Impairment Questionnaire Adapted for Caregiving (WPAI:CG) Caregiver Unchanged at Months 12, 24, and 30 | Month 12 | -6.6 Percentage activity impairment | Standard Deviation 30.71 |
| Ambulatory Participants With Age <6 Years | Change From Baseline in Percent Activity Impairment as Per Work Productivity and Activity Impairment Questionnaire Adapted for Caregiving (WPAI:CG) Caregiver Unchanged at Months 12, 24, and 30 | Month 30 | -6.7 Percentage activity impairment | Standard Deviation 31.14 |
| Ambulatory Participants With Age <6 Years | Change From Baseline in Percent Activity Impairment as Per Work Productivity and Activity Impairment Questionnaire Adapted for Caregiving (WPAI:CG) Caregiver Unchanged at Months 12, 24, and 30 | Month 24 | 7.4 Percentage activity impairment | Standard Deviation 32.22 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in Percent Activity Impairment as Per Work Productivity and Activity Impairment Questionnaire Adapted for Caregiving (WPAI:CG) Caregiver Unchanged at Months 12, 24, and 30 | Month 24 | 8.8 Percentage activity impairment | Standard Deviation 34.68 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in Percent Activity Impairment as Per Work Productivity and Activity Impairment Questionnaire Adapted for Caregiving (WPAI:CG) Caregiver Unchanged at Months 12, 24, and 30 | Month 12 | 5.6 Percentage activity impairment | Standard Deviation 32.08 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in Percent Activity Impairment as Per Work Productivity and Activity Impairment Questionnaire Adapted for Caregiving (WPAI:CG) Caregiver Unchanged at Months 12, 24, and 30 | Month 30 | 13.8 Percentage activity impairment | Standard Deviation 30.82 |
| Total Ambulatory Participants | Change From Baseline in Percent Activity Impairment as Per Work Productivity and Activity Impairment Questionnaire Adapted for Caregiving (WPAI:CG) Caregiver Unchanged at Months 12, 24, and 30 | Month 24 | 8.3 Percentage activity impairment | Standard Deviation 33.76 |
| Total Ambulatory Participants | Change From Baseline in Percent Activity Impairment as Per Work Productivity and Activity Impairment Questionnaire Adapted for Caregiving (WPAI:CG) Caregiver Unchanged at Months 12, 24, and 30 | Month 12 | 2.0 Percentage activity impairment | Standard Deviation 32.09 |
| Total Ambulatory Participants | Change From Baseline in Percent Activity Impairment as Per Work Productivity and Activity Impairment Questionnaire Adapted for Caregiving (WPAI:CG) Caregiver Unchanged at Months 12, 24, and 30 | Month 30 | 10.1 Percentage activity impairment | Standard Deviation 31.65 |
| Non-ambulatory Participants | Change From Baseline in Percent Activity Impairment as Per Work Productivity and Activity Impairment Questionnaire Adapted for Caregiving (WPAI:CG) Caregiver Unchanged at Months 12, 24, and 30 | Month 12 | -6.8 Percentage activity impairment | Standard Deviation 34.37 |
| Non-ambulatory Participants | Change From Baseline in Percent Activity Impairment as Per Work Productivity and Activity Impairment Questionnaire Adapted for Caregiving (WPAI:CG) Caregiver Unchanged at Months 12, 24, and 30 | Month 30 | 0.0 Percentage activity impairment | — |
| Non-ambulatory Participants | Change From Baseline in Percent Activity Impairment as Per Work Productivity and Activity Impairment Questionnaire Adapted for Caregiving (WPAI:CG) Caregiver Unchanged at Months 12, 24, and 30 | Month 24 | -7.9 Percentage activity impairment | Standard Deviation 31.02 |
| Total Participants | Change From Baseline in Percent Activity Impairment as Per Work Productivity and Activity Impairment Questionnaire Adapted for Caregiving (WPAI:CG) Caregiver Unchanged at Months 12, 24, and 30 | Month 24 | 6.6 Percentage activity impairment | Standard Deviation 33.77 |
| Total Participants | Change From Baseline in Percent Activity Impairment as Per Work Productivity and Activity Impairment Questionnaire Adapted for Caregiving (WPAI:CG) Caregiver Unchanged at Months 12, 24, and 30 | Month 12 | 0.9 Percentage activity impairment | Standard Deviation 32.41 |
| Total Participants | Change From Baseline in Percent Activity Impairment as Per Work Productivity and Activity Impairment Questionnaire Adapted for Caregiving (WPAI:CG) Caregiver Unchanged at Months 12, 24, and 30 | Month 30 | 10.0 Percentage activity impairment | Standard Deviation 31.43 |
Change From Baseline in Percent Overall Work Impairment WPAI: CG Caregiver Unchanged at Months 12, 24, and 30
WPAI:CG is a self-reported measure of work productivity and impairment, was completed by caregiver, which had four scores: absenteeism (work time missed); presenteeism (impairment at work/reduced on the job effectiveness); work productivity loss (overall work impairment/absenteeism plus presenteeism); and activity impairment. Each score was expressed as a percentage (0-100%) with higher score indicating greater impairment and less productivity.
Time frame: Baseline (Day 1) and Months 12, 24, and 30
Population: Full Analysis Set included all participants who had been enrolled in the study. 'Number of Participants Analyzed' signifies all participants in the Full Analysis Set and contributed data to the table; however, may not have evaluable data for every row. 'Number Analyzed' signifies participants evaluable for specified rows.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Ambulatory Participants With Age <6 Years | Change From Baseline in Percent Overall Work Impairment WPAI: CG Caregiver Unchanged at Months 12, 24, and 30 | Percent Overall Work Impairment, Month 12 | -5.2 Percentage work impairment | Standard Deviation 26.25 |
| Ambulatory Participants With Age <6 Years | Change From Baseline in Percent Overall Work Impairment WPAI: CG Caregiver Unchanged at Months 12, 24, and 30 | Percent Overall Work Impairment, Month 24 | 0.2 Percentage work impairment | Standard Deviation 27.83 |
| Ambulatory Participants With Age <6 Years | Change From Baseline in Percent Overall Work Impairment WPAI: CG Caregiver Unchanged at Months 12, 24, and 30 | Percent Overall Work Impairment, Month 30 | -11.9 Percentage work impairment | Standard Deviation 35.09 |
| Ambulatory Participants With Age <6 Years | Change From Baseline in Percent Overall Work Impairment WPAI: CG Caregiver Unchanged at Months 12, 24, and 30 | Percent impairment while working, Month 12 | -3.7 Percentage work impairment | Standard Deviation 19.87 |
| Ambulatory Participants With Age <6 Years | Change From Baseline in Percent Overall Work Impairment WPAI: CG Caregiver Unchanged at Months 12, 24, and 30 | Percent impairment while working, Month 24 | -1.2 Percentage work impairment | Standard Deviation 25.47 |
| Ambulatory Participants With Age <6 Years | Change From Baseline in Percent Overall Work Impairment WPAI: CG Caregiver Unchanged at Months 12, 24, and 30 | Percent impairment while working, Month 30 | 1.1 Percentage work impairment | Standard Deviation 28.48 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in Percent Overall Work Impairment WPAI: CG Caregiver Unchanged at Months 12, 24, and 30 | Percent impairment while working, Month 24 | 3.1 Percentage work impairment | Standard Deviation 26.82 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in Percent Overall Work Impairment WPAI: CG Caregiver Unchanged at Months 12, 24, and 30 | Percent impairment while working, Month 30 | 5.3 Percentage work impairment | Standard Deviation 25.03 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in Percent Overall Work Impairment WPAI: CG Caregiver Unchanged at Months 12, 24, and 30 | Percent Overall Work Impairment, Month 12 | 2.6 Percentage work impairment | Standard Deviation 25.35 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in Percent Overall Work Impairment WPAI: CG Caregiver Unchanged at Months 12, 24, and 30 | Percent Overall Work Impairment, Month 30 | 6.8 Percentage work impairment | Standard Deviation 24.29 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in Percent Overall Work Impairment WPAI: CG Caregiver Unchanged at Months 12, 24, and 30 | Percent impairment while working, Month 12 | 4.7 Percentage work impairment | Standard Deviation 24.08 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in Percent Overall Work Impairment WPAI: CG Caregiver Unchanged at Months 12, 24, and 30 | Percent Overall Work Impairment, Month 24 | 4.8 Percentage work impairment | Standard Deviation 26.78 |
| Total Ambulatory Participants | Change From Baseline in Percent Overall Work Impairment WPAI: CG Caregiver Unchanged at Months 12, 24, and 30 | Percent impairment while working, Month 12 | 1.5 Percentage work impairment | Standard Deviation 22.84 |
| Total Ambulatory Participants | Change From Baseline in Percent Overall Work Impairment WPAI: CG Caregiver Unchanged at Months 12, 24, and 30 | Percent impairment while working, Month 24 | 1.2 Percentage work impairment | Standard Deviation 26.15 |
| Total Ambulatory Participants | Change From Baseline in Percent Overall Work Impairment WPAI: CG Caregiver Unchanged at Months 12, 24, and 30 | Percent Overall Work Impairment, Month 12 | -0.4 Percentage work impairment | Standard Deviation 25.83 |
| Total Ambulatory Participants | Change From Baseline in Percent Overall Work Impairment WPAI: CG Caregiver Unchanged at Months 12, 24, and 30 | Percent Overall Work Impairment, Month 30 | 0.8 Percentage work impairment | Standard Deviation 28.94 |
| Total Ambulatory Participants | Change From Baseline in Percent Overall Work Impairment WPAI: CG Caregiver Unchanged at Months 12, 24, and 30 | Percent Overall Work Impairment, Month 24 | 2.7 Percentage work impairment | Standard Deviation 27.16 |
| Total Ambulatory Participants | Change From Baseline in Percent Overall Work Impairment WPAI: CG Caregiver Unchanged at Months 12, 24, and 30 | Percent impairment while working, Month 30 | 3.9 Percentage work impairment | Standard Deviation 25.72 |
| Non-ambulatory Participants | Change From Baseline in Percent Overall Work Impairment WPAI: CG Caregiver Unchanged at Months 12, 24, and 30 | Percent impairment while working, Month 12 | -14.0 Percentage work impairment | Standard Deviation 33.4 |
| Non-ambulatory Participants | Change From Baseline in Percent Overall Work Impairment WPAI: CG Caregiver Unchanged at Months 12, 24, and 30 | Percent Overall Work Impairment, Month 24 | -12.7 Percentage work impairment | Standard Deviation 39.72 |
| Non-ambulatory Participants | Change From Baseline in Percent Overall Work Impairment WPAI: CG Caregiver Unchanged at Months 12, 24, and 30 | Percent Overall Work Impairment, Month 30 | 30.0 Percentage work impairment | — |
| Non-ambulatory Participants | Change From Baseline in Percent Overall Work Impairment WPAI: CG Caregiver Unchanged at Months 12, 24, and 30 | Percent impairment while working, Month 30 | 30.0 Percentage work impairment | — |
| Non-ambulatory Participants | Change From Baseline in Percent Overall Work Impairment WPAI: CG Caregiver Unchanged at Months 12, 24, and 30 | Percent impairment while working, Month 24 | -15.0 Percentage work impairment | Standard Deviation 37.49 |
| Non-ambulatory Participants | Change From Baseline in Percent Overall Work Impairment WPAI: CG Caregiver Unchanged at Months 12, 24, and 30 | Percent Overall Work Impairment, Month 12 | -9.3 Percentage work impairment | Standard Deviation 36.17 |
| Total Participants | Change From Baseline in Percent Overall Work Impairment WPAI: CG Caregiver Unchanged at Months 12, 24, and 30 | Percent impairment while working, Month 24 | -0.7 Percentage work impairment | Standard Deviation 27.94 |
| Total Participants | Change From Baseline in Percent Overall Work Impairment WPAI: CG Caregiver Unchanged at Months 12, 24, and 30 | Percent Overall Work Impairment, Month 30 | 1.8 Percentage work impairment | Standard Deviation 28.93 |
| Total Participants | Change From Baseline in Percent Overall Work Impairment WPAI: CG Caregiver Unchanged at Months 12, 24, and 30 | Percent Overall Work Impairment, Month 24 | 0.9 Percentage work impairment | Standard Deviation 29.09 |
| Total Participants | Change From Baseline in Percent Overall Work Impairment WPAI: CG Caregiver Unchanged at Months 12, 24, and 30 | Percent impairment while working, Month 30 | 4.8 Percentage work impairment | Standard Deviation 25.72 |
| Total Participants | Change From Baseline in Percent Overall Work Impairment WPAI: CG Caregiver Unchanged at Months 12, 24, and 30 | Percent impairment while working, Month 12 | 0.0 Percentage work impairment | Standard Deviation 24.29 |
| Total Participants | Change From Baseline in Percent Overall Work Impairment WPAI: CG Caregiver Unchanged at Months 12, 24, and 30 | Percent Overall Work Impairment, Month 12 | -1.3 Percentage work impairment | Standard Deviation 26.93 |
Change From Baseline in Percent Work Time Missed as Per WPAI: CG Caregiver Unchanged at Month 12
WPAI:CG is a self-reported measure of work productivity and impairment, was completed by caregiver, which had four scores: absenteeism (work time missed); presenteeism (impairment at work/reduced on the job effectiveness); work productivity loss (overall work impairment/absenteeism plus presenteeism); and activity impairment. Each score was expressed as a percentage (0-100%) with higher score indicating greater impairment and less productivity.
Time frame: Baseline (Day 1) and Month 12
Population: Full Analysis Set included all participants who had been enrolled in the study. Here, Number of Participants Analyzed signifies participants evaluable for this outcome measure.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Ambulatory Participants With Age <6 Years | Change From Baseline in Percent Work Time Missed as Per WPAI: CG Caregiver Unchanged at Month 12 | -6.1 Percentage work time missed | Standard Deviation 25.47 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in Percent Work Time Missed as Per WPAI: CG Caregiver Unchanged at Month 12 | -5.0 Percentage work time missed | Standard Deviation 25.17 |
| Total Ambulatory Participants | Change From Baseline in Percent Work Time Missed as Per WPAI: CG Caregiver Unchanged at Month 12 | -5.5 Percentage work time missed | Standard Deviation 25.15 |
| Non-ambulatory Participants | Change From Baseline in Percent Work Time Missed as Per WPAI: CG Caregiver Unchanged at Month 12 | 3.7 Percentage work time missed | Standard Deviation 18.59 |
| Total Participants | Change From Baseline in Percent Work Time Missed as Per WPAI: CG Caregiver Unchanged at Month 12 | -4.5 Percentage work time missed | Standard Deviation 24.63 |
Change From Baseline in Percent Work Time Missed as Per WPAI: CG Caregiver Unchanged at Month 24
WPAI:CG is a self-reported measure of work productivity and impairment, was completed by caregiver, which had four scores: absenteeism (work time missed); presenteeism (impairment at work/reduced on the job effectiveness); work productivity loss (overall work impairment/absenteeism plus presenteeism); and activity impairment. Each score was expressed as a percentage (0-100%) with higher score indicating greater impairment and less productivity.
Time frame: Baseline (Day 1) and Month 24
Population: Full Analysis Set included all participants who had been enrolled in the study. Here, Number of Participants Analyzed signifies participants evaluable for this outcome measure.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Ambulatory Participants With Age <6 Years | Change From Baseline in Percent Work Time Missed as Per WPAI: CG Caregiver Unchanged at Month 24 | 1.1 Percentage work time missed | Standard Deviation 24.46 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in Percent Work Time Missed as Per WPAI: CG Caregiver Unchanged at Month 24 | 0.9 Percentage work time missed | Standard Deviation 29.04 |
| Total Ambulatory Participants | Change From Baseline in Percent Work Time Missed as Per WPAI: CG Caregiver Unchanged at Month 24 | 1.0 Percentage work time missed | Standard Deviation 26.91 |
| Non-ambulatory Participants | Change From Baseline in Percent Work Time Missed as Per WPAI: CG Caregiver Unchanged at Month 24 | -4.4 Percentage work time missed | Standard Deviation 23.92 |
| Total Participants | Change From Baseline in Percent Work Time Missed as Per WPAI: CG Caregiver Unchanged at Month 24 | 0.3 Percentage work time missed | Standard Deviation 26.47 |
Change From Baseline in Percent Work Time Missed as Per WPAI: CG Caregiver Unchanged at Month 30
WPAI:CG is a self-reported measure of work productivity and impairment, was completed by caregiver, which had four scores: absenteeism (work time missed); presenteeism (impairment at work/reduced on the job effectiveness); work productivity loss (overall work impairment/absenteeism plus presenteeism); and activity impairment. Each score was expressed as a percentage (0-100%) with higher score indicating greater impairment and less productivity.
Time frame: Baseline (Day 1) and Month 30
Population: Full Analysis Set included all participants who had been enrolled in the study. Here, Number of Participants Analyzed signifies participants evaluable for this outcome measure.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Ambulatory Participants With Age <6 Years | Change From Baseline in Percent Work Time Missed as Per WPAI: CG Caregiver Unchanged at Month 30 | -21.5 Percentage work time missed | Standard Deviation 26.9 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in Percent Work Time Missed as Per WPAI: CG Caregiver Unchanged at Month 30 | 2.0 Percentage work time missed | Standard Deviation 14.15 |
| Total Ambulatory Participants | Change From Baseline in Percent Work Time Missed as Per WPAI: CG Caregiver Unchanged at Month 30 | -5.6 Percentage work time missed | Standard Deviation 21.73 |
| Non-ambulatory Participants | Change From Baseline in Percent Work Time Missed as Per WPAI: CG Caregiver Unchanged at Month 30 | 0.0 Percentage work time missed | — |
| Total Participants | Change From Baseline in Percent Work Time Missed as Per WPAI: CG Caregiver Unchanged at Month 30 | -5.4 Percentage work time missed | Standard Deviation 21.36 |
Change From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Parent Report) at Months 6, 12, 18, 24 and 30
The PODCI is a participant-reported assessment of musculoskeletal health intended for use in children and adolescents. The pediatric version was intended for completion by parents or caregivers of children \<=10 years old. It included a Global Function Scale along with core scales: Upper Extremity and Physical Function Core Scale (8 items); Transfer and Basic Mobility Core Scale (11 items); Sports and Physical Functioning Core Scale (21 items); Pain/Comfort Core Scale (3 items); Happiness Core Scale (5 items). The scores of each PODCI global functioning scale and core scales are averaged over the number of items answered (omitted no entry items). Mean of the rescaled values is multiplied by a constant so that each global functioning scale and core scales has a final range of values between 0-100. The higher scores represent less disability and better functioning.
Time frame: Baseline (Day 1) and Months 6, 12, 18, 24 and 30
Population: Full Analysis Set included all participants who had been enrolled in the study. Here, Number of Participants Analyzed signifies all participants in the Full Analysis Set with age between 11-18 years contributed data to the table; however, may not have evaluable data for every row. 'Number Analyzed' signifies participants evaluable for specified rows.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Ambulatory Participants With Age <6 Years | Change From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Parent Report) at Months 6, 12, 18, 24 and 30 | Sports, Month 6 | -5.9 Units on a scale | Standard Deviation 14.24 |
| Ambulatory Participants With Age <6 Years | Change From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Parent Report) at Months 6, 12, 18, 24 and 30 | Global Function, Month 12 | -10.0 Units on a scale | Standard Deviation 9.34 |
| Ambulatory Participants With Age <6 Years | Change From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Parent Report) at Months 6, 12, 18, 24 and 30 | Happiness, Month 6 | -13.1 Units on a scale | Standard Deviation 19.57 |
| Ambulatory Participants With Age <6 Years | Change From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Parent Report) at Months 6, 12, 18, 24 and 30 | Sports, Month 12 | -12.4 Units on a scale | Standard Deviation 15.44 |
| Ambulatory Participants With Age <6 Years | Change From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Parent Report) at Months 6, 12, 18, 24 and 30 | Upper Extremity, Month 30 | -7.4 Units on a scale | Standard Deviation 10.21 |
| Ambulatory Participants With Age <6 Years | Change From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Parent Report) at Months 6, 12, 18, 24 and 30 | Pain, Month 30 | -25.9 Units on a scale | Standard Deviation 22.04 |
| Ambulatory Participants With Age <6 Years | Change From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Parent Report) at Months 6, 12, 18, 24 and 30 | Sports, Month 18 | -18.8 Units on a scale | Standard Deviation 17.62 |
| Ambulatory Participants With Age <6 Years | Change From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Parent Report) at Months 6, 12, 18, 24 and 30 | Upper Extremity, Month 6 | -2.1 Units on a scale | Standard Deviation 8.82 |
| Ambulatory Participants With Age <6 Years | Change From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Parent Report) at Months 6, 12, 18, 24 and 30 | Pain, Month 24 | -14.2 Units on a scale | Standard Deviation 20.41 |
| Ambulatory Participants With Age <6 Years | Change From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Parent Report) at Months 6, 12, 18, 24 and 30 | Sports, Month 24 | -23.8 Units on a scale | Standard Deviation 17.52 |
| Ambulatory Participants With Age <6 Years | Change From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Parent Report) at Months 6, 12, 18, 24 and 30 | Global Function, Month 6 | -5.0 Units on a scale | Standard Deviation 8.34 |
| Ambulatory Participants With Age <6 Years | Change From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Parent Report) at Months 6, 12, 18, 24 and 30 | Pain, Month 18 | -4.1 Units on a scale | Standard Deviation 20.3 |
| Ambulatory Participants With Age <6 Years | Change From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Parent Report) at Months 6, 12, 18, 24 and 30 | Sports, Month 30 | -24.7 Units on a scale | Standard Deviation 17.74 |
| Ambulatory Participants With Age <6 Years | Change From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Parent Report) at Months 6, 12, 18, 24 and 30 | Transfer and Mobility, Month 6 | -5.1 Units on a scale | Standard Deviation 13.87 |
| Ambulatory Participants With Age <6 Years | Change From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Parent Report) at Months 6, 12, 18, 24 and 30 | Pain, Month 12 | -9.0 Units on a scale | Standard Deviation 20.31 |
| Ambulatory Participants With Age <6 Years | Change From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Parent Report) at Months 6, 12, 18, 24 and 30 | Pain, Month 6 | -7.2 Units on a scale | Standard Deviation 14.64 |
| Ambulatory Participants With Age <6 Years | Change From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Parent Report) at Months 6, 12, 18, 24 and 30 | Global Function, Month 24 | -19.0 Units on a scale | Standard Deviation 12.31 |
| Ambulatory Participants With Age <6 Years | Change From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Parent Report) at Months 6, 12, 18, 24 and 30 | Happiness, Month 30 | -17.9 Units on a scale | Standard Deviation 24.3 |
| Ambulatory Participants With Age <6 Years | Change From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Parent Report) at Months 6, 12, 18, 24 and 30 | Transfer and Mobility, Month 12 | -14.6 Units on a scale | Standard Deviation 17.24 |
| Ambulatory Participants With Age <6 Years | Change From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Parent Report) at Months 6, 12, 18, 24 and 30 | Upper Extremity, Month 18 | -6.4 Units on a scale | Standard Deviation 8.34 |
| Ambulatory Participants With Age <6 Years | Change From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Parent Report) at Months 6, 12, 18, 24 and 30 | Happiness, Month 24 | -22.3 Units on a scale | Standard Deviation 20.23 |
| Ambulatory Participants With Age <6 Years | Change From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Parent Report) at Months 6, 12, 18, 24 and 30 | Transfer and Mobility, Month 18 | -19.3 Units on a scale | Standard Deviation 15.26 |
| Ambulatory Participants With Age <6 Years | Change From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Parent Report) at Months 6, 12, 18, 24 and 30 | Global Function, Month 30 | -21.7 Units on a scale | Standard Deviation 16.19 |
| Ambulatory Participants With Age <6 Years | Change From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Parent Report) at Months 6, 12, 18, 24 and 30 | Upper Extremity, Month 24 | -11.0 Units on a scale | Standard Deviation 13.47 |
| Ambulatory Participants With Age <6 Years | Change From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Parent Report) at Months 6, 12, 18, 24 and 30 | Transfer and Mobility, Month 24 | -27.1 Units on a scale | Standard Deviation 21.79 |
| Ambulatory Participants With Age <6 Years | Change From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Parent Report) at Months 6, 12, 18, 24 and 30 | Global Function, Month 18 | -12.1 Units on a scale | Standard Deviation 8.56 |
| Ambulatory Participants With Age <6 Years | Change From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Parent Report) at Months 6, 12, 18, 24 and 30 | Happiness, Month 18 | -15.3 Units on a scale | Standard Deviation 16.31 |
| Ambulatory Participants With Age <6 Years | Change From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Parent Report) at Months 6, 12, 18, 24 and 30 | Transfer and Mobility, Month 30 | -28.4 Units on a scale | Standard Deviation 25.83 |
| Ambulatory Participants With Age <6 Years | Change From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Parent Report) at Months 6, 12, 18, 24 and 30 | Upper Extremity, Month 12 | -4.4 Units on a scale | Standard Deviation 9.24 |
| Ambulatory Participants With Age <6 Years | Change From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Parent Report) at Months 6, 12, 18, 24 and 30 | Happiness, Month 12 | -17.4 Units on a scale | Standard Deviation 19.43 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Parent Report) at Months 6, 12, 18, 24 and 30 | Happiness, Month 18 | -10.0 Units on a scale | Standard Deviation 22.91 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Parent Report) at Months 6, 12, 18, 24 and 30 | Upper Extremity, Month 6 | -18.8 Units on a scale | Standard Deviation 8.42 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Parent Report) at Months 6, 12, 18, 24 and 30 | Upper Extremity, Month 12 | -2.4 Units on a scale | Standard Deviation 16.17 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Parent Report) at Months 6, 12, 18, 24 and 30 | Upper Extremity, Month 18 | 1.3 Units on a scale | Standard Deviation 9.24 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Parent Report) at Months 6, 12, 18, 24 and 30 | Upper Extremity, Month 24 | -7.5 Units on a scale | Standard Deviation 16.51 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Parent Report) at Months 6, 12, 18, 24 and 30 | Upper Extremity, Month 30 | -8.0 Units on a scale | Standard Deviation 11.31 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Parent Report) at Months 6, 12, 18, 24 and 30 | Transfer and Mobility, Month 6 | -5.8 Units on a scale | Standard Deviation 5.62 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Parent Report) at Months 6, 12, 18, 24 and 30 | Transfer and Mobility, Month 12 | -9.2 Units on a scale | Standard Deviation 13.31 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Parent Report) at Months 6, 12, 18, 24 and 30 | Transfer and Mobility, Month 18 | 5.7 Units on a scale | Standard Deviation 20.65 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Parent Report) at Months 6, 12, 18, 24 and 30 | Transfer and Mobility, Month 24 | -10.3 Units on a scale | Standard Deviation 12.68 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Parent Report) at Months 6, 12, 18, 24 and 30 | Transfer and Mobility, Month 30 | -1.5 Units on a scale | Standard Deviation 6.36 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Parent Report) at Months 6, 12, 18, 24 and 30 | Sports, Month 6 | -3.0 Units on a scale | Standard Deviation 7.87 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Parent Report) at Months 6, 12, 18, 24 and 30 | Sports, Month 12 | -5.4 Units on a scale | Standard Deviation 11.21 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Parent Report) at Months 6, 12, 18, 24 and 30 | Sports, Month 18 | -4.7 Units on a scale | Standard Deviation 4.73 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Parent Report) at Months 6, 12, 18, 24 and 30 | Sports, Month 24 | -2.6 Units on a scale | Standard Deviation 8.99 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Parent Report) at Months 6, 12, 18, 24 and 30 | Sports, Month 30 | -9.5 Units on a scale | Standard Deviation 13.44 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Parent Report) at Months 6, 12, 18, 24 and 30 | Pain, Month 6 | -0.5 Units on a scale | Standard Deviation 22.65 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Parent Report) at Months 6, 12, 18, 24 and 30 | Pain, Month 12 | 11.3 Units on a scale | Standard Deviation 34.97 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Parent Report) at Months 6, 12, 18, 24 and 30 | Pain, Month 18 | -10.3 Units on a scale | Standard Deviation 12.01 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Parent Report) at Months 6, 12, 18, 24 and 30 | Pain, Month 24 | 4.9 Units on a scale | Standard Deviation 29.67 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Parent Report) at Months 6, 12, 18, 24 and 30 | Pain, Month 30 | 9.0 Units on a scale | Standard Deviation 12.73 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Parent Report) at Months 6, 12, 18, 24 and 30 | Happiness, Month 6 | 7.5 Units on a scale | Standard Deviation 36.63 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Parent Report) at Months 6, 12, 18, 24 and 30 | Happiness, Month 12 | 1.6 Units on a scale | Standard Deviation 22.24 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Parent Report) at Months 6, 12, 18, 24 and 30 | Happiness, Month 24 | -2.1 Units on a scale | Standard Deviation 25.74 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Parent Report) at Months 6, 12, 18, 24 and 30 | Happiness, Month 30 | -17.5 Units on a scale | Standard Deviation 24.75 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Parent Report) at Months 6, 12, 18, 24 and 30 | Global Function, Month 6 | -7.3 Units on a scale | Standard Deviation 7.76 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Parent Report) at Months 6, 12, 18, 24 and 30 | Global Function, Month 12 | -1.5 Units on a scale | Standard Deviation 12.1 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Parent Report) at Months 6, 12, 18, 24 and 30 | Global Function, Month 18 | -2.0 Units on a scale | Standard Deviation 3.61 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Parent Report) at Months 6, 12, 18, 24 and 30 | Global Function, Month 24 | -3.8 Units on a scale | Standard Deviation 12.63 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Parent Report) at Months 6, 12, 18, 24 and 30 | Global Function, Month 30 | -2.5 Units on a scale | Standard Deviation 2.12 |
| Total Ambulatory Participants | Change From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Parent Report) at Months 6, 12, 18, 24 and 30 | Sports, Month 6 | -5.5 Units on a scale | Standard Deviation 13.52 |
| Total Ambulatory Participants | Change From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Parent Report) at Months 6, 12, 18, 24 and 30 | Upper Extremity, Month 18 | -5.1 Units on a scale | Standard Deviation 8.72 |
| Total Ambulatory Participants | Change From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Parent Report) at Months 6, 12, 18, 24 and 30 | Happiness, Month 6 | -10.5 Units on a scale | Standard Deviation 22.71 |
| Total Ambulatory Participants | Change From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Parent Report) at Months 6, 12, 18, 24 and 30 | Transfer and Mobility, Month 30 | -22.4 Units on a scale | Standard Deviation 25.42 |
| Total Ambulatory Participants | Change From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Parent Report) at Months 6, 12, 18, 24 and 30 | Upper Extremity, Month 6 | -4.3 Units on a scale | Standard Deviation 10.32 |
| Total Ambulatory Participants | Change From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Parent Report) at Months 6, 12, 18, 24 and 30 | Happiness, Month 12 | -9.2 Units on a scale | Standard Deviation 22.54 |
| Total Ambulatory Participants | Change From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Parent Report) at Months 6, 12, 18, 24 and 30 | Transfer and Mobility, Month 24 | -19.4 Units on a scale | Standard Deviation 19.84 |
| Total Ambulatory Participants | Change From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Parent Report) at Months 6, 12, 18, 24 and 30 | Transfer and Mobility, Month 18 | -15.2 Units on a scale | Standard Deviation 18.27 |
| Total Ambulatory Participants | Change From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Parent Report) at Months 6, 12, 18, 24 and 30 | Happiness, Month 18 | -14.4 Units on a scale | Standard Deviation 16.88 |
| Total Ambulatory Participants | Change From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Parent Report) at Months 6, 12, 18, 24 and 30 | Transfer and Mobility, Month 12 | -12.2 Units on a scale | Standard Deviation 15.73 |
| Total Ambulatory Participants | Change From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Parent Report) at Months 6, 12, 18, 24 and 30 | Global Function, Month 18 | -10.4 Units on a scale | Standard Deviation 8.77 |
| Total Ambulatory Participants | Change From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Parent Report) at Months 6, 12, 18, 24 and 30 | Happiness, Month 24 | -13.0 Units on a scale | Standard Deviation 24.79 |
| Total Ambulatory Participants | Change From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Parent Report) at Months 6, 12, 18, 24 and 30 | Transfer and Mobility, Month 6 | -5.2 Units on a scale | Standard Deviation 13.03 |
| Total Ambulatory Participants | Change From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Parent Report) at Months 6, 12, 18, 24 and 30 | Upper Extremity, Month 12 | -3.5 Units on a scale | Standard Deviation 12.57 |
| Total Ambulatory Participants | Change From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Parent Report) at Months 6, 12, 18, 24 and 30 | Happiness, Month 30 | -17.8 Units on a scale | Standard Deviation 22.79 |
| Total Ambulatory Participants | Change From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Parent Report) at Months 6, 12, 18, 24 and 30 | Upper Extremity, Month 30 | -7.6 Units on a scale | Standard Deviation 9.71 |
| Total Ambulatory Participants | Change From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Parent Report) at Months 6, 12, 18, 24 and 30 | Global Function, Month 30 | -17.4 Units on a scale | Standard Deviation 16.4 |
| Total Ambulatory Participants | Change From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Parent Report) at Months 6, 12, 18, 24 and 30 | Pain, Month 6 | -6.3 Units on a scale | Standard Deviation 15.57 |
| Total Ambulatory Participants | Change From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Parent Report) at Months 6, 12, 18, 24 and 30 | Sports, Month 30 | -21.3 Units on a scale | Standard Deviation 17.42 |
| Total Ambulatory Participants | Change From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Parent Report) at Months 6, 12, 18, 24 and 30 | Global Function, Month 6 | -5.3 Units on a scale | Standard Deviation 8.18 |
| Total Ambulatory Participants | Change From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Parent Report) at Months 6, 12, 18, 24 and 30 | Pain, Month 12 | -0.3 Units on a scale | Standard Deviation 29.07 |
| Total Ambulatory Participants | Change From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Parent Report) at Months 6, 12, 18, 24 and 30 | Sports, Month 24 | -14.1 Units on a scale | Standard Deviation 17.69 |
| Total Ambulatory Participants | Change From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Parent Report) at Months 6, 12, 18, 24 and 30 | Upper Extremity, Month 24 | -9.4 Units on a scale | Standard Deviation 14.83 |
| Total Ambulatory Participants | Change From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Parent Report) at Months 6, 12, 18, 24 and 30 | Pain, Month 18 | -5.2 Units on a scale | Standard Deviation 19.03 |
| Total Ambulatory Participants | Change From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Parent Report) at Months 6, 12, 18, 24 and 30 | Sports, Month 18 | -16.4 Units on a scale | Standard Deviation 16.96 |
| Total Ambulatory Participants | Change From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Parent Report) at Months 6, 12, 18, 24 and 30 | Global Function, Month 24 | -12.0 Units on a scale | Standard Deviation 14.48 |
| Total Ambulatory Participants | Change From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Parent Report) at Months 6, 12, 18, 24 and 30 | Pain, Month 24 | -5.4 Units on a scale | Standard Deviation 26.52 |
| Total Ambulatory Participants | Change From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Parent Report) at Months 6, 12, 18, 24 and 30 | Sports, Month 12 | -9.4 Units on a scale | Standard Deviation 14.07 |
| Total Ambulatory Participants | Change From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Parent Report) at Months 6, 12, 18, 24 and 30 | Global Function, Month 12 | -6.4 Units on a scale | Standard Deviation 11.32 |
| Total Ambulatory Participants | Change From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Parent Report) at Months 6, 12, 18, 24 and 30 | Pain, Month 30 | -18.1 Units on a scale | Standard Deviation 24.92 |
Change From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Self Report) at Months 6, 12, 18, 24 and 30
The PODCI is a participant-reported assessment of musculoskeletal health intended for use in children and adolescents. The pediatric version was intended for completion by parents or caregivers of children \<=10 years old. It included a Global Function Scale along with core scales: Upper Extremity and Physical Function Core Scale (8 items); Transfer and Basic Mobility Core Scale (11 items); Sports and Physical Functioning Core Scale (21 items); Pain/Comfort Core Scale (3 items); Happiness Core Scale (5 items). The scores of each PODCI global functioning scale and core scales are averaged over the number of items answered (omitted no entry items). Mean of the rescaled values is multiplied by a constant so that each global functioning scale and core scales has a final range of values between 0-100. The higher scores represent less disability and better functioning.
Time frame: Baseline (Day 1) and Months 6, 12, 18, 24 and 30
Population: Full Analysis Set included all participants who had been enrolled in the study. Here, Number of Participants Analyzed signifies all participants in the Full Analysis Set with age between 11-18 years contributed data to the table; however, may not have evaluable data for every row. 'Number Analyzed' signifies participants evaluable for specified rows.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Ambulatory Participants With Age <6 Years | Change From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Self Report) at Months 6, 12, 18, 24 and 30 | Sports, Month 6 | -0.9 Units on a scale | Standard Deviation 14.11 |
| Ambulatory Participants With Age <6 Years | Change From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Self Report) at Months 6, 12, 18, 24 and 30 | Upper Extremity, Month 24 | -5.3 Units on a scale | Standard Deviation 10.93 |
| Ambulatory Participants With Age <6 Years | Change From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Self Report) at Months 6, 12, 18, 24 and 30 | Pain, Month 30 | 13.9 Units on a scale | Standard Deviation 23.1 |
| Ambulatory Participants With Age <6 Years | Change From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Self Report) at Months 6, 12, 18, 24 and 30 | Sports, Month 12 | -4.6 Units on a scale | Standard Deviation 19.6 |
| Ambulatory Participants With Age <6 Years | Change From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Self Report) at Months 6, 12, 18, 24 and 30 | Global Function, Month 12 | -4.4 Units on a scale | Standard Deviation 12.66 |
| Ambulatory Participants With Age <6 Years | Change From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Self Report) at Months 6, 12, 18, 24 and 30 | Pain, Month 24 | -12.4 Units on a scale | Standard Deviation 24.21 |
| Ambulatory Participants With Age <6 Years | Change From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Self Report) at Months 6, 12, 18, 24 and 30 | Sports, Month 18 | -8.7 Units on a scale | Standard Deviation 14.39 |
| Ambulatory Participants With Age <6 Years | Change From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Self Report) at Months 6, 12, 18, 24 and 30 | Upper Extremity, Month 30 | -5.4 Units on a scale | Standard Deviation 7.16 |
| Ambulatory Participants With Age <6 Years | Change From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Self Report) at Months 6, 12, 18, 24 and 30 | Pain, Month 18 | -2.6 Units on a scale | Standard Deviation 17.19 |
| Ambulatory Participants With Age <6 Years | Change From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Self Report) at Months 6, 12, 18, 24 and 30 | Sports, Month 24 | -21.4 Units on a scale | Standard Deviation 19.71 |
| Ambulatory Participants With Age <6 Years | Change From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Self Report) at Months 6, 12, 18, 24 and 30 | Upper Extremity, Month 12 | -4.6 Units on a scale | Standard Deviation 10.1 |
| Ambulatory Participants With Age <6 Years | Change From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Self Report) at Months 6, 12, 18, 24 and 30 | Pain, Month 12 | 2.1 Units on a scale | Standard Deviation 26.07 |
| Ambulatory Participants With Age <6 Years | Change From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Self Report) at Months 6, 12, 18, 24 and 30 | Sports, Month 30 | -10.4 Units on a scale | Standard Deviation 13.45 |
| Ambulatory Participants With Age <6 Years | Change From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Self Report) at Months 6, 12, 18, 24 and 30 | Global Function, Month 6 | -2.4 Units on a scale | Standard Deviation 6.62 |
| Ambulatory Participants With Age <6 Years | Change From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Self Report) at Months 6, 12, 18, 24 and 30 | Pain, Month 6 | -2.7 Units on a scale | Standard Deviation 17.96 |
| Ambulatory Participants With Age <6 Years | Change From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Self Report) at Months 6, 12, 18, 24 and 30 | Transfer and Mobility, Month 6 | -4.5 Units on a scale | Standard Deviation 10.71 |
| Ambulatory Participants With Age <6 Years | Change From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Self Report) at Months 6, 12, 18, 24 and 30 | Upper Extremity, Month 6 | -1.6 Units on a scale | Standard Deviation 8.15 |
| Ambulatory Participants With Age <6 Years | Change From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Self Report) at Months 6, 12, 18, 24 and 30 | Happiness, Month 30 | -2.9 Units on a scale | Standard Deviation 16.29 |
| Ambulatory Participants With Age <6 Years | Change From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Self Report) at Months 6, 12, 18, 24 and 30 | Transfer and Mobility, Month 12 | -10.6 Units on a scale | Standard Deviation 18.2 |
| Ambulatory Participants With Age <6 Years | Change From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Self Report) at Months 6, 12, 18, 24 and 30 | Global Function, Month 24 | -15.9 Units on a scale | Standard Deviation 12.85 |
| Ambulatory Participants With Age <6 Years | Change From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Self Report) at Months 6, 12, 18, 24 and 30 | Happiness, Month 24 | -2.0 Units on a scale | Standard Deviation 31.47 |
| Ambulatory Participants With Age <6 Years | Change From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Self Report) at Months 6, 12, 18, 24 and 30 | Transfer and Mobility, Month 18 | -9.6 Units on a scale | Standard Deviation 11.78 |
| Ambulatory Participants With Age <6 Years | Change From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Self Report) at Months 6, 12, 18, 24 and 30 | Upper Extremity, Month 18 | 0.3 Units on a scale | Standard Deviation 7.14 |
| Ambulatory Participants With Age <6 Years | Change From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Self Report) at Months 6, 12, 18, 24 and 30 | Happiness, Month 18 | -3.3 Units on a scale | Standard Deviation 17.29 |
| Ambulatory Participants With Age <6 Years | Change From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Self Report) at Months 6, 12, 18, 24 and 30 | Transfer and Mobility, Month 24 | -24.9 Units on a scale | Standard Deviation 19.56 |
| Ambulatory Participants With Age <6 Years | Change From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Self Report) at Months 6, 12, 18, 24 and 30 | Global Function, Month 30 | -4.7 Units on a scale | Standard Deviation 12.46 |
| Ambulatory Participants With Age <6 Years | Change From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Self Report) at Months 6, 12, 18, 24 and 30 | Happiness, Month 12 | -4.8 Units on a scale | Standard Deviation 23.34 |
| Ambulatory Participants With Age <6 Years | Change From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Self Report) at Months 6, 12, 18, 24 and 30 | Transfer and Mobility, Month 30 | -17.0 Units on a scale | Standard Deviation 19.71 |
| Ambulatory Participants With Age <6 Years | Change From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Self Report) at Months 6, 12, 18, 24 and 30 | Global Function, Month 18 | -5.0 Units on a scale | Standard Deviation 7.52 |
| Ambulatory Participants With Age <6 Years | Change From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Self Report) at Months 6, 12, 18, 24 and 30 | Happiness, Month 6 | -7.8 Units on a scale | Standard Deviation 23.14 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Self Report) at Months 6, 12, 18, 24 and 30 | Happiness, Month 18 | -8.3 Units on a scale | Standard Deviation 7.64 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Self Report) at Months 6, 12, 18, 24 and 30 | Upper Extremity, Month 6 | -1.0 Units on a scale | Standard Deviation 8.29 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Self Report) at Months 6, 12, 18, 24 and 30 | Upper Extremity, Month 12 | -3.3 Units on a scale | Standard Deviation 13.53 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Self Report) at Months 6, 12, 18, 24 and 30 | Upper Extremity, Month 18 | -5.7 Units on a scale | Standard Deviation 12.7 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Self Report) at Months 6, 12, 18, 24 and 30 | Upper Extremity, Month 30 | -2.0 Units on a scale | Standard Deviation 2.83 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Self Report) at Months 6, 12, 18, 24 and 30 | Transfer and Mobility, Month 6 | -2.0 Units on a scale | Standard Deviation 18.09 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Self Report) at Months 6, 12, 18, 24 and 30 | Transfer and Mobility, Month 12 | -6.3 Units on a scale | Standard Deviation 16.4 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Self Report) at Months 6, 12, 18, 24 and 30 | Transfer and Mobility, Month 18 | -9.7 Units on a scale | Standard Deviation 4.04 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Self Report) at Months 6, 12, 18, 24 and 30 | Transfer and Mobility, Month 24 | -7.9 Units on a scale | Standard Deviation 16.34 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Self Report) at Months 6, 12, 18, 24 and 30 | Transfer and Mobility, Month 30 | -10.0 Units on a scale | Standard Deviation 8.49 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Self Report) at Months 6, 12, 18, 24 and 30 | Sports, Month 6 | -2.8 Units on a scale | Standard Deviation 10.4 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Self Report) at Months 6, 12, 18, 24 and 30 | Sports, Month 12 | -3.2 Units on a scale | Standard Deviation 11.03 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Self Report) at Months 6, 12, 18, 24 and 30 | Sports, Month 18 | -2.7 Units on a scale | Standard Deviation 7.77 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Self Report) at Months 6, 12, 18, 24 and 30 | Sports, Month 24 | -8.2 Units on a scale | Standard Deviation 12.58 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Self Report) at Months 6, 12, 18, 24 and 30 | Sports, Month 30 | -1.5 Units on a scale | Standard Deviation 2.12 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Self Report) at Months 6, 12, 18, 24 and 30 | Pain, Month 6 | 5.5 Units on a scale | Standard Deviation 11.47 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Self Report) at Months 6, 12, 18, 24 and 30 | Pain, Month 12 | 8.3 Units on a scale | Standard Deviation 20.53 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Self Report) at Months 6, 12, 18, 24 and 30 | Pain, Month 18 | -7.7 Units on a scale | Standard Deviation 27.32 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Self Report) at Months 6, 12, 18, 24 and 30 | Pain, Month 24 | 4.0 Units on a scale | Standard Deviation 20.55 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Self Report) at Months 6, 12, 18, 24 and 30 | Pain, Month 30 | 0.0 Units on a scale | Standard Deviation 0 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Self Report) at Months 6, 12, 18, 24 and 30 | Happiness, Month 6 | -8.8 Units on a scale | Standard Deviation 8.54 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Self Report) at Months 6, 12, 18, 24 and 30 | Happiness, Month 12 | 2.6 Units on a scale | Standard Deviation 15.58 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Self Report) at Months 6, 12, 18, 24 and 30 | Upper Extremity, Month 24 | -5.5 Units on a scale | Standard Deviation 12.06 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Self Report) at Months 6, 12, 18, 24 and 30 | Happiness, Month 24 | -10.6 Units on a scale | Standard Deviation 19.11 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Self Report) at Months 6, 12, 18, 24 and 30 | Happiness, Month 30 | -2.5 Units on a scale | Standard Deviation 10.61 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Self Report) at Months 6, 12, 18, 24 and 30 | Global Function, Month 6 | 0.3 Units on a scale | Standard Deviation 8.77 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Self Report) at Months 6, 12, 18, 24 and 30 | Global Function, Month 12 | -0.9 Units on a scale | Standard Deviation 8.18 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Self Report) at Months 6, 12, 18, 24 and 30 | Global Function, Month 18 | -6.3 Units on a scale | Standard Deviation 10.41 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Self Report) at Months 6, 12, 18, 24 and 30 | Global Function, Month 24 | -4.2 Units on a scale | Standard Deviation 7.37 |
| Ambulatory Participants With Age >=6 Years | Change From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Self Report) at Months 6, 12, 18, 24 and 30 | Global Function, Month 30 | -3.5 Units on a scale | Standard Deviation 0.71 |
| Total Ambulatory Participants | Change From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Self Report) at Months 6, 12, 18, 24 and 30 | Transfer and Mobility, Month 30 | -15.4 Units on a scale | Standard Deviation 17.61 |
| Total Ambulatory Participants | Change From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Self Report) at Months 6, 12, 18, 24 and 30 | Global Function, Month 12 | -2.9 Units on a scale | Standard Deviation 10.98 |
| Total Ambulatory Participants | Change From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Self Report) at Months 6, 12, 18, 24 and 30 | Happiness, Month 6 | -7.9 Units on a scale | Standard Deviation 21.71 |
| Total Ambulatory Participants | Change From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Self Report) at Months 6, 12, 18, 24 and 30 | Transfer and Mobility, Month 24 | -17.1 Units on a scale | Standard Deviation 19.86 |
| Total Ambulatory Participants | Change From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Self Report) at Months 6, 12, 18, 24 and 30 | Upper Extremity, Month 18 | -0.7 Units on a scale | Standard Deviation 8.13 |
| Total Ambulatory Participants | Change From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Self Report) at Months 6, 12, 18, 24 and 30 | Happiness, Month 12 | -1.6 Units on a scale | Standard Deviation 20.48 |
| Total Ambulatory Participants | Change From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Self Report) at Months 6, 12, 18, 24 and 30 | Transfer and Mobility, Month 18 | -9.6 Units on a scale | Standard Deviation 10.78 |
| Total Ambulatory Participants | Change From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Self Report) at Months 6, 12, 18, 24 and 30 | Upper Extremity, Month 6 | -1.5 Units on a scale | Standard Deviation 8.03 |
| Total Ambulatory Participants | Change From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Self Report) at Months 6, 12, 18, 24 and 30 | Happiness, Month 18 | -4.2 Units on a scale | Standard Deviation 16.02 |
| Total Ambulatory Participants | Change From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Self Report) at Months 6, 12, 18, 24 and 30 | Transfer and Mobility, Month 12 | -8.8 Units on a scale | Standard Deviation 17.38 |
| Total Ambulatory Participants | Change From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Self Report) at Months 6, 12, 18, 24 and 30 | Global Function, Month 18 | -5.2 Units on a scale | Standard Deviation 7.72 |
| Total Ambulatory Participants | Change From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Self Report) at Months 6, 12, 18, 24 and 30 | Happiness, Month 24 | -5.9 Units on a scale | Standard Deviation 26.53 |
| Total Ambulatory Participants | Change From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Self Report) at Months 6, 12, 18, 24 and 30 | Transfer and Mobility, Month 6 | -4.2 Units on a scale | Standard Deviation 11.53 |
| Total Ambulatory Participants | Change From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Self Report) at Months 6, 12, 18, 24 and 30 | Upper Extremity, Month 12 | -4.0 Units on a scale | Standard Deviation 11.58 |
| Total Ambulatory Participants | Change From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Self Report) at Months 6, 12, 18, 24 and 30 | Happiness, Month 30 | -2.8 Units on a scale | Standard Deviation 14.6 |
| Total Ambulatory Participants | Change From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Self Report) at Months 6, 12, 18, 24 and 30 | Sports, Month 30 | -8.4 Units on a scale | Standard Deviation 12.32 |
| Total Ambulatory Participants | Change From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Self Report) at Months 6, 12, 18, 24 and 30 | Upper Extremity, Month 30 | -4.7 Units on a scale | Standard Deviation 6.46 |
| Total Ambulatory Participants | Change From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Self Report) at Months 6, 12, 18, 24 and 30 | Pain, Month 6 | -1.6 Units on a scale | Standard Deviation 17.34 |
| Total Ambulatory Participants | Change From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Self Report) at Months 6, 12, 18, 24 and 30 | Sports, Month 24 | -15.3 Units on a scale | Standard Deviation 17.87 |
| Total Ambulatory Participants | Change From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Self Report) at Months 6, 12, 18, 24 and 30 | Global Function, Month 30 | -4.4 Units on a scale | Standard Deviation 10.81 |
| Total Ambulatory Participants | Change From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Self Report) at Months 6, 12, 18, 24 and 30 | Pain, Month 12 | 4.8 Units on a scale | Standard Deviation 23.77 |
| Total Ambulatory Participants | Change From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Self Report) at Months 6, 12, 18, 24 and 30 | Sports, Month 18 | -7.7 Units on a scale | Standard Deviation 13.52 |
| Total Ambulatory Participants | Change From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Self Report) at Months 6, 12, 18, 24 and 30 | Global Function, Month 6 | -2.1 Units on a scale | Standard Deviation 6.82 |
| Total Ambulatory Participants | Change From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Self Report) at Months 6, 12, 18, 24 and 30 | Pain, Month 18 | -3.4 Units on a scale | Standard Deviation 18.3 |
| Total Ambulatory Participants | Change From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Self Report) at Months 6, 12, 18, 24 and 30 | Sports, Month 12 | -4.0 Units on a scale | Standard Deviation 16.3 |
| Total Ambulatory Participants | Change From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Self Report) at Months 6, 12, 18, 24 and 30 | Upper Extremity, Month 24 | -5.4 Units on a scale | Standard Deviation 11.3 |
| Total Ambulatory Participants | Change From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Self Report) at Months 6, 12, 18, 24 and 30 | Pain, Month 24 | -4.8 Units on a scale | Standard Deviation 23.78 |
| Total Ambulatory Participants | Change From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Self Report) at Months 6, 12, 18, 24 and 30 | Sports, Month 6 | -1.2 Units on a scale | Standard Deviation 13.56 |
| Total Ambulatory Participants | Change From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Self Report) at Months 6, 12, 18, 24 and 30 | Global Function, Month 24 | -10.5 Units on a scale | Standard Deviation 12.07 |
| Total Ambulatory Participants | Change From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Self Report) at Months 6, 12, 18, 24 and 30 | Pain, Month 30 | 10.8 Units on a scale | Standard Deviation 20.92 |
Number of Participants According to Response to Each EQ-5D-3L 5 Dimensions at Month 24
EQ-5D-3L is a participant completed questionnaire designed to assess impact on health related quality of life. It is comprised of five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. The responses record three levels of severity (no problems/some or moderate problems/extreme problems) within a particular EQ-5D dimension. EQ-5D-3L assessment was only performed in participants \>= 16 years old as pre-specified in protocol.
Time frame: Month 24
Population: Full Analysis Set included all participants who had been enrolled in the study. Here, Number of Participants Analyzed signifies participants evaluable for this outcome measure. 'Number Analyzed' signifies participants evaluable for specified rows.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Ambulatory Participants With Age <6 Years | Number of Participants According to Response to Each EQ-5D-3L 5 Dimensions at Month 24 | Usual Activities, extreme problems, Month 24 | 1 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants According to Response to Each EQ-5D-3L 5 Dimensions at Month 24 | Usual Activities, some problems, Month 24 | 0 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants According to Response to Each EQ-5D-3L 5 Dimensions at Month 24 | Self-Care, some problems, Month 24 | 1 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants According to Response to Each EQ-5D-3L 5 Dimensions at Month 24 | Usual Activities, no problems, Month 24 | 1 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants According to Response to Each EQ-5D-3L 5 Dimensions at Month 24 | Self-Care, extreme problems, Month 24 | 1 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants According to Response to Each EQ-5D-3L 5 Dimensions at Month 24 | Mobility, some problems, Month 24 | 0 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants According to Response to Each EQ-5D-3L 5 Dimensions at Month 24 | Mobility, no problems, Month 24 | 1 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants According to Response to Each EQ-5D-3L 5 Dimensions at Month 24 | Anxiety/Depression, no problems, Month 24 | 1 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants According to Response to Each EQ-5D-3L 5 Dimensions at Month 24 | Pain/Discomfort, extreme problems, Month 24 | 0 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants According to Response to Each EQ-5D-3L 5 Dimensions at Month 24 | Mobility, extreme problems, Month 24 | 1 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants According to Response to Each EQ-5D-3L 5 Dimensions at Month 24 | Anxiety/Depression, extreme problems, Month 24 | 0 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants According to Response to Each EQ-5D-3L 5 Dimensions at Month 24 | Pain/Discomfort, some problems, Month 24 | 1 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants According to Response to Each EQ-5D-3L 5 Dimensions at Month 24 | Pain/Discomfort, no problems, Month 24 | 1 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants According to Response to Each EQ-5D-3L 5 Dimensions at Month 24 | Self-Care, no problems, Month 24 | 0 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants According to Response to Each EQ-5D-3L 5 Dimensions at Month 24 | Anxiety/Depression, some problems, Month 24 | 1 Participants |
| Ambulatory Participants With Age >=6 Years | Number of Participants According to Response to Each EQ-5D-3L 5 Dimensions at Month 24 | Self-Care, some problems, Month 24 | 1 Participants |
| Ambulatory Participants With Age >=6 Years | Number of Participants According to Response to Each EQ-5D-3L 5 Dimensions at Month 24 | Mobility, no problems, Month 24 | 1 Participants |
| Ambulatory Participants With Age >=6 Years | Number of Participants According to Response to Each EQ-5D-3L 5 Dimensions at Month 24 | Mobility, some problems, Month 24 | 0 Participants |
| Ambulatory Participants With Age >=6 Years | Number of Participants According to Response to Each EQ-5D-3L 5 Dimensions at Month 24 | Mobility, extreme problems, Month 24 | 1 Participants |
| Ambulatory Participants With Age >=6 Years | Number of Participants According to Response to Each EQ-5D-3L 5 Dimensions at Month 24 | Self-Care, no problems, Month 24 | 0 Participants |
| Ambulatory Participants With Age >=6 Years | Number of Participants According to Response to Each EQ-5D-3L 5 Dimensions at Month 24 | Self-Care, extreme problems, Month 24 | 1 Participants |
| Ambulatory Participants With Age >=6 Years | Number of Participants According to Response to Each EQ-5D-3L 5 Dimensions at Month 24 | Usual Activities, no problems, Month 24 | 1 Participants |
| Ambulatory Participants With Age >=6 Years | Number of Participants According to Response to Each EQ-5D-3L 5 Dimensions at Month 24 | Usual Activities, some problems, Month 24 | 0 Participants |
| Ambulatory Participants With Age >=6 Years | Number of Participants According to Response to Each EQ-5D-3L 5 Dimensions at Month 24 | Usual Activities, extreme problems, Month 24 | 1 Participants |
| Ambulatory Participants With Age >=6 Years | Number of Participants According to Response to Each EQ-5D-3L 5 Dimensions at Month 24 | Pain/Discomfort, no problems, Month 24 | 1 Participants |
| Ambulatory Participants With Age >=6 Years | Number of Participants According to Response to Each EQ-5D-3L 5 Dimensions at Month 24 | Pain/Discomfort, some problems, Month 24 | 1 Participants |
| Ambulatory Participants With Age >=6 Years | Number of Participants According to Response to Each EQ-5D-3L 5 Dimensions at Month 24 | Pain/Discomfort, extreme problems, Month 24 | 0 Participants |
| Ambulatory Participants With Age >=6 Years | Number of Participants According to Response to Each EQ-5D-3L 5 Dimensions at Month 24 | Anxiety/Depression, no problems, Month 24 | 1 Participants |
| Ambulatory Participants With Age >=6 Years | Number of Participants According to Response to Each EQ-5D-3L 5 Dimensions at Month 24 | Anxiety/Depression, some problems, Month 24 | 1 Participants |
| Ambulatory Participants With Age >=6 Years | Number of Participants According to Response to Each EQ-5D-3L 5 Dimensions at Month 24 | Anxiety/Depression, extreme problems, Month 24 | 0 Participants |
| Total Ambulatory Participants | Number of Participants According to Response to Each EQ-5D-3L 5 Dimensions at Month 24 | Usual Activities, some problems, Month 24 | 5 Participants |
| Total Ambulatory Participants | Number of Participants According to Response to Each EQ-5D-3L 5 Dimensions at Month 24 | Self-Care, no problems, Month 24 | 0 Participants |
| Total Ambulatory Participants | Number of Participants According to Response to Each EQ-5D-3L 5 Dimensions at Month 24 | Anxiety/Depression, extreme problems, Month 24 | 0 Participants |
| Total Ambulatory Participants | Number of Participants According to Response to Each EQ-5D-3L 5 Dimensions at Month 24 | Usual Activities, extreme problems, Month 24 | 3 Participants |
| Total Ambulatory Participants | Number of Participants According to Response to Each EQ-5D-3L 5 Dimensions at Month 24 | Anxiety/Depression, some problems, Month 24 | 1 Participants |
| Total Ambulatory Participants | Number of Participants According to Response to Each EQ-5D-3L 5 Dimensions at Month 24 | Pain/Discomfort, no problems, Month 24 | 5 Participants |
| Total Ambulatory Participants | Number of Participants According to Response to Each EQ-5D-3L 5 Dimensions at Month 24 | Mobility, extreme problems, Month 24 | 4 Participants |
| Total Ambulatory Participants | Number of Participants According to Response to Each EQ-5D-3L 5 Dimensions at Month 24 | Pain/Discomfort, some problems, Month 24 | 3 Participants |
| Total Ambulatory Participants | Number of Participants According to Response to Each EQ-5D-3L 5 Dimensions at Month 24 | Mobility, no problems, Month 24 | 0 Participants |
| Total Ambulatory Participants | Number of Participants According to Response to Each EQ-5D-3L 5 Dimensions at Month 24 | Pain/Discomfort, extreme problems, Month 24 | 0 Participants |
| Total Ambulatory Participants | Number of Participants According to Response to Each EQ-5D-3L 5 Dimensions at Month 24 | Mobility, some problems, Month 24 | 4 Participants |
| Total Ambulatory Participants | Number of Participants According to Response to Each EQ-5D-3L 5 Dimensions at Month 24 | Anxiety/Depression, no problems, Month 24 | 7 Participants |
| Total Ambulatory Participants | Number of Participants According to Response to Each EQ-5D-3L 5 Dimensions at Month 24 | Self-Care, extreme problems, Month 24 | 5 Participants |
| Total Ambulatory Participants | Number of Participants According to Response to Each EQ-5D-3L 5 Dimensions at Month 24 | Self-Care, some problems, Month 24 | 3 Participants |
| Total Ambulatory Participants | Number of Participants According to Response to Each EQ-5D-3L 5 Dimensions at Month 24 | Usual Activities, no problems, Month 24 | 0 Participants |
| Non-ambulatory Participants | Number of Participants According to Response to Each EQ-5D-3L 5 Dimensions at Month 24 | Self-Care, extreme problems, Month 24 | 6 Participants |
| Non-ambulatory Participants | Number of Participants According to Response to Each EQ-5D-3L 5 Dimensions at Month 24 | Usual Activities, some problems, Month 24 | 5 Participants |
| Non-ambulatory Participants | Number of Participants According to Response to Each EQ-5D-3L 5 Dimensions at Month 24 | Self-Care, no problems, Month 24 | 0 Participants |
| Non-ambulatory Participants | Number of Participants According to Response to Each EQ-5D-3L 5 Dimensions at Month 24 | Pain/Discomfort, extreme problems, Month 24 | 0 Participants |
| Non-ambulatory Participants | Number of Participants According to Response to Each EQ-5D-3L 5 Dimensions at Month 24 | Anxiety/Depression, no problems, Month 24 | 8 Participants |
| Non-ambulatory Participants | Number of Participants According to Response to Each EQ-5D-3L 5 Dimensions at Month 24 | Usual Activities, extreme problems, Month 24 | 4 Participants |
| Non-ambulatory Participants | Number of Participants According to Response to Each EQ-5D-3L 5 Dimensions at Month 24 | Mobility, extreme problems, Month 24 | 5 Participants |
| Non-ambulatory Participants | Number of Participants According to Response to Each EQ-5D-3L 5 Dimensions at Month 24 | Anxiety/Depression, extreme problems, Month 24 | 0 Participants |
| Non-ambulatory Participants | Number of Participants According to Response to Each EQ-5D-3L 5 Dimensions at Month 24 | Self-Care, some problems, Month 24 | 4 Participants |
| Non-ambulatory Participants | Number of Participants According to Response to Each EQ-5D-3L 5 Dimensions at Month 24 | Pain/Discomfort, no problems, Month 24 | 6 Participants |
| Non-ambulatory Participants | Number of Participants According to Response to Each EQ-5D-3L 5 Dimensions at Month 24 | Mobility, no problems, Month 24 | 1 Participants |
| Non-ambulatory Participants | Number of Participants According to Response to Each EQ-5D-3L 5 Dimensions at Month 24 | Anxiety/Depression, some problems, Month 24 | 2 Participants |
| Non-ambulatory Participants | Number of Participants According to Response to Each EQ-5D-3L 5 Dimensions at Month 24 | Usual Activities, no problems, Month 24 | 1 Participants |
| Non-ambulatory Participants | Number of Participants According to Response to Each EQ-5D-3L 5 Dimensions at Month 24 | Pain/Discomfort, some problems, Month 24 | 4 Participants |
| Non-ambulatory Participants | Number of Participants According to Response to Each EQ-5D-3L 5 Dimensions at Month 24 | Mobility, some problems, Month 24 | 4 Participants |
Number of Participants According to Response to Each EQ-5D-3L 5 Dimensions at Month 30
EQ-5D-3L is a participant completed questionnaire designed to assess impact on health related quality of life. It is comprised of five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. The responses record three levels of severity (no problems/some or moderate problems/extreme problems) within a particular EQ-5D dimension. EQ-5D-3L assessment was only performed in participants \>= 16 years old as pre-specified in protocol.
Time frame: Month 30
Population: Full Analysis Set included all participants who had been enrolled in the study. Here, Number of Participants Analyzed signifies participants evaluable for this outcome measure. No participants were available for analysis at Month 30 in arms 'ambulatory participants with age \>=6 years' and 'total ambulatory participants' hence, 'Number of Participants Analyzed' and 'Number Analyzed' were kept 0 for these arms.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Total Ambulatory Participants | Number of Participants According to Response to Each EQ-5D-3L 5 Dimensions at Month 30 | Self-Care, some problems, Month 30 | 0 Participants |
| Total Ambulatory Participants | Number of Participants According to Response to Each EQ-5D-3L 5 Dimensions at Month 30 | Usual Activities, extreme problems, Month 30 | 1 Participants |
| Total Ambulatory Participants | Number of Participants According to Response to Each EQ-5D-3L 5 Dimensions at Month 30 | Mobility, no problems, Month 30 | 0 Participants |
| Total Ambulatory Participants | Number of Participants According to Response to Each EQ-5D-3L 5 Dimensions at Month 30 | Pain/Discomfort, no problems, Month 30 | 1 Participants |
| Total Ambulatory Participants | Number of Participants According to Response to Each EQ-5D-3L 5 Dimensions at Month 30 | Self-Care, extreme problems, Month 30 | 1 Participants |
| Total Ambulatory Participants | Number of Participants According to Response to Each EQ-5D-3L 5 Dimensions at Month 30 | Pain/Discomfort, some problems, Month 30 | 0 Participants |
| Total Ambulatory Participants | Number of Participants According to Response to Each EQ-5D-3L 5 Dimensions at Month 30 | Self-Care, no problems, Month 30 | 0 Participants |
| Total Ambulatory Participants | Number of Participants According to Response to Each EQ-5D-3L 5 Dimensions at Month 30 | Pain/Discomfort, extreme problems, Month 30 | 0 Participants |
| Total Ambulatory Participants | Number of Participants According to Response to Each EQ-5D-3L 5 Dimensions at Month 30 | Usual Activities, no problems, Month 30 | 0 Participants |
| Total Ambulatory Participants | Number of Participants According to Response to Each EQ-5D-3L 5 Dimensions at Month 30 | Anxiety/Depression, no problems, Month 30 | 1 Participants |
| Total Ambulatory Participants | Number of Participants According to Response to Each EQ-5D-3L 5 Dimensions at Month 30 | Mobility, extreme problems, Month 30 | 0 Participants |
| Total Ambulatory Participants | Number of Participants According to Response to Each EQ-5D-3L 5 Dimensions at Month 30 | Anxiety/Depression, some problems, Month 30 | 0 Participants |
| Total Ambulatory Participants | Number of Participants According to Response to Each EQ-5D-3L 5 Dimensions at Month 30 | Usual Activities, some problems, Month 30 | 0 Participants |
| Total Ambulatory Participants | Number of Participants According to Response to Each EQ-5D-3L 5 Dimensions at Month 30 | Anxiety/Depression, extreme problems, Month 30 | 0 Participants |
| Total Ambulatory Participants | Number of Participants According to Response to Each EQ-5D-3L 5 Dimensions at Month 30 | Mobility, some problems, Month 30 | 1 Participants |
| Non-ambulatory Participants | Number of Participants According to Response to Each EQ-5D-3L 5 Dimensions at Month 30 | Anxiety/Depression, extreme problems, Month 30 | 0 Participants |
| Non-ambulatory Participants | Number of Participants According to Response to Each EQ-5D-3L 5 Dimensions at Month 30 | Mobility, no problems, Month 30 | 0 Participants |
| Non-ambulatory Participants | Number of Participants According to Response to Each EQ-5D-3L 5 Dimensions at Month 30 | Mobility, some problems, Month 30 | 1 Participants |
| Non-ambulatory Participants | Number of Participants According to Response to Each EQ-5D-3L 5 Dimensions at Month 30 | Mobility, extreme problems, Month 30 | 0 Participants |
| Non-ambulatory Participants | Number of Participants According to Response to Each EQ-5D-3L 5 Dimensions at Month 30 | Self-Care, no problems, Month 30 | 0 Participants |
| Non-ambulatory Participants | Number of Participants According to Response to Each EQ-5D-3L 5 Dimensions at Month 30 | Self-Care, some problems, Month 30 | 0 Participants |
| Non-ambulatory Participants | Number of Participants According to Response to Each EQ-5D-3L 5 Dimensions at Month 30 | Self-Care, extreme problems, Month 30 | 1 Participants |
| Non-ambulatory Participants | Number of Participants According to Response to Each EQ-5D-3L 5 Dimensions at Month 30 | Usual Activities, no problems, Month 30 | 0 Participants |
| Non-ambulatory Participants | Number of Participants According to Response to Each EQ-5D-3L 5 Dimensions at Month 30 | Usual Activities, some problems, Month 30 | 0 Participants |
| Non-ambulatory Participants | Number of Participants According to Response to Each EQ-5D-3L 5 Dimensions at Month 30 | Usual Activities, extreme problems, Month 30 | 1 Participants |
| Non-ambulatory Participants | Number of Participants According to Response to Each EQ-5D-3L 5 Dimensions at Month 30 | Pain/Discomfort, no problems, Month 30 | 1 Participants |
| Non-ambulatory Participants | Number of Participants According to Response to Each EQ-5D-3L 5 Dimensions at Month 30 | Pain/Discomfort, some problems, Month 30 | 0 Participants |
| Non-ambulatory Participants | Number of Participants According to Response to Each EQ-5D-3L 5 Dimensions at Month 30 | Pain/Discomfort, extreme problems, Month 30 | 0 Participants |
| Non-ambulatory Participants | Number of Participants According to Response to Each EQ-5D-3L 5 Dimensions at Month 30 | Anxiety/Depression, no problems, Month 30 | 1 Participants |
| Non-ambulatory Participants | Number of Participants According to Response to Each EQ-5D-3L 5 Dimensions at Month 30 | Anxiety/Depression, some problems, Month 30 | 0 Participants |
Number of Participants According to Response to Each EQ-5D-Y 5 Dimensions at Month 24
EQ-5D-Y is participant completed questionnaire designed to assess impact on health related quality of life in children and adolescents \<16 years old. It is comprised of five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 3 levels: 1=no problems, 2=some problems, and 3=extreme problems.
Time frame: Month 24
Population: Full Analysis Set included all participants who had been enrolled in the study. All participants reported under Number of Participants Analyzed contributed data to the table; however, may not have evaluable data for every row. 'Number Analyzed' signifies participants evaluable for specified rows.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Ambulatory Participants With Age <6 Years | Number of Participants According to Response to Each EQ-5D-Y 5 Dimensions at Month 24 | Pain/Discomfort, no problems, Month 24 | 38 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants According to Response to Each EQ-5D-Y 5 Dimensions at Month 24 | Usual Activities, extreme problems, Month 24 | 1 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants According to Response to Each EQ-5D-Y 5 Dimensions at Month 24 | Usual Activities, some problems, Month 24 | 15 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants According to Response to Each EQ-5D-Y 5 Dimensions at Month 24 | Mobility, no problems, Month 24 | 48 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants According to Response to Each EQ-5D-Y 5 Dimensions at Month 24 | Anxiety/Depression, some problems, Month 24 | 14 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants According to Response to Each EQ-5D-Y 5 Dimensions at Month 24 | Mobility, extreme problems, Month 24 | 0 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants According to Response to Each EQ-5D-Y 5 Dimensions at Month 24 | Anxiety/Depression, no problems, Month 24 | 43 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants According to Response to Each EQ-5D-Y 5 Dimensions at Month 24 | Self-Care, no problems, Month 24 | 32 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants According to Response to Each EQ-5D-Y 5 Dimensions at Month 24 | Anxiety/Depression, extreme problems, Month 24 | 1 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants According to Response to Each EQ-5D-Y 5 Dimensions at Month 24 | Pain/Discomfort, extreme problems, Month 24 | 1 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants According to Response to Each EQ-5D-Y 5 Dimensions at Month 24 | Self-Care, some problems, Month 24 | 21 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants According to Response to Each EQ-5D-Y 5 Dimensions at Month 24 | Mobility, some problems, Month 24 | 10 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants According to Response to Each EQ-5D-Y 5 Dimensions at Month 24 | Pain/Discomfort, some problems, Month 24 | 19 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants According to Response to Each EQ-5D-Y 5 Dimensions at Month 24 | Self-Care, extreme problems, Month 24 | 5 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants According to Response to Each EQ-5D-Y 5 Dimensions at Month 24 | Usual Activities, no problems, Month 24 | 42 Participants |
| Ambulatory Participants With Age >=6 Years | Number of Participants According to Response to Each EQ-5D-Y 5 Dimensions at Month 24 | Self-Care, extreme problems, Month 24 | 16 Participants |
| Ambulatory Participants With Age >=6 Years | Number of Participants According to Response to Each EQ-5D-Y 5 Dimensions at Month 24 | Usual Activities, no problems, Month 24 | 49 Participants |
| Ambulatory Participants With Age >=6 Years | Number of Participants According to Response to Each EQ-5D-Y 5 Dimensions at Month 24 | Mobility, no problems, Month 24 | 56 Participants |
| Ambulatory Participants With Age >=6 Years | Number of Participants According to Response to Each EQ-5D-Y 5 Dimensions at Month 24 | Usual Activities, extreme problems, Month 24 | 25 Participants |
| Ambulatory Participants With Age >=6 Years | Number of Participants According to Response to Each EQ-5D-Y 5 Dimensions at Month 24 | Self-Care, no problems, Month 24 | 65 Participants |
| Ambulatory Participants With Age >=6 Years | Number of Participants According to Response to Each EQ-5D-Y 5 Dimensions at Month 24 | Pain/Discomfort, some problems, Month 24 | 52 Participants |
| Ambulatory Participants With Age >=6 Years | Number of Participants According to Response to Each EQ-5D-Y 5 Dimensions at Month 24 | Usual Activities, some problems, Month 24 | 60 Participants |
| Ambulatory Participants With Age >=6 Years | Number of Participants According to Response to Each EQ-5D-Y 5 Dimensions at Month 24 | Pain/Discomfort, extreme problems, Month 24 | 2 Participants |
| Ambulatory Participants With Age >=6 Years | Number of Participants According to Response to Each EQ-5D-Y 5 Dimensions at Month 24 | Anxiety/Depression, some problems, Month 24 | 41 Participants |
| Ambulatory Participants With Age >=6 Years | Number of Participants According to Response to Each EQ-5D-Y 5 Dimensions at Month 24 | Mobility, some problems, Month 24 | 55 Participants |
| Ambulatory Participants With Age >=6 Years | Number of Participants According to Response to Each EQ-5D-Y 5 Dimensions at Month 24 | Pain/Discomfort, no problems, Month 24 | 80 Participants |
| Ambulatory Participants With Age >=6 Years | Number of Participants According to Response to Each EQ-5D-Y 5 Dimensions at Month 24 | Mobility, extreme problems, Month 24 | 23 Participants |
| Ambulatory Participants With Age >=6 Years | Number of Participants According to Response to Each EQ-5D-Y 5 Dimensions at Month 24 | Anxiety/Depression, extreme problems, Month 24 | 2 Participants |
| Ambulatory Participants With Age >=6 Years | Number of Participants According to Response to Each EQ-5D-Y 5 Dimensions at Month 24 | Anxiety/Depression, no problems, Month 24 | 91 Participants |
| Ambulatory Participants With Age >=6 Years | Number of Participants According to Response to Each EQ-5D-Y 5 Dimensions at Month 24 | Self-Care, some problems, Month 24 | 53 Participants |
| Total Ambulatory Participants | Number of Participants According to Response to Each EQ-5D-Y 5 Dimensions at Month 24 | Usual Activities, some problems, Month 24 | 75 Participants |
| Total Ambulatory Participants | Number of Participants According to Response to Each EQ-5D-Y 5 Dimensions at Month 24 | Mobility, no problems, Month 24 | 104 Participants |
| Total Ambulatory Participants | Number of Participants According to Response to Each EQ-5D-Y 5 Dimensions at Month 24 | Mobility, some problems, Month 24 | 65 Participants |
| Total Ambulatory Participants | Number of Participants According to Response to Each EQ-5D-Y 5 Dimensions at Month 24 | Mobility, extreme problems, Month 24 | 23 Participants |
| Total Ambulatory Participants | Number of Participants According to Response to Each EQ-5D-Y 5 Dimensions at Month 24 | Self-Care, no problems, Month 24 | 97 Participants |
| Total Ambulatory Participants | Number of Participants According to Response to Each EQ-5D-Y 5 Dimensions at Month 24 | Self-Care, some problems, Month 24 | 74 Participants |
| Total Ambulatory Participants | Number of Participants According to Response to Each EQ-5D-Y 5 Dimensions at Month 24 | Self-Care, extreme problems, Month 24 | 21 Participants |
| Total Ambulatory Participants | Number of Participants According to Response to Each EQ-5D-Y 5 Dimensions at Month 24 | Usual Activities, no problems, Month 24 | 91 Participants |
| Total Ambulatory Participants | Number of Participants According to Response to Each EQ-5D-Y 5 Dimensions at Month 24 | Usual Activities, extreme problems, Month 24 | 26 Participants |
| Total Ambulatory Participants | Number of Participants According to Response to Each EQ-5D-Y 5 Dimensions at Month 24 | Pain/Discomfort, no problems, Month 24 | 118 Participants |
| Total Ambulatory Participants | Number of Participants According to Response to Each EQ-5D-Y 5 Dimensions at Month 24 | Pain/Discomfort, some problems, Month 24 | 71 Participants |
| Total Ambulatory Participants | Number of Participants According to Response to Each EQ-5D-Y 5 Dimensions at Month 24 | Pain/Discomfort, extreme problems, Month 24 | 3 Participants |
| Total Ambulatory Participants | Number of Participants According to Response to Each EQ-5D-Y 5 Dimensions at Month 24 | Anxiety/Depression, no problems, Month 24 | 134 Participants |
| Total Ambulatory Participants | Number of Participants According to Response to Each EQ-5D-Y 5 Dimensions at Month 24 | Anxiety/Depression, some problems, Month 24 | 55 Participants |
| Total Ambulatory Participants | Number of Participants According to Response to Each EQ-5D-Y 5 Dimensions at Month 24 | Anxiety/Depression, extreme problems, Month 24 | 3 Participants |
| Non-ambulatory Participants | Number of Participants According to Response to Each EQ-5D-Y 5 Dimensions at Month 24 | Pain/Discomfort, some problems, Month 24 | 3 Participants |
| Non-ambulatory Participants | Number of Participants According to Response to Each EQ-5D-Y 5 Dimensions at Month 24 | Mobility, extreme problems, Month 24 | 15 Participants |
| Non-ambulatory Participants | Number of Participants According to Response to Each EQ-5D-Y 5 Dimensions at Month 24 | Pain/Discomfort, no problems, Month 24 | 12 Participants |
| Non-ambulatory Participants | Number of Participants According to Response to Each EQ-5D-Y 5 Dimensions at Month 24 | Anxiety/Depression, no problems, Month 24 | 11 Participants |
| Non-ambulatory Participants | Number of Participants According to Response to Each EQ-5D-Y 5 Dimensions at Month 24 | Self-Care, some problems, Month 24 | 5 Participants |
| Non-ambulatory Participants | Number of Participants According to Response to Each EQ-5D-Y 5 Dimensions at Month 24 | Self-Care, no problems, Month 24 | 1 Participants |
| Non-ambulatory Participants | Number of Participants According to Response to Each EQ-5D-Y 5 Dimensions at Month 24 | Mobility, some problems, Month 24 | 0 Participants |
| Non-ambulatory Participants | Number of Participants According to Response to Each EQ-5D-Y 5 Dimensions at Month 24 | Anxiety/Depression, extreme problems, Month 24 | 1 Participants |
| Non-ambulatory Participants | Number of Participants According to Response to Each EQ-5D-Y 5 Dimensions at Month 24 | Usual Activities, some problems, Month 24 | 3 Participants |
| Non-ambulatory Participants | Number of Participants According to Response to Each EQ-5D-Y 5 Dimensions at Month 24 | Mobility, no problems, Month 24 | 0 Participants |
| Non-ambulatory Participants | Number of Participants According to Response to Each EQ-5D-Y 5 Dimensions at Month 24 | Pain/Discomfort, extreme problems, Month 24 | 0 Participants |
| Non-ambulatory Participants | Number of Participants According to Response to Each EQ-5D-Y 5 Dimensions at Month 24 | Usual Activities, no problems, Month 24 | 6 Participants |
| Non-ambulatory Participants | Number of Participants According to Response to Each EQ-5D-Y 5 Dimensions at Month 24 | Anxiety/Depression, some problems, Month 24 | 3 Participants |
| Non-ambulatory Participants | Number of Participants According to Response to Each EQ-5D-Y 5 Dimensions at Month 24 | Usual Activities, extreme problems, Month 24 | 6 Participants |
| Non-ambulatory Participants | Number of Participants According to Response to Each EQ-5D-Y 5 Dimensions at Month 24 | Self-Care, extreme problems, Month 24 | 9 Participants |
| Total Participants | Number of Participants According to Response to Each EQ-5D-Y 5 Dimensions at Month 24 | Usual Activities, extreme problems, Month 24 | 32 Participants |
| Total Participants | Number of Participants According to Response to Each EQ-5D-Y 5 Dimensions at Month 24 | Anxiety/Depression, some problems, Month 24 | 58 Participants |
| Total Participants | Number of Participants According to Response to Each EQ-5D-Y 5 Dimensions at Month 24 | Pain/Discomfort, no problems, Month 24 | 130 Participants |
| Total Participants | Number of Participants According to Response to Each EQ-5D-Y 5 Dimensions at Month 24 | Self-Care, some problems, Month 24 | 79 Participants |
| Total Participants | Number of Participants According to Response to Each EQ-5D-Y 5 Dimensions at Month 24 | Mobility, no problems, Month 24 | 104 Participants |
| Total Participants | Number of Participants According to Response to Each EQ-5D-Y 5 Dimensions at Month 24 | Pain/Discomfort, some problems, Month 24 | 74 Participants |
| Total Participants | Number of Participants According to Response to Each EQ-5D-Y 5 Dimensions at Month 24 | Self-Care, no problems, Month 24 | 98 Participants |
| Total Participants | Number of Participants According to Response to Each EQ-5D-Y 5 Dimensions at Month 24 | Pain/Discomfort, extreme problems, Month 24 | 3 Participants |
| Total Participants | Number of Participants According to Response to Each EQ-5D-Y 5 Dimensions at Month 24 | Mobility, extreme problems, Month 24 | 38 Participants |
| Total Participants | Number of Participants According to Response to Each EQ-5D-Y 5 Dimensions at Month 24 | Anxiety/Depression, extreme problems, Month 24 | 4 Participants |
| Total Participants | Number of Participants According to Response to Each EQ-5D-Y 5 Dimensions at Month 24 | Anxiety/Depression, no problems, Month 24 | 145 Participants |
| Total Participants | Number of Participants According to Response to Each EQ-5D-Y 5 Dimensions at Month 24 | Mobility, some problems, Month 24 | 65 Participants |
| Total Participants | Number of Participants According to Response to Each EQ-5D-Y 5 Dimensions at Month 24 | Usual Activities, some problems, Month 24 | 78 Participants |
| Total Participants | Number of Participants According to Response to Each EQ-5D-Y 5 Dimensions at Month 24 | Usual Activities, no problems, Month 24 | 97 Participants |
| Total Participants | Number of Participants According to Response to Each EQ-5D-Y 5 Dimensions at Month 24 | Self-Care, extreme problems, Month 24 | 30 Participants |
Number of Participants According to Response to Each European Quality of Life (EuroQoL) 5 Dimension 3 Level (EQ-5D-3L) 5 Dimensions at Month 12
EQ-5D-3L is a participant completed questionnaire designed to assess impact on health related quality of life. It is comprised of five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. The responses record three levels of severity (no problems/some or moderate problems/extreme problems) within a particular EQ-5D dimension. EQ-5D-3L assessment was only performed in participants \>= 16 years old as pre-specified in protocol.
Time frame: Months 12
Population: Full Analysis Set included all participants who had been enrolled in the study. Here, Number of Participants Analyzed signifies participants evaluable for this outcome measure. 'Number Analyzed' signifies participants evaluable for specified rows. No ambulatory participants were \>=16 years hence N=0 in arms Ambulatory participants with aged \>=6 years and Total Ambulatory Participants.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Total Ambulatory Participants | Number of Participants According to Response to Each European Quality of Life (EuroQoL) 5 Dimension 3 Level (EQ-5D-3L) 5 Dimensions at Month 12 | Self-Care, some problems, Month 12 | 4 Participants |
| Total Ambulatory Participants | Number of Participants According to Response to Each European Quality of Life (EuroQoL) 5 Dimension 3 Level (EQ-5D-3L) 5 Dimensions at Month 12 | Usual Activities, extreme problems, Month 12 | 2 Participants |
| Total Ambulatory Participants | Number of Participants According to Response to Each European Quality of Life (EuroQoL) 5 Dimension 3 Level (EQ-5D-3L) 5 Dimensions at Month 12 | Mobility, some problems, Month 12 | 3 Participants |
| Total Ambulatory Participants | Number of Participants According to Response to Each European Quality of Life (EuroQoL) 5 Dimension 3 Level (EQ-5D-3L) 5 Dimensions at Month 12 | Pain/Discomfort, no problems, Month 12 | 5 Participants |
| Total Ambulatory Participants | Number of Participants According to Response to Each European Quality of Life (EuroQoL) 5 Dimension 3 Level (EQ-5D-3L) 5 Dimensions at Month 12 | Self-Care, extreme problems, Month 12 | 2 Participants |
| Total Ambulatory Participants | Number of Participants According to Response to Each European Quality of Life (EuroQoL) 5 Dimension 3 Level (EQ-5D-3L) 5 Dimensions at Month 12 | Pain/Discomfort, some problems, Month 12 | 1 Participants |
| Total Ambulatory Participants | Number of Participants According to Response to Each European Quality of Life (EuroQoL) 5 Dimension 3 Level (EQ-5D-3L) 5 Dimensions at Month 12 | Self-Care, no problems, Month 12 | 0 Participants |
| Total Ambulatory Participants | Number of Participants According to Response to Each European Quality of Life (EuroQoL) 5 Dimension 3 Level (EQ-5D-3L) 5 Dimensions at Month 12 | Pain/Discomfort, extreme problems, Month 12 | 0 Participants |
| Total Ambulatory Participants | Number of Participants According to Response to Each European Quality of Life (EuroQoL) 5 Dimension 3 Level (EQ-5D-3L) 5 Dimensions at Month 12 | Usual Activities, no problems, Month 12 | 1 Participants |
| Total Ambulatory Participants | Number of Participants According to Response to Each European Quality of Life (EuroQoL) 5 Dimension 3 Level (EQ-5D-3L) 5 Dimensions at Month 12 | Anxiety/Depression, no problems, Month 12 | 5 Participants |
| Total Ambulatory Participants | Number of Participants According to Response to Each European Quality of Life (EuroQoL) 5 Dimension 3 Level (EQ-5D-3L) 5 Dimensions at Month 12 | Mobility, extreme problems, Month 12 | 3 Participants |
| Total Ambulatory Participants | Number of Participants According to Response to Each European Quality of Life (EuroQoL) 5 Dimension 3 Level (EQ-5D-3L) 5 Dimensions at Month 12 | Anxiety/Depression, some problems, Month 12 | 1 Participants |
| Total Ambulatory Participants | Number of Participants According to Response to Each European Quality of Life (EuroQoL) 5 Dimension 3 Level (EQ-5D-3L) 5 Dimensions at Month 12 | Usual Activities, some problems, Month 12 | 3 Participants |
| Total Ambulatory Participants | Number of Participants According to Response to Each European Quality of Life (EuroQoL) 5 Dimension 3 Level (EQ-5D-3L) 5 Dimensions at Month 12 | Anxiety/Depression, extreme problems, Month 12 | 0 Participants |
| Total Ambulatory Participants | Number of Participants According to Response to Each European Quality of Life (EuroQoL) 5 Dimension 3 Level (EQ-5D-3L) 5 Dimensions at Month 12 | Mobility, no problems, Month 12 | 0 Participants |
| Non-ambulatory Participants | Number of Participants According to Response to Each European Quality of Life (EuroQoL) 5 Dimension 3 Level (EQ-5D-3L) 5 Dimensions at Month 12 | Anxiety/Depression, extreme problems, Month 12 | 0 Participants |
| Non-ambulatory Participants | Number of Participants According to Response to Each European Quality of Life (EuroQoL) 5 Dimension 3 Level (EQ-5D-3L) 5 Dimensions at Month 12 | Mobility, no problems, Month 12 | 0 Participants |
| Non-ambulatory Participants | Number of Participants According to Response to Each European Quality of Life (EuroQoL) 5 Dimension 3 Level (EQ-5D-3L) 5 Dimensions at Month 12 | Mobility, some problems, Month 12 | 3 Participants |
| Non-ambulatory Participants | Number of Participants According to Response to Each European Quality of Life (EuroQoL) 5 Dimension 3 Level (EQ-5D-3L) 5 Dimensions at Month 12 | Mobility, extreme problems, Month 12 | 3 Participants |
| Non-ambulatory Participants | Number of Participants According to Response to Each European Quality of Life (EuroQoL) 5 Dimension 3 Level (EQ-5D-3L) 5 Dimensions at Month 12 | Self-Care, no problems, Month 12 | 0 Participants |
| Non-ambulatory Participants | Number of Participants According to Response to Each European Quality of Life (EuroQoL) 5 Dimension 3 Level (EQ-5D-3L) 5 Dimensions at Month 12 | Self-Care, some problems, Month 12 | 4 Participants |
| Non-ambulatory Participants | Number of Participants According to Response to Each European Quality of Life (EuroQoL) 5 Dimension 3 Level (EQ-5D-3L) 5 Dimensions at Month 12 | Self-Care, extreme problems, Month 12 | 2 Participants |
| Non-ambulatory Participants | Number of Participants According to Response to Each European Quality of Life (EuroQoL) 5 Dimension 3 Level (EQ-5D-3L) 5 Dimensions at Month 12 | Usual Activities, no problems, Month 12 | 1 Participants |
| Non-ambulatory Participants | Number of Participants According to Response to Each European Quality of Life (EuroQoL) 5 Dimension 3 Level (EQ-5D-3L) 5 Dimensions at Month 12 | Usual Activities, some problems, Month 12 | 3 Participants |
| Non-ambulatory Participants | Number of Participants According to Response to Each European Quality of Life (EuroQoL) 5 Dimension 3 Level (EQ-5D-3L) 5 Dimensions at Month 12 | Usual Activities, extreme problems, Month 12 | 2 Participants |
| Non-ambulatory Participants | Number of Participants According to Response to Each European Quality of Life (EuroQoL) 5 Dimension 3 Level (EQ-5D-3L) 5 Dimensions at Month 12 | Pain/Discomfort, no problems, Month 12 | 5 Participants |
| Non-ambulatory Participants | Number of Participants According to Response to Each European Quality of Life (EuroQoL) 5 Dimension 3 Level (EQ-5D-3L) 5 Dimensions at Month 12 | Pain/Discomfort, some problems, Month 12 | 1 Participants |
| Non-ambulatory Participants | Number of Participants According to Response to Each European Quality of Life (EuroQoL) 5 Dimension 3 Level (EQ-5D-3L) 5 Dimensions at Month 12 | Pain/Discomfort, extreme problems, Month 12 | 0 Participants |
| Non-ambulatory Participants | Number of Participants According to Response to Each European Quality of Life (EuroQoL) 5 Dimension 3 Level (EQ-5D-3L) 5 Dimensions at Month 12 | Anxiety/Depression, no problems, Month 12 | 5 Participants |
| Non-ambulatory Participants | Number of Participants According to Response to Each European Quality of Life (EuroQoL) 5 Dimension 3 Level (EQ-5D-3L) 5 Dimensions at Month 12 | Anxiety/Depression, some problems, Month 12 | 1 Participants |
Number of Participants According to Response to Each EuroQoL 5 Dimension Youth (EQ-5D-Y) 5 Dimensions at Month 12
EQ-5D-Y is participant completed questionnaire designed to assess impact on health related quality of life in children and adolescents \<16 years old. It is comprised of five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 3 levels: 1=no problems, 2=some problems, and 3=extreme problems.
Time frame: Month 12
Population: Full Analysis Set included all participants who had been enrolled in the study. All participants reported under Number of Participants Analyzed contributed data to the table; however, may not have evaluable data for every row. 'Number Analyzed' signifies participants evaluable for specified rows.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Ambulatory Participants With Age <6 Years | Number of Participants According to Response to Each EuroQoL 5 Dimension Youth (EQ-5D-Y) 5 Dimensions at Month 12 | Pain/Discomfort, no problems, Month 12 | 36 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants According to Response to Each EuroQoL 5 Dimension Youth (EQ-5D-Y) 5 Dimensions at Month 12 | Usual Activities, extreme problems, Month 12 | 0 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants According to Response to Each EuroQoL 5 Dimension Youth (EQ-5D-Y) 5 Dimensions at Month 12 | Usual Activities, some problems, Month 12 | 17 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants According to Response to Each EuroQoL 5 Dimension Youth (EQ-5D-Y) 5 Dimensions at Month 12 | Mobility, no problems, Month 12 | 45 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants According to Response to Each EuroQoL 5 Dimension Youth (EQ-5D-Y) 5 Dimensions at Month 12 | Anxiety/Depression, some problems, Month 12 | 8 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants According to Response to Each EuroQoL 5 Dimension Youth (EQ-5D-Y) 5 Dimensions at Month 12 | Mobility, extreme problems, Month 12 | 0 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants According to Response to Each EuroQoL 5 Dimension Youth (EQ-5D-Y) 5 Dimensions at Month 12 | Anxiety/Depression, no problems, Month 12 | 45 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants According to Response to Each EuroQoL 5 Dimension Youth (EQ-5D-Y) 5 Dimensions at Month 12 | Self-Care, no problems, Month 12 | 22 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants According to Response to Each EuroQoL 5 Dimension Youth (EQ-5D-Y) 5 Dimensions at Month 12 | Anxiety/Depression, extreme problems, Month 12 | 4 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants According to Response to Each EuroQoL 5 Dimension Youth (EQ-5D-Y) 5 Dimensions at Month 12 | Pain/Discomfort, extreme problems, Month 12 | 0 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants According to Response to Each EuroQoL 5 Dimension Youth (EQ-5D-Y) 5 Dimensions at Month 12 | Self-Care, some problems, Month 12 | 25 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants According to Response to Each EuroQoL 5 Dimension Youth (EQ-5D-Y) 5 Dimensions at Month 12 | Mobility, some problems, Month 12 | 12 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants According to Response to Each EuroQoL 5 Dimension Youth (EQ-5D-Y) 5 Dimensions at Month 12 | Pain/Discomfort, some problems, Month 12 | 21 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants According to Response to Each EuroQoL 5 Dimension Youth (EQ-5D-Y) 5 Dimensions at Month 12 | Self-Care, extreme problems, Month 12 | 10 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants According to Response to Each EuroQoL 5 Dimension Youth (EQ-5D-Y) 5 Dimensions at Month 12 | Usual Activities, no problems, Month 12 | 40 Participants |
| Ambulatory Participants With Age >=6 Years | Number of Participants According to Response to Each EuroQoL 5 Dimension Youth (EQ-5D-Y) 5 Dimensions at Month 12 | Self-Care, extreme problems, Month 12 | 17 Participants |
| Ambulatory Participants With Age >=6 Years | Number of Participants According to Response to Each EuroQoL 5 Dimension Youth (EQ-5D-Y) 5 Dimensions at Month 12 | Usual Activities, no problems, Month 12 | 70 Participants |
| Ambulatory Participants With Age >=6 Years | Number of Participants According to Response to Each EuroQoL 5 Dimension Youth (EQ-5D-Y) 5 Dimensions at Month 12 | Mobility, no problems, Month 12 | 91 Participants |
| Ambulatory Participants With Age >=6 Years | Number of Participants According to Response to Each EuroQoL 5 Dimension Youth (EQ-5D-Y) 5 Dimensions at Month 12 | Usual Activities, extreme problems, Month 12 | 16 Participants |
| Ambulatory Participants With Age >=6 Years | Number of Participants According to Response to Each EuroQoL 5 Dimension Youth (EQ-5D-Y) 5 Dimensions at Month 12 | Self-Care, no problems, Month 12 | 70 Participants |
| Ambulatory Participants With Age >=6 Years | Number of Participants According to Response to Each EuroQoL 5 Dimension Youth (EQ-5D-Y) 5 Dimensions at Month 12 | Pain/Discomfort, some problems, Month 12 | 57 Participants |
| Ambulatory Participants With Age >=6 Years | Number of Participants According to Response to Each EuroQoL 5 Dimension Youth (EQ-5D-Y) 5 Dimensions at Month 12 | Usual Activities, some problems, Month 12 | 74 Participants |
| Ambulatory Participants With Age >=6 Years | Number of Participants According to Response to Each EuroQoL 5 Dimension Youth (EQ-5D-Y) 5 Dimensions at Month 12 | Pain/Discomfort, extreme problems, Month 12 | 2 Participants |
| Ambulatory Participants With Age >=6 Years | Number of Participants According to Response to Each EuroQoL 5 Dimension Youth (EQ-5D-Y) 5 Dimensions at Month 12 | Anxiety/Depression, some problems, Month 12 | 41 Participants |
| Ambulatory Participants With Age >=6 Years | Number of Participants According to Response to Each EuroQoL 5 Dimension Youth (EQ-5D-Y) 5 Dimensions at Month 12 | Mobility, some problems, Month 12 | 52 Participants |
| Ambulatory Participants With Age >=6 Years | Number of Participants According to Response to Each EuroQoL 5 Dimension Youth (EQ-5D-Y) 5 Dimensions at Month 12 | Pain/Discomfort, no problems, Month 12 | 101 Participants |
| Ambulatory Participants With Age >=6 Years | Number of Participants According to Response to Each EuroQoL 5 Dimension Youth (EQ-5D-Y) 5 Dimensions at Month 12 | Mobility, extreme problems, Month 12 | 17 Participants |
| Ambulatory Participants With Age >=6 Years | Number of Participants According to Response to Each EuroQoL 5 Dimension Youth (EQ-5D-Y) 5 Dimensions at Month 12 | Anxiety/Depression, extreme problems, Month 12 | 9 Participants |
| Ambulatory Participants With Age >=6 Years | Number of Participants According to Response to Each EuroQoL 5 Dimension Youth (EQ-5D-Y) 5 Dimensions at Month 12 | Anxiety/Depression, no problems, Month 12 | 110 Participants |
| Ambulatory Participants With Age >=6 Years | Number of Participants According to Response to Each EuroQoL 5 Dimension Youth (EQ-5D-Y) 5 Dimensions at Month 12 | Self-Care, some problems, Month 12 | 73 Participants |
| Total Ambulatory Participants | Number of Participants According to Response to Each EuroQoL 5 Dimension Youth (EQ-5D-Y) 5 Dimensions at Month 12 | Usual Activities, some problems, Month 12 | 91 Participants |
| Total Ambulatory Participants | Number of Participants According to Response to Each EuroQoL 5 Dimension Youth (EQ-5D-Y) 5 Dimensions at Month 12 | Mobility, no problems, Month 12 | 136 Participants |
| Total Ambulatory Participants | Number of Participants According to Response to Each EuroQoL 5 Dimension Youth (EQ-5D-Y) 5 Dimensions at Month 12 | Mobility, some problems, Month 12 | 64 Participants |
| Total Ambulatory Participants | Number of Participants According to Response to Each EuroQoL 5 Dimension Youth (EQ-5D-Y) 5 Dimensions at Month 12 | Mobility, extreme problems, Month 12 | 17 Participants |
| Total Ambulatory Participants | Number of Participants According to Response to Each EuroQoL 5 Dimension Youth (EQ-5D-Y) 5 Dimensions at Month 12 | Self-Care, no problems, Month 12 | 92 Participants |
| Total Ambulatory Participants | Number of Participants According to Response to Each EuroQoL 5 Dimension Youth (EQ-5D-Y) 5 Dimensions at Month 12 | Self-Care, some problems, Month 12 | 98 Participants |
| Total Ambulatory Participants | Number of Participants According to Response to Each EuroQoL 5 Dimension Youth (EQ-5D-Y) 5 Dimensions at Month 12 | Self-Care, extreme problems, Month 12 | 27 Participants |
| Total Ambulatory Participants | Number of Participants According to Response to Each EuroQoL 5 Dimension Youth (EQ-5D-Y) 5 Dimensions at Month 12 | Usual Activities, no problems, Month 12 | 110 Participants |
| Total Ambulatory Participants | Number of Participants According to Response to Each EuroQoL 5 Dimension Youth (EQ-5D-Y) 5 Dimensions at Month 12 | Usual Activities, extreme problems, Month 12 | 16 Participants |
| Total Ambulatory Participants | Number of Participants According to Response to Each EuroQoL 5 Dimension Youth (EQ-5D-Y) 5 Dimensions at Month 12 | Pain/Discomfort, no problems, Month 12 | 137 Participants |
| Total Ambulatory Participants | Number of Participants According to Response to Each EuroQoL 5 Dimension Youth (EQ-5D-Y) 5 Dimensions at Month 12 | Pain/Discomfort, some problems, Month 12 | 78 Participants |
| Total Ambulatory Participants | Number of Participants According to Response to Each EuroQoL 5 Dimension Youth (EQ-5D-Y) 5 Dimensions at Month 12 | Pain/Discomfort, extreme problems, Month 12 | 2 Participants |
| Total Ambulatory Participants | Number of Participants According to Response to Each EuroQoL 5 Dimension Youth (EQ-5D-Y) 5 Dimensions at Month 12 | Anxiety/Depression, no problems, Month 12 | 155 Participants |
| Total Ambulatory Participants | Number of Participants According to Response to Each EuroQoL 5 Dimension Youth (EQ-5D-Y) 5 Dimensions at Month 12 | Anxiety/Depression, some problems, Month 12 | 49 Participants |
| Total Ambulatory Participants | Number of Participants According to Response to Each EuroQoL 5 Dimension Youth (EQ-5D-Y) 5 Dimensions at Month 12 | Anxiety/Depression, extreme problems, Month 12 | 13 Participants |
| Non-ambulatory Participants | Number of Participants According to Response to Each EuroQoL 5 Dimension Youth (EQ-5D-Y) 5 Dimensions at Month 12 | Pain/Discomfort, some problems, Month 12 | 7 Participants |
| Non-ambulatory Participants | Number of Participants According to Response to Each EuroQoL 5 Dimension Youth (EQ-5D-Y) 5 Dimensions at Month 12 | Mobility, extreme problems, Month 12 | 24 Participants |
| Non-ambulatory Participants | Number of Participants According to Response to Each EuroQoL 5 Dimension Youth (EQ-5D-Y) 5 Dimensions at Month 12 | Pain/Discomfort, no problems, Month 12 | 17 Participants |
| Non-ambulatory Participants | Number of Participants According to Response to Each EuroQoL 5 Dimension Youth (EQ-5D-Y) 5 Dimensions at Month 12 | Anxiety/Depression, no problems, Month 12 | 14 Participants |
| Non-ambulatory Participants | Number of Participants According to Response to Each EuroQoL 5 Dimension Youth (EQ-5D-Y) 5 Dimensions at Month 12 | Self-Care, some problems, Month 12 | 7 Participants |
| Non-ambulatory Participants | Number of Participants According to Response to Each EuroQoL 5 Dimension Youth (EQ-5D-Y) 5 Dimensions at Month 12 | Self-Care, no problems, Month 12 | 3 Participants |
| Non-ambulatory Participants | Number of Participants According to Response to Each EuroQoL 5 Dimension Youth (EQ-5D-Y) 5 Dimensions at Month 12 | Mobility, some problems, Month 12 | 0 Participants |
| Non-ambulatory Participants | Number of Participants According to Response to Each EuroQoL 5 Dimension Youth (EQ-5D-Y) 5 Dimensions at Month 12 | Anxiety/Depression, extreme problems, Month 12 | 1 Participants |
| Non-ambulatory Participants | Number of Participants According to Response to Each EuroQoL 5 Dimension Youth (EQ-5D-Y) 5 Dimensions at Month 12 | Usual Activities, some problems, Month 12 | 6 Participants |
| Non-ambulatory Participants | Number of Participants According to Response to Each EuroQoL 5 Dimension Youth (EQ-5D-Y) 5 Dimensions at Month 12 | Mobility, no problems, Month 12 | 0 Participants |
| Non-ambulatory Participants | Number of Participants According to Response to Each EuroQoL 5 Dimension Youth (EQ-5D-Y) 5 Dimensions at Month 12 | Pain/Discomfort, extreme problems, Month 12 | 0 Participants |
| Non-ambulatory Participants | Number of Participants According to Response to Each EuroQoL 5 Dimension Youth (EQ-5D-Y) 5 Dimensions at Month 12 | Usual Activities, no problems, Month 12 | 4 Participants |
| Non-ambulatory Participants | Number of Participants According to Response to Each EuroQoL 5 Dimension Youth (EQ-5D-Y) 5 Dimensions at Month 12 | Anxiety/Depression, some problems, Month 12 | 9 Participants |
| Non-ambulatory Participants | Number of Participants According to Response to Each EuroQoL 5 Dimension Youth (EQ-5D-Y) 5 Dimensions at Month 12 | Usual Activities, extreme problems, Month 12 | 14 Participants |
| Non-ambulatory Participants | Number of Participants According to Response to Each EuroQoL 5 Dimension Youth (EQ-5D-Y) 5 Dimensions at Month 12 | Self-Care, extreme problems, Month 12 | 14 Participants |
| Total Participants | Number of Participants According to Response to Each EuroQoL 5 Dimension Youth (EQ-5D-Y) 5 Dimensions at Month 12 | Usual Activities, extreme problems, Month 12 | 30 Participants |
| Total Participants | Number of Participants According to Response to Each EuroQoL 5 Dimension Youth (EQ-5D-Y) 5 Dimensions at Month 12 | Anxiety/Depression, some problems, Month 12 | 58 Participants |
| Total Participants | Number of Participants According to Response to Each EuroQoL 5 Dimension Youth (EQ-5D-Y) 5 Dimensions at Month 12 | Pain/Discomfort, no problems, Month 12 | 154 Participants |
| Total Participants | Number of Participants According to Response to Each EuroQoL 5 Dimension Youth (EQ-5D-Y) 5 Dimensions at Month 12 | Self-Care, some problems, Month 12 | 105 Participants |
| Total Participants | Number of Participants According to Response to Each EuroQoL 5 Dimension Youth (EQ-5D-Y) 5 Dimensions at Month 12 | Mobility, no problems, Month 12 | 136 Participants |
| Total Participants | Number of Participants According to Response to Each EuroQoL 5 Dimension Youth (EQ-5D-Y) 5 Dimensions at Month 12 | Pain/Discomfort, some problems, Month 12 | 85 Participants |
| Total Participants | Number of Participants According to Response to Each EuroQoL 5 Dimension Youth (EQ-5D-Y) 5 Dimensions at Month 12 | Self-Care, no problems, Month 12 | 95 Participants |
| Total Participants | Number of Participants According to Response to Each EuroQoL 5 Dimension Youth (EQ-5D-Y) 5 Dimensions at Month 12 | Pain/Discomfort, extreme problems, Month 12 | 2 Participants |
| Total Participants | Number of Participants According to Response to Each EuroQoL 5 Dimension Youth (EQ-5D-Y) 5 Dimensions at Month 12 | Mobility, extreme problems, Month 12 | 41 Participants |
| Total Participants | Number of Participants According to Response to Each EuroQoL 5 Dimension Youth (EQ-5D-Y) 5 Dimensions at Month 12 | Anxiety/Depression, extreme problems, Month 12 | 14 Participants |
| Total Participants | Number of Participants According to Response to Each EuroQoL 5 Dimension Youth (EQ-5D-Y) 5 Dimensions at Month 12 | Anxiety/Depression, no problems, Month 12 | 169 Participants |
| Total Participants | Number of Participants According to Response to Each EuroQoL 5 Dimension Youth (EQ-5D-Y) 5 Dimensions at Month 12 | Mobility, some problems, Month 12 | 64 Participants |
| Total Participants | Number of Participants According to Response to Each EuroQoL 5 Dimension Youth (EQ-5D-Y) 5 Dimensions at Month 12 | Usual Activities, some problems, Month 12 | 97 Participants |
| Total Participants | Number of Participants According to Response to Each EuroQoL 5 Dimension Youth (EQ-5D-Y) 5 Dimensions at Month 12 | Usual Activities, no problems, Month 12 | 114 Participants |
| Total Participants | Number of Participants According to Response to Each EuroQoL 5 Dimension Youth (EQ-5D-Y) 5 Dimensions at Month 12 | Self-Care, extreme problems, Month 12 | 41 Participants |
Number of Participants According to Response to EQ-5D-Y 5 Dimensions at Month 30
EQ-5D-Y is participant completed questionnaire designed to assess impact on health related quality of life in children and adolescents \<16 years old. It is comprised of five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 3 levels: 1=no problems, 2=some problems, and 3=extreme problems.
Time frame: Month 30
Population: Full Analysis Set included all participants who had been enrolled in the study. All participants reported under Number of Participants Analyzed contributed data to the table; however, may not have evaluable data for every row. 'Number Analyzed' signifies participants evaluable for specified rows.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Ambulatory Participants With Age <6 Years | Number of Participants According to Response to EQ-5D-Y 5 Dimensions at Month 30 | Mobility, no problems, Month 30 | 26 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants According to Response to EQ-5D-Y 5 Dimensions at Month 30 | Pain/Discomfort, some problems, Month 30 | 9 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants According to Response to EQ-5D-Y 5 Dimensions at Month 30 | Mobility, extreme problems, Month 30 | 0 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants According to Response to EQ-5D-Y 5 Dimensions at Month 30 | Self-Care, extreme problems, Month 30 | 2 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants According to Response to EQ-5D-Y 5 Dimensions at Month 30 | Anxiety/Depression, no problems, Month 30 | 18 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants According to Response to EQ-5D-Y 5 Dimensions at Month 30 | Usual Activities, some problems, Month 30 | 10 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants According to Response to EQ-5D-Y 5 Dimensions at Month 30 | Pain/Discomfort, no problems, Month 30 | 17 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants According to Response to EQ-5D-Y 5 Dimensions at Month 30 | Self-Care, no problems, Month 30 | 16 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants According to Response to EQ-5D-Y 5 Dimensions at Month 30 | Pain/Discomfort, extreme problems, Month 30 | 0 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants According to Response to EQ-5D-Y 5 Dimensions at Month 30 | Mobility, some problems, Month 30 | 0 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants According to Response to EQ-5D-Y 5 Dimensions at Month 30 | Usual Activities, no problems, Month 30 | 16 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants According to Response to EQ-5D-Y 5 Dimensions at Month 30 | Usual Activities, extreme problems, Month 30 | 0 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants According to Response to EQ-5D-Y 5 Dimensions at Month 30 | Self-Care, some problems, Month 30 | 8 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants According to Response to EQ-5D-Y 5 Dimensions at Month 30 | Anxiety/Depression, extreme problems, Month 30 | 0 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants According to Response to EQ-5D-Y 5 Dimensions at Month 30 | Anxiety/Depression, some problems, Month 30 | 8 Participants |
| Ambulatory Participants With Age >=6 Years | Number of Participants According to Response to EQ-5D-Y 5 Dimensions at Month 30 | Pain/Discomfort, some problems, Month 30 | 30 Participants |
| Ambulatory Participants With Age >=6 Years | Number of Participants According to Response to EQ-5D-Y 5 Dimensions at Month 30 | Self-Care, extreme problems, Month 30 | 10 Participants |
| Ambulatory Participants With Age >=6 Years | Number of Participants According to Response to EQ-5D-Y 5 Dimensions at Month 30 | Anxiety/Depression, no problems, Month 30 | 48 Participants |
| Ambulatory Participants With Age >=6 Years | Number of Participants According to Response to EQ-5D-Y 5 Dimensions at Month 30 | Usual Activities, no problems, Month 30 | 28 Participants |
| Ambulatory Participants With Age >=6 Years | Number of Participants According to Response to EQ-5D-Y 5 Dimensions at Month 30 | Mobility, no problems, Month 30 | 34 Participants |
| Ambulatory Participants With Age >=6 Years | Number of Participants According to Response to EQ-5D-Y 5 Dimensions at Month 30 | Pain/Discomfort, extreme problems, Month 30 | 4 Participants |
| Ambulatory Participants With Age >=6 Years | Number of Participants According to Response to EQ-5D-Y 5 Dimensions at Month 30 | Mobility, some problems, Month 30 | 34 Participants |
| Ambulatory Participants With Age >=6 Years | Number of Participants According to Response to EQ-5D-Y 5 Dimensions at Month 30 | Usual Activities, some problems, Month 30 | 40 Participants |
| Ambulatory Participants With Age >=6 Years | Number of Participants According to Response to EQ-5D-Y 5 Dimensions at Month 30 | Mobility, extreme problems, Month 30 | 10 Participants |
| Ambulatory Participants With Age >=6 Years | Number of Participants According to Response to EQ-5D-Y 5 Dimensions at Month 30 | Anxiety/Depression, extreme problems, Month 30 | 4 Participants |
| Ambulatory Participants With Age >=6 Years | Number of Participants According to Response to EQ-5D-Y 5 Dimensions at Month 30 | Pain/Discomfort, no problems, Month 30 | 44 Participants |
| Ambulatory Participants With Age >=6 Years | Number of Participants According to Response to EQ-5D-Y 5 Dimensions at Month 30 | Self-Care, no problems, Month 30 | 45 Participants |
| Ambulatory Participants With Age >=6 Years | Number of Participants According to Response to EQ-5D-Y 5 Dimensions at Month 30 | Anxiety/Depression, some problems, Month 30 | 26 Participants |
| Ambulatory Participants With Age >=6 Years | Number of Participants According to Response to EQ-5D-Y 5 Dimensions at Month 30 | Usual Activities, extreme problems, Month 30 | 10 Participants |
| Ambulatory Participants With Age >=6 Years | Number of Participants According to Response to EQ-5D-Y 5 Dimensions at Month 30 | Self-Care, some problems, Month 30 | 23 Participants |
| Total Ambulatory Participants | Number of Participants According to Response to EQ-5D-Y 5 Dimensions at Month 30 | Mobility, no problems, Month 30 | 60 Participants |
| Total Ambulatory Participants | Number of Participants According to Response to EQ-5D-Y 5 Dimensions at Month 30 | Anxiety/Depression, extreme problems, Month 30 | 4 Participants |
| Total Ambulatory Participants | Number of Participants According to Response to EQ-5D-Y 5 Dimensions at Month 30 | Mobility, some problems, Month 30 | 34 Participants |
| Total Ambulatory Participants | Number of Participants According to Response to EQ-5D-Y 5 Dimensions at Month 30 | Mobility, extreme problems, Month 30 | 10 Participants |
| Total Ambulatory Participants | Number of Participants According to Response to EQ-5D-Y 5 Dimensions at Month 30 | Self-Care, no problems, Month 30 | 61 Participants |
| Total Ambulatory Participants | Number of Participants According to Response to EQ-5D-Y 5 Dimensions at Month 30 | Self-Care, some problems, Month 30 | 31 Participants |
| Total Ambulatory Participants | Number of Participants According to Response to EQ-5D-Y 5 Dimensions at Month 30 | Self-Care, extreme problems, Month 30 | 12 Participants |
| Total Ambulatory Participants | Number of Participants According to Response to EQ-5D-Y 5 Dimensions at Month 30 | Usual Activities, no problems, Month 30 | 44 Participants |
| Total Ambulatory Participants | Number of Participants According to Response to EQ-5D-Y 5 Dimensions at Month 30 | Usual Activities, some problems, Month 30 | 50 Participants |
| Total Ambulatory Participants | Number of Participants According to Response to EQ-5D-Y 5 Dimensions at Month 30 | Usual Activities, extreme problems, Month 30 | 10 Participants |
| Total Ambulatory Participants | Number of Participants According to Response to EQ-5D-Y 5 Dimensions at Month 30 | Pain/Discomfort, no problems, Month 30 | 61 Participants |
| Total Ambulatory Participants | Number of Participants According to Response to EQ-5D-Y 5 Dimensions at Month 30 | Pain/Discomfort, some problems, Month 30 | 39 Participants |
| Total Ambulatory Participants | Number of Participants According to Response to EQ-5D-Y 5 Dimensions at Month 30 | Pain/Discomfort, extreme problems, Month 30 | 4 Participants |
| Total Ambulatory Participants | Number of Participants According to Response to EQ-5D-Y 5 Dimensions at Month 30 | Anxiety/Depression, no problems, Month 30 | 66 Participants |
| Total Ambulatory Participants | Number of Participants According to Response to EQ-5D-Y 5 Dimensions at Month 30 | Anxiety/Depression, some problems, Month 30 | 34 Participants |
| Non-ambulatory Participants | Number of Participants According to Response to EQ-5D-Y 5 Dimensions at Month 30 | Usual Activities, some problems, Month 30 | 0 Participants |
| Non-ambulatory Participants | Number of Participants According to Response to EQ-5D-Y 5 Dimensions at Month 30 | Self-Care, no problems, Month 30 | 0 Participants |
| Non-ambulatory Participants | Number of Participants According to Response to EQ-5D-Y 5 Dimensions at Month 30 | Usual Activities, extreme problems, Month 30 | 0 Participants |
| Non-ambulatory Participants | Number of Participants According to Response to EQ-5D-Y 5 Dimensions at Month 30 | Mobility, extreme problems, Month 30 | 3 Participants |
| Non-ambulatory Participants | Number of Participants According to Response to EQ-5D-Y 5 Dimensions at Month 30 | Anxiety/Depression, no problems, Month 30 | 1 Participants |
| Non-ambulatory Participants | Number of Participants According to Response to EQ-5D-Y 5 Dimensions at Month 30 | Pain/Discomfort, no problems, Month 30 | 3 Participants |
| Non-ambulatory Participants | Number of Participants According to Response to EQ-5D-Y 5 Dimensions at Month 30 | Mobility, some problems, Month 30 | 0 Participants |
| Non-ambulatory Participants | Number of Participants According to Response to EQ-5D-Y 5 Dimensions at Month 30 | Pain/Discomfort, some problems, Month 30 | 0 Participants |
| Non-ambulatory Participants | Number of Participants According to Response to EQ-5D-Y 5 Dimensions at Month 30 | Mobility, no problems, Month 30 | 0 Participants |
| Non-ambulatory Participants | Number of Participants According to Response to EQ-5D-Y 5 Dimensions at Month 30 | Anxiety/Depression, extreme problems, Month 30 | 1 Participants |
| Non-ambulatory Participants | Number of Participants According to Response to EQ-5D-Y 5 Dimensions at Month 30 | Pain/Discomfort, extreme problems, Month 30 | 0 Participants |
| Non-ambulatory Participants | Number of Participants According to Response to EQ-5D-Y 5 Dimensions at Month 30 | Self-Care, extreme problems, Month 30 | 1 Participants |
| Non-ambulatory Participants | Number of Participants According to Response to EQ-5D-Y 5 Dimensions at Month 30 | Anxiety/Depression, some problems, Month 30 | 1 Participants |
| Non-ambulatory Participants | Number of Participants According to Response to EQ-5D-Y 5 Dimensions at Month 30 | Usual Activities, no problems, Month 30 | 3 Participants |
| Non-ambulatory Participants | Number of Participants According to Response to EQ-5D-Y 5 Dimensions at Month 30 | Self-Care, some problems, Month 30 | 2 Participants |
| Total Participants | Number of Participants According to Response to EQ-5D-Y 5 Dimensions at Month 30 | Self-Care, extreme problems, Month 30 | 13 Participants |
| Total Participants | Number of Participants According to Response to EQ-5D-Y 5 Dimensions at Month 30 | Usual Activities, some problems, Month 30 | 50 Participants |
| Total Participants | Number of Participants According to Response to EQ-5D-Y 5 Dimensions at Month 30 | Self-Care, no problems, Month 30 | 61 Participants |
| Total Participants | Number of Participants According to Response to EQ-5D-Y 5 Dimensions at Month 30 | Pain/Discomfort, some problems, Month 30 | 39 Participants |
| Total Participants | Number of Participants According to Response to EQ-5D-Y 5 Dimensions at Month 30 | Anxiety/Depression, some problems, Month 30 | 35 Participants |
| Total Participants | Number of Participants According to Response to EQ-5D-Y 5 Dimensions at Month 30 | Mobility, no problems, Month 30 | 60 Participants |
| Total Participants | Number of Participants According to Response to EQ-5D-Y 5 Dimensions at Month 30 | Usual Activities, extreme problems, Month 30 | 10 Participants |
| Total Participants | Number of Participants According to Response to EQ-5D-Y 5 Dimensions at Month 30 | Mobility, extreme problems, Month 30 | 13 Participants |
| Total Participants | Number of Participants According to Response to EQ-5D-Y 5 Dimensions at Month 30 | Usual Activities, no problems, Month 30 | 47 Participants |
| Total Participants | Number of Participants According to Response to EQ-5D-Y 5 Dimensions at Month 30 | Self-Care, some problems, Month 30 | 33 Participants |
| Total Participants | Number of Participants According to Response to EQ-5D-Y 5 Dimensions at Month 30 | Anxiety/Depression, extreme problems, Month 30 | 5 Participants |
| Total Participants | Number of Participants According to Response to EQ-5D-Y 5 Dimensions at Month 30 | Pain/Discomfort, no problems, Month 30 | 64 Participants |
| Total Participants | Number of Participants According to Response to EQ-5D-Y 5 Dimensions at Month 30 | Mobility, some problems, Month 30 | 34 Participants |
| Total Participants | Number of Participants According to Response to EQ-5D-Y 5 Dimensions at Month 30 | Pain/Discomfort, extreme problems, Month 30 | 4 Participants |
| Total Participants | Number of Participants According to Response to EQ-5D-Y 5 Dimensions at Month 30 | Anxiety/Depression, no problems, Month 30 | 67 Participants |
Number of Participants With DMD Mutations Affecting Any Exon Between Exon 9 and Exon 13 or Deletion That Affects Both Exon 29 and Exon 30
Number of participants with DMD mutations affecting any exon between exon 9 and exon 13 or deletion that affects both exon 29 and exon 30 is presented in this outcome measure.
Time frame: Up to Month 30
Population: Full Analysis Set included all participants who had been enrolled in the study.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Ambulatory Participants With Age <6 Years | Number of Participants With DMD Mutations Affecting Any Exon Between Exon 9 and Exon 13 or Deletion That Affects Both Exon 29 and Exon 30 | Any mutation affecting any exon between exon 9 and exon 13 | 11 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants With DMD Mutations Affecting Any Exon Between Exon 9 and Exon 13 or Deletion That Affects Both Exon 29 and Exon 30 | Deletion affects both exon 29 and exon 30 | 2 Participants |
| Ambulatory Participants With Age >=6 Years | Number of Participants With DMD Mutations Affecting Any Exon Between Exon 9 and Exon 13 or Deletion That Affects Both Exon 29 and Exon 30 | Deletion affects both exon 29 and exon 30 | 6 Participants |
| Ambulatory Participants With Age >=6 Years | Number of Participants With DMD Mutations Affecting Any Exon Between Exon 9 and Exon 13 or Deletion That Affects Both Exon 29 and Exon 30 | Any mutation affecting any exon between exon 9 and exon 13 | 20 Participants |
| Total Ambulatory Participants | Number of Participants With DMD Mutations Affecting Any Exon Between Exon 9 and Exon 13 or Deletion That Affects Both Exon 29 and Exon 30 | Any mutation affecting any exon between exon 9 and exon 13 | 2 Participants |
| Total Ambulatory Participants | Number of Participants With DMD Mutations Affecting Any Exon Between Exon 9 and Exon 13 or Deletion That Affects Both Exon 29 and Exon 30 | Deletion affects both exon 29 and exon 30 | 1 Participants |
| Non-ambulatory Participants | Number of Participants With DMD Mutations Affecting Any Exon Between Exon 9 and Exon 13 or Deletion That Affects Both Exon 29 and Exon 30 | Any mutation affecting any exon between exon 9 and exon 13 | 33 Participants |
| Non-ambulatory Participants | Number of Participants With DMD Mutations Affecting Any Exon Between Exon 9 and Exon 13 or Deletion That Affects Both Exon 29 and Exon 30 | Deletion affects both exon 29 and exon 30 | 9 Participants |
Number of Participants With Each Affected Exon by Mutation Types
Number of participants with each affected exon by mutation types is presented in this outcome measure. Only those categories with non-zero values have been reported.
Time frame: Up to Month 30
Population: Full Analysis Set included all participants who had been enrolled in the study. 'Number of Participants Analyzed' signifies all participants in the Full Analysis Set with affected exon. The frequency (count) of each affected exon by mutation types was defined to be plotted for 3 groups combined, because the mutation types/affected exons were not anticipated to be varied in different age groups or by ambulation status according to available evidence globally.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Ambulatory Participants With Age <6 Years | Number of Participants With Each Affected Exon by Mutation Types | Exon 1, Exon deletion | 3 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants With Each Affected Exon by Mutation Types | Exon 2, Exon deletion | 3 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants With Each Affected Exon by Mutation Types | Exon 2, Exon duplication | 6 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants With Each Affected Exon by Mutation Types | Exon 3, Exon deletion | 16 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants With Each Affected Exon by Mutation Types | Exon 3, Exon duplication | 5 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants With Each Affected Exon by Mutation Types | Exon 4, Exon deletion | 16 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants With Each Affected Exon by Mutation Types | Exon 7, Exon deletion | 20 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants With Each Affected Exon by Mutation Types | Exon 4, Exon duplication | 5 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants With Each Affected Exon by Mutation Types | Exon 5, Exon deletion | 21 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants With Each Affected Exon by Mutation Types | Exon 5, Exon duplication | 7 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants With Each Affected Exon by Mutation Types | Exon 5, Point Mutation | 1 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants With Each Affected Exon by Mutation Types | Exon 6, Exon deletion | 20 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants With Each Affected Exon by Mutation Types | Exon 6, Exon duplication | 8 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants With Each Affected Exon by Mutation Types | Exon 6, Point Mutation | 1 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants With Each Affected Exon by Mutation Types | Exon 6, Others | 1 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants With Each Affected Exon by Mutation Types | Exon 7, Exon duplication | 8 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants With Each Affected Exon by Mutation Types | Exon 8, Exon deletion | 21 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants With Each Affected Exon by Mutation Types | Exon 8, Exon duplication | 6 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants With Each Affected Exon by Mutation Types | Exon 9, Exon deletion | 21 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants With Each Affected Exon by Mutation Types | Exon 9, Exon duplication | 5 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants With Each Affected Exon by Mutation Types | Exon 10, Exon deletion | 17 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants With Each Affected Exon by Mutation Types | Exon 10, Exon duplication | 4 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants With Each Affected Exon by Mutation Types | Exon 10, Point Mutation | 1 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants With Each Affected Exon by Mutation Types | Exon 11, Exon deletion | 17 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants With Each Affected Exon by Mutation Types | Exon 11, Exon duplication | 5 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants With Each Affected Exon by Mutation Types | Exon 12, Exon deletion | 16 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants With Each Affected Exon by Mutation Types | Exon 12, Exon duplication | 4 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants With Each Affected Exon by Mutation Types | Exon 13, Exon deletion | 17 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants With Each Affected Exon by Mutation Types | Exon 13, Exon duplication | 3 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants With Each Affected Exon by Mutation Types | Exon 13, Small deletion | 1 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants With Each Affected Exon by Mutation Types | Exon 14, Exon deletion | 17 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants With Each Affected Exon by Mutation Types | Exon 14, Exon duplication | 3 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants With Each Affected Exon by Mutation Types | Exon 15, Exon deletion | 17 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants With Each Affected Exon by Mutation Types | Exon 15, Exon duplication | 3 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants With Each Affected Exon by Mutation Types | Exon 15, Point Mutation | 1 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants With Each Affected Exon by Mutation Types | Exon 16, Exon deletion | 18 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants With Each Affected Exon by Mutation Types | Exon 16, Exon duplication | 3 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants With Each Affected Exon by Mutation Types | Exon 17, Exon deletion | 20 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants With Each Affected Exon by Mutation Types | Exon 17, Exon duplication | 2 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants With Each Affected Exon by Mutation Types | Exon 18, Exon deletion | 15 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants With Each Affected Exon by Mutation Types | Exon 18, Exon duplication | 3 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants With Each Affected Exon by Mutation Types | Exon 19, Exon deletion | 14 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants With Each Affected Exon by Mutation Types | Exon 19, Exon duplication | 3 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants With Each Affected Exon by Mutation Types | Exon 19, Point Mutation | 2 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants With Each Affected Exon by Mutation Types | Exon 20, Exon deletion | 13 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants With Each Affected Exon by Mutation Types | Exon 20, Exon duplication | 3 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants With Each Affected Exon by Mutation Types | Exon 20, Point Mutation | 3 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants With Each Affected Exon by Mutation Types | Exon 21, Exon deletion | 12 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants With Each Affected Exon by Mutation Types | Exon 21, Exon duplication | 3 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants With Each Affected Exon by Mutation Types | Exon 21, Point Mutation | 1 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants With Each Affected Exon by Mutation Types | Exon 22, Exon deletion | 12 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants With Each Affected Exon by Mutation Types | Exon 22, Exon duplication | 3 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants With Each Affected Exon by Mutation Types | Exon 22, Point Mutation | 1 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants With Each Affected Exon by Mutation Types | Exon 23, Exon deletion | 12 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants With Each Affected Exon by Mutation Types | Exon 23, Exon duplication | 3 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants With Each Affected Exon by Mutation Types | Exon 23, Point Mutation | 4 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants With Each Affected Exon by Mutation Types | Exon 24, Exon deletion | 12 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants With Each Affected Exon by Mutation Types | Exon 24, Exon duplication | 3 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants With Each Affected Exon by Mutation Types | Exon 24, Point Mutation | 3 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants With Each Affected Exon by Mutation Types | Exon 24, Small insertion | 1 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants With Each Affected Exon by Mutation Types | Exon 25, Exon deletion | 12 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants With Each Affected Exon by Mutation Types | Exon 25, Exon duplication | 3 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants With Each Affected Exon by Mutation Types | Exon 25, Point Mutation | 1 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants With Each Affected Exon by Mutation Types | Exon 25, Small deletion | 1 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants With Each Affected Exon by Mutation Types | Exon 26, Exon deletion | 12 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants With Each Affected Exon by Mutation Types | Exon 26, Exon duplication | 2 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants With Each Affected Exon by Mutation Types | Exon 26, Point Mutation | 3 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants With Each Affected Exon by Mutation Types | Exon 26, Small insertion | 1 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants With Each Affected Exon by Mutation Types | Exon 26, Small deletion | 1 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants With Each Affected Exon by Mutation Types | Exon 27, Exon deletion | 12 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants With Each Affected Exon by Mutation Types | Exon 27, Exon duplication | 2 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants With Each Affected Exon by Mutation Types | Exon 27, Point Mutation | 1 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants With Each Affected Exon by Mutation Types | Exon 27, Small deletion | 1 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants With Each Affected Exon by Mutation Types | Exon 28, Exon deletion | 12 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants With Each Affected Exon by Mutation Types | Exon 28, Exon duplication | 2 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants With Each Affected Exon by Mutation Types | Exon 28, Point Mutation | 1 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants With Each Affected Exon by Mutation Types | Exon 29, Exon deletion | 12 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants With Each Affected Exon by Mutation Types | Exon 29, Exon duplication | 2 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants With Each Affected Exon by Mutation Types | Exon 29, Point Mutation | 2 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants With Each Affected Exon by Mutation Types | Exon 30, Exon deletion | 9 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants With Each Affected Exon by Mutation Types | Exon 30, Exon duplication | 3 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants With Each Affected Exon by Mutation Types | Exon 30, Point Mutation | 2 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants With Each Affected Exon by Mutation Types | Exon 31, Exon deletion | 9 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants With Each Affected Exon by Mutation Types | Exon 31, Exon duplication | 3 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants With Each Affected Exon by Mutation Types | Exon 31, Point Mutation | 1 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants With Each Affected Exon by Mutation Types | Exon 32, Exon deletion | 9 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants With Each Affected Exon by Mutation Types | Exon 32, Exon duplication | 3 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants With Each Affected Exon by Mutation Types | Exon 32, Point Mutation | 3 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants With Each Affected Exon by Mutation Types | Exon 32, Small deletion | 1 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants With Each Affected Exon by Mutation Types | Exon 33, Exon deletion | 9 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants With Each Affected Exon by Mutation Types | Exon 33, Exon duplication | 3 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants With Each Affected Exon by Mutation Types | Exon 33, Point Mutation | 3 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants With Each Affected Exon by Mutation Types | Exon 33, Small deletion | 1 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants With Each Affected Exon by Mutation Types | Exon 34, Exon deletion | 8 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants With Each Affected Exon by Mutation Types | Exon 34, Exon duplication | 3 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants With Each Affected Exon by Mutation Types | Exon 34, Point Mutation | 1 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants With Each Affected Exon by Mutation Types | Exon 35, Exon deletion | 7 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants With Each Affected Exon by Mutation Types | Exon 35, Exon duplication | 3 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants With Each Affected Exon by Mutation Types | Exon 35, Point Mutation | 2 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants With Each Affected Exon by Mutation Types | Exon 36, Exon deletion | 7 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants With Each Affected Exon by Mutation Types | Exon 36, Exon duplication | 3 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants With Each Affected Exon by Mutation Types | Exon 36, Point Mutation | 2 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants With Each Affected Exon by Mutation Types | Exon 37, Exon deletion | 7 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants With Each Affected Exon by Mutation Types | Exon 37, Exon duplication | 4 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants With Each Affected Exon by Mutation Types | Exon 37, Point Mutation | 2 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants With Each Affected Exon by Mutation Types | Exon 38, Exon deletion | 8 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants With Each Affected Exon by Mutation Types | Exon 38, Exon duplication | 4 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants With Each Affected Exon by Mutation Types | Exon 38, Point Mutation | 1 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants With Each Affected Exon by Mutation Types | Exon 39, Exon deletion | 7 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants With Each Affected Exon by Mutation Types | Exon 39, Exon duplication | 4 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants With Each Affected Exon by Mutation Types | Exon 39, Point Mutation | 1 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants With Each Affected Exon by Mutation Types | Exon 39, Small deletion | 1 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants With Each Affected Exon by Mutation Types | Exon 39, Others | 1 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants With Each Affected Exon by Mutation Types | Exon 40, Exon deletion | 7 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants With Each Affected Exon by Mutation Types | Exon 40, Exon duplication | 4 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants With Each Affected Exon by Mutation Types | Exon 40, Point Mutation | 1 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants With Each Affected Exon by Mutation Types | Exon 40, Small insertion | 1 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants With Each Affected Exon by Mutation Types | Exon 41, Exon deletion | 7 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants With Each Affected Exon by Mutation Types | Exon 41, Exon duplication | 4 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants With Each Affected Exon by Mutation Types | Exon 41, Point Mutation | 2 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants With Each Affected Exon by Mutation Types | Exon 42, Exon deletion | 7 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants With Each Affected Exon by Mutation Types | Exon 42, Exon duplication | 3 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants With Each Affected Exon by Mutation Types | Exon 42, Point Mutation | 1 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants With Each Affected Exon by Mutation Types | Exon 43, Exon deletion | 9 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants With Each Affected Exon by Mutation Types | Exon 43, Exon duplication | 5 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants With Each Affected Exon by Mutation Types | Exon 43, Point Mutation | 1 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants With Each Affected Exon by Mutation Types | Exon 44, Exon deletion | 20 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants With Each Affected Exon by Mutation Types | Exon 44, Exon duplication | 4 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants With Each Affected Exon by Mutation Types | Exon 44, Point Mutation | 3 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants With Each Affected Exon by Mutation Types | Exon 44, Small deletion | 1 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants With Each Affected Exon by Mutation Types | Exon 45, Exon deletion | 42 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants With Each Affected Exon by Mutation Types | Exon 45, Exon duplication | 4 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants With Each Affected Exon by Mutation Types | Exon 46, Exon deletion | 73 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants With Each Affected Exon by Mutation Types | Exon 46, Exon duplication | 3 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants With Each Affected Exon by Mutation Types | Exon 46, Point Mutation | 1 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants With Each Affected Exon by Mutation Types | Exon 47, Exon deletion | 73 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants With Each Affected Exon by Mutation Types | Exon 47, Exon duplication | 3 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants With Each Affected Exon by Mutation Types | Exon 47, Point Mutation | 1 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants With Each Affected Exon by Mutation Types | Exon 47, Small deletion | 1 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants With Each Affected Exon by Mutation Types | Exon 48, Exon deletion | 83 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants With Each Affected Exon by Mutation Types | Exon 48, Exon duplication | 2 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants With Each Affected Exon by Mutation Types | Exon 48, Point Mutation | 1 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants With Each Affected Exon by Mutation Types | Exon 48, Small insertion | 1 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants With Each Affected Exon by Mutation Types | Exon 49, Exon deletion | 96 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants With Each Affected Exon by Mutation Types | Exon 49, Exon duplication | 2 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants With Each Affected Exon by Mutation Types | Exon 49, Point Mutation | 1 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants With Each Affected Exon by Mutation Types | Exon 50, Exon deletion | 94 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants With Each Affected Exon by Mutation Types | Exon 50, Exon duplication | 2 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants With Each Affected Exon by Mutation Types | Exon 51, Exon deletion | 64 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants With Each Affected Exon by Mutation Types | Exon 51, Exon duplication | 3 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants With Each Affected Exon by Mutation Types | Exon 52, Exon deletion | 56 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants With Each Affected Exon by Mutation Types | Exon 52, Exon duplication | 3 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants With Each Affected Exon by Mutation Types | Exon 53, Exon deletion | 24 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants With Each Affected Exon by Mutation Types | Exon 53, Exon duplication | 2 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants With Each Affected Exon by Mutation Types | Exon 53, Point Mutation | 2 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants With Each Affected Exon by Mutation Types | Exon 54, Exon deletion | 22 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants With Each Affected Exon by Mutation Types | Exon 54, Exon duplication | 4 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants With Each Affected Exon by Mutation Types | Exon 55, Exon deletion | 6 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants With Each Affected Exon by Mutation Types | Exon 55, Exon duplication | 3 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants With Each Affected Exon by Mutation Types | Exon 55, Point Mutation | 1 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants With Each Affected Exon by Mutation Types | Exon 56, Exon deletion | 2 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants With Each Affected Exon by Mutation Types | Exon 56, Exon duplication | 2 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants With Each Affected Exon by Mutation Types | Exon 56, Small deletion | 2 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants With Each Affected Exon by Mutation Types | Exon 57, Exon deletion | 1 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants With Each Affected Exon by Mutation Types | Exon 57, Exon duplication | 2 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants With Each Affected Exon by Mutation Types | Exon 57, Point Mutation | 2 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants With Each Affected Exon by Mutation Types | Exon 58, Exon duplication | 2 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants With Each Affected Exon by Mutation Types | Exon 58, Point Mutation | 1 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants With Each Affected Exon by Mutation Types | Exon 58, Small deletion | 1 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants With Each Affected Exon by Mutation Types | Exon 59, Exon duplication | 2 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants With Each Affected Exon by Mutation Types | Exon 59, Point Mutation | 1 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants With Each Affected Exon by Mutation Types | Exon 60, Exon duplication | 2 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants With Each Affected Exon by Mutation Types | Exon 61, Exon duplication | 2 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants With Each Affected Exon by Mutation Types | Exon 62, Exon duplication | 1 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants With Each Affected Exon by Mutation Types | Exon 62, Point Mutation | 2 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants With Each Affected Exon by Mutation Types | Exon 63, Exon deletion | 1 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants With Each Affected Exon by Mutation Types | Exon 63, Exon duplication | 2 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants With Each Affected Exon by Mutation Types | Exon 64, Exon duplication | 2 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants With Each Affected Exon by Mutation Types | Exon 65, Exon deletion | 1 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants With Each Affected Exon by Mutation Types | Exon 65, Exon duplication | 3 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants With Each Affected Exon by Mutation Types | Exon 66, Exon duplication | 3 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants With Each Affected Exon by Mutation Types | Exon 67, Exon duplication | 3 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants With Each Affected Exon by Mutation Types | Exon 68, Exon duplication | 3 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants With Each Affected Exon by Mutation Types | Exon 69, Exon duplication | 2 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants With Each Affected Exon by Mutation Types | Exon 70, Exon duplication | 2 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants With Each Affected Exon by Mutation Types | Exon 70, Point Mutation | 1 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants With Each Affected Exon by Mutation Types | Exon 71, Exon duplication | 2 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants With Each Affected Exon by Mutation Types | Exon 72, Exon duplication | 1 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants With Each Affected Exon by Mutation Types | Exon 73, Exon duplication | 1 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants With Each Affected Exon by Mutation Types | Exon 74, Exon duplication | 1 Participants |
Number of Participants With Type of DMD Mutation
Number of participants as per type of mutation: exon deletion, exon duplication, point mutation, small insertion, small deletion and others is presented in this outcome measure. One participant could have more than 1 mutation type.
Time frame: Up to Month 30
Population: Full Analysis Set included all participants who had been enrolled in the study.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Ambulatory Participants With Age <6 Years | Number of Participants With Type of DMD Mutation | Exon Deletion | 64 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants With Type of DMD Mutation | Exon Duplication | 10 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants With Type of DMD Mutation | Point Mutation | 18 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants With Type of DMD Mutation | Small Insertion | 1 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants With Type of DMD Mutation | Small Deletion | 5 Participants |
| Ambulatory Participants With Age <6 Years | Number of Participants With Type of DMD Mutation | Others | 2 Participants |
| Ambulatory Participants With Age >=6 Years | Number of Participants With Type of DMD Mutation | Others | 1 Participants |
| Ambulatory Participants With Age >=6 Years | Number of Participants With Type of DMD Mutation | Small Insertion | 1 Participants |
| Ambulatory Participants With Age >=6 Years | Number of Participants With Type of DMD Mutation | Exon Deletion | 127 Participants |
| Ambulatory Participants With Age >=6 Years | Number of Participants With Type of DMD Mutation | Point Mutation | 21 Participants |
| Ambulatory Participants With Age >=6 Years | Number of Participants With Type of DMD Mutation | Exon Duplication | 21 Participants |
| Ambulatory Participants With Age >=6 Years | Number of Participants With Type of DMD Mutation | Small Deletion | 7 Participants |
| Total Ambulatory Participants | Number of Participants With Type of DMD Mutation | Exon Duplication | 6 Participants |
| Total Ambulatory Participants | Number of Participants With Type of DMD Mutation | Point Mutation | 8 Participants |
| Total Ambulatory Participants | Number of Participants With Type of DMD Mutation | Small Insertion | 3 Participants |
| Total Ambulatory Participants | Number of Participants With Type of DMD Mutation | Others | 0 Participants |
| Total Ambulatory Participants | Number of Participants With Type of DMD Mutation | Small Deletion | 1 Participants |
| Total Ambulatory Participants | Number of Participants With Type of DMD Mutation | Exon Deletion | 18 Participants |
| Non-ambulatory Participants | Number of Participants With Type of DMD Mutation | Small Deletion | 13 Participants |
| Non-ambulatory Participants | Number of Participants With Type of DMD Mutation | Others | 3 Participants |
| Non-ambulatory Participants | Number of Participants With Type of DMD Mutation | Exon Duplication | 37 Participants |
| Non-ambulatory Participants | Number of Participants With Type of DMD Mutation | Small Insertion | 5 Participants |
| Non-ambulatory Participants | Number of Participants With Type of DMD Mutation | Exon Deletion | 209 Participants |
| Non-ambulatory Participants | Number of Participants With Type of DMD Mutation | Point Mutation | 47 Participants |
Percent Activity Impairment Score as Per WPAI: CG at Months 12, 24, and 30
WPAI:CG is a self-reported measure of work productivity and impairment, was completed by caregiver, which had four scores: absenteeism (work time missed); presenteeism (impairment at work/reduced on the job effectiveness); work productivity loss (overall work impairment/absenteeism plus presenteeism); and activity impairment. Each score was expressed as a percentage (0-100%) with higher score indicating greater impairment and less productivity.
Time frame: Months 12, 24, and 30
Population: Full Analysis Set included all participants who had been enrolled in the study. 'Number of Participants Analyzed' signifies all participants in the Full Analysis Set and contributed data to the table; however, may not have evaluable data for every row. 'Number Analyzed' signifies participants evaluable for specified rows.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Ambulatory Participants With Age <6 Years | Percent Activity Impairment Score as Per WPAI: CG at Months 12, 24, and 30 | Month 12 | 30.9 Percentage activity impairment | Standard Deviation 26.63 |
| Ambulatory Participants With Age <6 Years | Percent Activity Impairment Score as Per WPAI: CG at Months 12, 24, and 30 | Month 30 | 23.7 Percentage activity impairment | Standard Deviation 23.41 |
| Ambulatory Participants With Age <6 Years | Percent Activity Impairment Score as Per WPAI: CG at Months 12, 24, and 30 | Month 24 | 41.3 Percentage activity impairment | Standard Deviation 29.38 |
| Ambulatory Participants With Age >=6 Years | Percent Activity Impairment Score as Per WPAI: CG at Months 12, 24, and 30 | Month 24 | 51.8 Percentage activity impairment | Standard Deviation 27.98 |
| Ambulatory Participants With Age >=6 Years | Percent Activity Impairment Score as Per WPAI: CG at Months 12, 24, and 30 | Month 12 | 48.3 Percentage activity impairment | Standard Deviation 29.02 |
| Ambulatory Participants With Age >=6 Years | Percent Activity Impairment Score as Per WPAI: CG at Months 12, 24, and 30 | Month 30 | 56.2 Percentage activity impairment | Standard Deviation 26.49 |
| Total Ambulatory Participants | Percent Activity Impairment Score as Per WPAI: CG at Months 12, 24, and 30 | Month 24 | 48.1 Percentage activity impairment | Standard Deviation 28.85 |
| Total Ambulatory Participants | Percent Activity Impairment Score as Per WPAI: CG at Months 12, 24, and 30 | Month 12 | 42.5 Percentage activity impairment | Standard Deviation 29.36 |
| Total Ambulatory Participants | Percent Activity Impairment Score as Per WPAI: CG at Months 12, 24, and 30 | Month 30 | 47.1 Percentage activity impairment | Standard Deviation 29.45 |
| Non-ambulatory Participants | Percent Activity Impairment Score as Per WPAI: CG at Months 12, 24, and 30 | Month 24 | 62.6 Percentage activity impairment | Standard Deviation 32.78 |
| Non-ambulatory Participants | Percent Activity Impairment Score as Per WPAI: CG at Months 12, 24, and 30 | Month 12 | 61.7 Percentage activity impairment | Standard Deviation 31.63 |
| Non-ambulatory Participants | Percent Activity Impairment Score as Per WPAI: CG at Months 12, 24, and 30 | Month 30 | 65.0 Percentage activity impairment | Standard Deviation 31.09 |
| Total Participants | Percent Activity Impairment Score as Per WPAI: CG at Months 12, 24, and 30 | Month 24 | 49.5 Percentage activity impairment | Standard Deviation 29.5 |
| Total Participants | Percent Activity Impairment Score as Per WPAI: CG at Months 12, 24, and 30 | Month 12 | 44.6 Percentage activity impairment | Standard Deviation 30.17 |
| Total Participants | Percent Activity Impairment Score as Per WPAI: CG at Months 12, 24, and 30 | Month 30 | 47.8 Percentage activity impairment | Standard Deviation 29.55 |
Percent Overall Work Impairment Scores as Per WPAI: CG at Months 12, 24, and 30
WPAI:CG is a self-reported measure of work productivity and impairment, was completed by caregiver, which had four scores: absenteeism (work time missed); presenteeism (impairment at work/reduced on the job effectiveness); work productivity loss (overall work impairment/absenteeism plus presenteeism); and activity impairment. Each score was expressed as a percentage (0-100%) with higher score indicating greater impairment and less productivity.
Time frame: Months 12, 24, and 30
Population: Full Analysis Set included all participants who had been enrolled in the study. 'Number of Participants Analyzed' signifies all participants in the Full Analysis Set and contributed data to the table; however, may not have evaluable data for every row. 'Number Analyzed' signifies participants evaluable for specified rows.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Ambulatory Participants With Age <6 Years | Percent Overall Work Impairment Scores as Per WPAI: CG at Months 12, 24, and 30 | Percent Overall Work Impairment, Month 12 | 32.0 Percentage work impairment | Standard Deviation 25.7 |
| Ambulatory Participants With Age <6 Years | Percent Overall Work Impairment Scores as Per WPAI: CG at Months 12, 24, and 30 | Percent Overall Work Impairment, Month 24 | 37.2 Percentage work impairment | Standard Deviation 27.64 |
| Ambulatory Participants With Age <6 Years | Percent Overall Work Impairment Scores as Per WPAI: CG at Months 12, 24, and 30 | Percent Overall Work Impairment, Month 30 | 23.3 Percentage work impairment | Standard Deviation 24.41 |
| Ambulatory Participants With Age <6 Years | Percent Overall Work Impairment Scores as Per WPAI: CG at Months 12, 24, and 30 | Percent impairment while working, Month 12 | 27.9 Percentage work impairment | Standard Deviation 23.9 |
| Ambulatory Participants With Age <6 Years | Percent Overall Work Impairment Scores as Per WPAI: CG at Months 12, 24, and 30 | Percent impairment while working, Month 24 | 32.5 Percentage work impairment | Standard Deviation 24.95 |
| Ambulatory Participants With Age <6 Years | Percent Overall Work Impairment Scores as Per WPAI: CG at Months 12, 24, and 30 | Percent impairment while working, Month 30 | 21.1 Percentage work impairment | Standard Deviation 24.23 |
| Ambulatory Participants With Age >=6 Years | Percent Overall Work Impairment Scores as Per WPAI: CG at Months 12, 24, and 30 | Percent impairment while working, Month 24 | 37.7 Percentage work impairment | Standard Deviation 25.92 |
| Ambulatory Participants With Age >=6 Years | Percent Overall Work Impairment Scores as Per WPAI: CG at Months 12, 24, and 30 | Percent impairment while working, Month 30 | 45.3 Percentage work impairment | Standard Deviation 24.6 |
| Ambulatory Participants With Age >=6 Years | Percent Overall Work Impairment Scores as Per WPAI: CG at Months 12, 24, and 30 | Percent Overall Work Impairment, Month 12 | 45.1 Percentage work impairment | Standard Deviation 26.4 |
| Ambulatory Participants With Age >=6 Years | Percent Overall Work Impairment Scores as Per WPAI: CG at Months 12, 24, and 30 | Percent Overall Work Impairment, Month 30 | 51.9 Percentage work impairment | Standard Deviation 25.52 |
| Ambulatory Participants With Age >=6 Years | Percent Overall Work Impairment Scores as Per WPAI: CG at Months 12, 24, and 30 | Percent impairment while working, Month 12 | 41.3 Percentage work impairment | Standard Deviation 25.01 |
| Ambulatory Participants With Age >=6 Years | Percent Overall Work Impairment Scores as Per WPAI: CG at Months 12, 24, and 30 | Percent Overall Work Impairment, Month 24 | 44.3 Percentage work impairment | Standard Deviation 27.53 |
| Total Ambulatory Participants | Percent Overall Work Impairment Scores as Per WPAI: CG at Months 12, 24, and 30 | Percent impairment while working, Month 12 | 36.1 Percentage work impairment | Standard Deviation 25.36 |
| Total Ambulatory Participants | Percent Overall Work Impairment Scores as Per WPAI: CG at Months 12, 24, and 30 | Percent impairment while working, Month 24 | 35.4 Percentage work impairment | Standard Deviation 25.52 |
| Total Ambulatory Participants | Percent Overall Work Impairment Scores as Per WPAI: CG at Months 12, 24, and 30 | Percent Overall Work Impairment, Month 12 | 39.9 Percentage work impairment | Standard Deviation 26.6 |
| Total Ambulatory Participants | Percent Overall Work Impairment Scores as Per WPAI: CG at Months 12, 24, and 30 | Percent Overall Work Impairment, Month 30 | 40.4 Percentage work impairment | Standard Deviation 28.63 |
| Total Ambulatory Participants | Percent Overall Work Impairment Scores as Per WPAI: CG at Months 12, 24, and 30 | Percent Overall Work Impairment, Month 24 | 41.1 Percentage work impairment | Standard Deviation 27.7 |
| Total Ambulatory Participants | Percent Overall Work Impairment Scores as Per WPAI: CG at Months 12, 24, and 30 | Percent impairment while working, Month 30 | 35.5 Percentage work impairment | Standard Deviation 27.04 |
| Non-ambulatory Participants | Percent Overall Work Impairment Scores as Per WPAI: CG at Months 12, 24, and 30 | Percent impairment while working, Month 12 | 40.7 Percentage work impairment | Standard Deviation 26.58 |
| Non-ambulatory Participants | Percent Overall Work Impairment Scores as Per WPAI: CG at Months 12, 24, and 30 | Percent Overall Work Impairment, Month 24 | 45.9 Percentage work impairment | Standard Deviation 29.86 |
| Non-ambulatory Participants | Percent Overall Work Impairment Scores as Per WPAI: CG at Months 12, 24, and 30 | Percent Overall Work Impairment, Month 30 | 56.7 Percentage work impairment | Standard Deviation 20.82 |
| Non-ambulatory Participants | Percent Overall Work Impairment Scores as Per WPAI: CG at Months 12, 24, and 30 | Percent impairment while working, Month 30 | 56.7 Percentage work impairment | Standard Deviation 20.82 |
| Non-ambulatory Participants | Percent Overall Work Impairment Scores as Per WPAI: CG at Months 12, 24, and 30 | Percent impairment while working, Month 24 | 41.3 Percentage work impairment | Standard Deviation 28 |
| Non-ambulatory Participants | Percent Overall Work Impairment Scores as Per WPAI: CG at Months 12, 24, and 30 | Percent Overall Work Impairment, Month 12 | 46.6 Percentage work impairment | Standard Deviation 29.38 |
| Total Participants | Percent Overall Work Impairment Scores as Per WPAI: CG at Months 12, 24, and 30 | Percent impairment while working, Month 24 | 36.0 Percentage work impairment | Standard Deviation 25.75 |
| Total Participants | Percent Overall Work Impairment Scores as Per WPAI: CG at Months 12, 24, and 30 | Percent Overall Work Impairment, Month 30 | 41.1 Percentage work impairment | Standard Deviation 28.42 |
| Total Participants | Percent Overall Work Impairment Scores as Per WPAI: CG at Months 12, 24, and 30 | Percent Overall Work Impairment, Month 24 | 41.6 Percentage work impairment | Standard Deviation 27.86 |
| Total Participants | Percent Overall Work Impairment Scores as Per WPAI: CG at Months 12, 24, and 30 | Percent impairment while working, Month 30 | 36.4 Percentage work impairment | Standard Deviation 27.03 |
| Total Participants | Percent Overall Work Impairment Scores as Per WPAI: CG at Months 12, 24, and 30 | Percent impairment while working, Month 12 | 36.5 Percentage work impairment | Standard Deviation 25.43 |
| Total Participants | Percent Overall Work Impairment Scores as Per WPAI: CG at Months 12, 24, and 30 | Percent Overall Work Impairment, Month 12 | 40.5 Percentage work impairment | Standard Deviation 26.85 |
Percent Work Time Missed Score as Per WPAI: CG at Month 12
WPAI:CG is a self-reported measure of work productivity and impairment, was completed by caregiver, which had four scores: absenteeism (work time missed); presenteeism (impairment at work/reduced on the job effectiveness); work productivity loss (overall work impairment/absenteeism plus presenteeism); and activity impairment. Each score was expressed as a percentage (0-100%) with higher score indicating greater impairment and less productivity.
Time frame: Month 12
Population: Full Analysis Set included all participants who had been enrolled in the study. 'Number of Participants Analyzed' signifies all participants evaluable for this outcome measure.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Ambulatory Participants With Age <6 Years | Percent Work Time Missed Score as Per WPAI: CG at Month 12 | 6.8 Percentage work time missed | Standard Deviation 14.98 |
| Ambulatory Participants With Age >=6 Years | Percent Work Time Missed Score as Per WPAI: CG at Month 12 | 7.3 Percentage work time missed | Standard Deviation 14.11 |
| Total Ambulatory Participants | Percent Work Time Missed Score as Per WPAI: CG at Month 12 | 7.1 Percentage work time missed | Standard Deviation 14.41 |
| Non-ambulatory Participants | Percent Work Time Missed Score as Per WPAI: CG at Month 12 | 21.1 Percentage work time missed | Standard Deviation 28.81 |
| Total Participants | Percent Work Time Missed Score as Per WPAI: CG at Month 12 | 8.5 Percentage work time missed | Standard Deviation 16.78 |
Percent Work Time Missed Score as Per WPAI: CG at Month 24
WPAI:CG is a self-reported measure of work productivity and impairment, was completed by caregiver, which had four scores: absenteeism (work time missed); presenteeism (impairment at work/reduced on the job effectiveness); work productivity loss (overall work impairment/absenteeism plus presenteeism); and activity impairment. Each score was expressed as a percentage (0-100%) with higher score indicating greater impairment and less productivity.
Time frame: Month 24
Population: Full Analysis Set included all participants who had been enrolled in the study. 'Number of Participants Analyzed' signifies all participants evaluable for this outcome measure.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Ambulatory Participants With Age <6 Years | Percent Work Time Missed Score as Per WPAI: CG at Month 24 | 10.5 Percentage work time missed | Standard Deviation 19.7 |
| Ambulatory Participants With Age >=6 Years | Percent Work Time Missed Score as Per WPAI: CG at Month 24 | 13.0 Percentage work time missed | Standard Deviation 23.1 |
| Total Ambulatory Participants | Percent Work Time Missed Score as Per WPAI: CG at Month 24 | 11.9 Percentage work time missed | Standard Deviation 21.56 |
| Non-ambulatory Participants | Percent Work Time Missed Score as Per WPAI: CG at Month 24 | 8.7 Percentage work time missed | Standard Deviation 16.5 |
| Total Participants | Percent Work Time Missed Score as Per WPAI: CG at Month 24 | 11.5 Percentage work time missed | Standard Deviation 21.07 |
Percent Work Time Missed Score as Per WPAI: CG at Month 30
WPAI:CG is a self-reported measure of work productivity and impairment, was completed by caregiver, which had four scores: absenteeism (work time missed); presenteeism (impairment at work/reduced on the job effectiveness); work productivity loss (overall work impairment/absenteeism plus presenteeism); and activity impairment. Each score was expressed as a percentage (0-100%) with higher score indicating greater impairment and less productivity.
Time frame: Month 30
Population: Full Analysis Set included all participants who had been enrolled in the study. 'Number of Participants Analyzed' signifies all participants evaluable for this outcome measure.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Ambulatory Participants With Age <6 Years | Percent Work Time Missed Score as Per WPAI: CG at Month 30 | 2.9 Percentage work time missed | Standard Deviation 6.67 |
| Ambulatory Participants With Age >=6 Years | Percent Work Time Missed Score as Per WPAI: CG at Month 30 | 13.8 Percentage work time missed | Standard Deviation 19.15 |
| Total Ambulatory Participants | Percent Work Time Missed Score as Per WPAI: CG at Month 30 | 9.4 Percentage work time missed | Standard Deviation 16.21 |
| Non-ambulatory Participants | Percent Work Time Missed Score as Per WPAI: CG at Month 30 | 0.0 Percentage work time missed | Standard Deviation 0 |
| Total Participants | Percent Work Time Missed Score as Per WPAI: CG at Month 30 | 9.0 Percentage work time missed | Standard Deviation 15.97 |